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Ítaca 
 
Se um dia partires rumo a Ítaca, 
reza para que o caminho seja longo, 
cheio de aventura e de conhecimento. 
Não temas monstros como os Ciclopes ou o zangado Poseidon: 
Nunca os encontrarás no teu caminho 
enquanto mantiveres o teu espírito elevado, 
enquanto uma rara excitação agitar o teu espírito e o teu corpo. 
Nunca encontrarás os Ciclopes ou outros monstros 
a não ser que os tragas contigo dentro da tua alma, 
a não ser que a tua alma os crie em frente a ti. 
Deseja que o caminho seja bem longo 
para que haja muitas manhãs de Verão em que, 
com quanto prazer, com tanta alegria, 
entres em portos que vês pela primeira vez; 
Para que possas parar em postos de comércio fenícios 
aí comprar coisas finas, madrepérola, coral e âmbar, 
e perfumes sensuais de todos os tipos 
tantos quantos puderes encontrar; 
e para que possas visitar muitas cidades egípcias 
e aprender e continuar sempre a aprender com os seus escolares. 
Tem sempre Ítaca na tua mente. 
Chegar lá é o teu destino. 
Mas não te apresses na viagem. 
Será melhor que ela dure muitos anos 
para que sejas velho quando chegares à ilha, 
rico com tudo o que encontraste no caminho, 
sem esperares que Ítaca te traga riquezas. 
Ítaca deu-te a tua bela viagem. 
Sem ela não terias sequer partido. 
Não tem mais nada a dar-te. 
E, sábio como te terás tornado, 
tão cheio de sabedoria e experiência, 
já terás percebido, à chegada, o que significa uma Ítaca. 
 
Konstantinos Kaváfis (1863-1933) 
.
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Ithaca 
 
When you set out on your journey to Ithaca, 
pray that the road is long, 
full of adventure, full of knowledge. 
The Lestrygonians and the Cyclops, 
the angry Poseidon -- do not fear them: 
You will never find such as these on your path, 
if your thoughts remain lofty, if a fine 
emotion touches your spirit and your body. 
The Lestrygonians and the Cyclops, 
the fierce Poseidon you will never encounter, 
if you do not carry them within your soul, 
if your soul does not set them up before you. 
Pray that the road is long. 
That the summer mornings are many, when, 
with such pleasure, with such joy 
you will enter ports seen for the first time; 
stop at Phoenician markets, 
and purchase fine merchandise, 
mother-of-pearl and coral, amber and ebony, 
and sensual perfumes of all kinds, 
as many sensual perfumes as you can; 
visit many Egyptian cities, 
to learn and learn from scholars. 
Always keep Ithaca in your mind. 
To arrive there is your ultimate goal. 
But do not hurry the voyage at all. 
It is better to let it last for many years; 
and to anchor at the island when you are old, 
rich with all you have gained on the way, 
not expecting that Ithaca will offer you riches. 
Ithaca has given you the beautiful voyage. 
Without her you would have never set out on the road. 
She has nothing more to give you. 
And if you find her poor, Ithaca has not deceived you. 
Wise as you have become, with so much experience, 
you must already have understood what Ithacas mean.  
 
Konstantinos Kaváfis (1863-1933) 
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and mefloquine resistant, obtained from the AS-15CQ by mefloquine drug pressure 
AS-30CQ -  Plasmodium chabaudi parasite clone, pyrimethamine and high chloroquine resistant, 
obtained from the AS-15CQ by cloroquine drug pressure 
ARMD -  Accelerated resistant to multiple drugs phenotype  
ama-1 -  Apical membrane antigen-1 
ATN -  Artesunate 
atp6 -  Encoding the Sarcoplasmic and Endoplasmic Reticulum Ca2+ atpase gene  
C -  Cysteine (Cys) 
CDC -  National Center for Disease Control  
cDNA -  Complementary DNA 
cg10 -  Gene coding for a putative protein transporter, P. chabaudi orthologue of the P. falciparum 
crt. 
CI -  Comparative intensity 
CQ -  Chloroquine 
crt -  Chloroquine resistance transporter gene 
CSP -  Circumsporozoite protein  
D -  Aspartic acid (Asp) 
Dd2 P. falciparum culture, from Indochina, pyrimethamine, mefloquine and chloroquine 
resistant  
DDT -  Dichloro-diphenyl-trichloroethane  
DHA -  Dihydroartemisinin 
DHFR Dihydrofolate-reductase enzyme 
DMSO -   Dimethyl sulfoxide 
DNA -  Deoxyribonucleic acid  
F -  Phenylalanine (Phe) 
gDNA -  Genomic DNA 
HB3 -  P. falciparum culture, from Honduras, pyrimethamine, mefloquine and chloroquine 
resistant  
IC50 -  The drug dose necessary to eliminate 50% of the parasites 
II Intensity index 
i. p. -  Intraperitoneally 
iRBC -   Infected red blood cells (erythrocytes)  
Ki Biochemistry catalytic constant 
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L Leucine (Leu) 
LDH -  Lactate dehydrogenase 
LGS -  Linkage group selection 
Mb -  Mega base 
MCD -  Minimum curative dose  
mdr1 -  Multi drug resistance 1 gene 
msp-1 Merozoite surface protein-1 
msp-2 -  Merozoite surface protein-2 
N -  Asparagine (Asn) 
NADH -  Hydrogen nicotinamide adenine dinucleotide 
NCBI/NIH -  National Institute of Health 
nM -  Nanomolar 
PABA -  Paraminobenzoic acid  
pcdhps -  Gene of Plasmodium chabaudi codifying for enzyme dihydropteroate synthetase 
PCR -  Polymerase chain reaction 
Phe -  Phenylalanine 
PYR -  Pyrimethamine 
RBC -  Red blood cells (erythrocytes)  
RIIs -  Relative intensity indices 
RMP -  Rodent malaria parasite   
RNA -  Ribonucleic acid 
rRNA -  Ribosomal RNA  
RTQ-PCR -  Real time quantitative – PCR 
S -  Serine (Ser) 
s. c. -   Subcutaneous 
SDS -  Sodium dodecyl sulfate 
sRNA -  Small RNA 
SP -  Sulfadoxine-pyrimethamine 
T -  Tymine 
tctp -   Translationally controlled tumour protein gene 
tRNA -  Transfer RNA  
Tyr -  Tyrosine 
ubp-1 -  De-ubiquitinating enzyme, ubiquitin carboxyl-terminal hydrolase, putative, 1 
ubp-1 De-ubiquitinating enzyme, ubiquitin carboxyl-terminal hydrolase, putative, 1 gene 
V -  Valine (Val) 
WHO -  World Heath Organization 
Y -  Tyrosine (Tyr) 
6-PGD -  6-Phosphogluconate dehydrogenase 
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ABSTRACT 
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Resistance of Plasmodium falciparum to multiple drugs including chloroquine (CQ) and 
sulfadoxine-pyrimethamine (SP) is a major problem in malaria control. New drugs, such as 
artemisinin (ART) derivatives, particularly in combination with other drugs, are thus 
increasingly used to treat malaria. Although stable resistance to ART has yet to be reported 
from laboratory or field studies, its emergence would be disastrous because of the lack of 
alternative treatments.  
The work presented in this thesis describes the selection of parasites with stable resistance to 
ART and artesunate (ATN), and their genetic analysis. This work was carried out using the 
rodent malaria parasite Plasmodium chabaudi chabaudi (Plasmodium chabaudi). 
Two different rodent malaria parasite lines AS-15CQ and AS-30CQ were continually 
passaged in the presence of increasing concentrations of ATN or ART, respectively. After 
selection, these lines, named AS-ATN and AS-ART, showed 6-fold and 15-fold increased 
resistance to ATN and ART respectively. Resistance remained stable after cloning, 
freeze/thawing, blood passage in the absence of drug pressure and transmission through 
mosquitoes. The nucleotide sequences and the gene copy number of the possible genetic 
modulators of ART resistance mdr1, cg10, tctp and atp6; were compared between sensitive 
and resistant parasites. No mutations or changes in the gene copy number of these genes were 
found.  
Linkage Group Selection (LGS) was used to investigate the genetic basis of ART resistance. 
Genetic crosses between AS-ART or AS-ATN and the ART-sensitive clone AJ were analysed 
before and after drug treatment. Using quantitative markers, a genetic locus on chromosome 2 
was found to be under strong selection. Loci on chromosomes 1, 8 and 14 of P. chabaudi also 
appear to be under selection. On chromosome 2, two different mutations V739F and V770F in 
a de-ubiquitinating enzyme (ubp-1) were identified in AS-ATN and AS-ART respectively, 
relative to their sensitive progenitors. The implications of these results are discussed. 
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A existência de estirpes do parasita, Plasmodium falciparum resistentes a multiplos fármacos 
tais como; cloroquina (CQ) e sulfadoxina-pirimetamina (SP) é um dos problemas mais graves 
no controlo da malária.  
Novos fármacos, como a artemisinina (ART) e seus derivados, particularmente em 
combinação com outros fármacos, são cada vez mais utilizados no tratamento da malaria. 
Embora até ao momento a fármaco-resistência estável à ART quer in vitro quer in vivo não 
tenha sido registada, o seu surgimento seria desastroso devido á falta de alternativas.  
O trabalho apresentado nesta tese descreve a selecção de resistência estável a ART e ao 
artesunato (ATN). Este trabalho foi realizado usando o modelo roedor de malária Plasmodium 
chabaudi chabaudi (Plasmodium chabaudi). 
Duas linhas parasitáricas diferentes, AS-15CQ e AS-30CQ, foram feitas crescer na presença 
de concentrações crescentes de ATN e ART, e que no final apresentavam uma resistência de 6 
e 15 vezes superior ao ATN e à ART, respectivamente (estas novas linhas obtidas foram 
nomeadas AS-ATN e AS-ART).  
A resistência é estável mesmo após clonagem, congelamento/descongelamento, passagem 
sanguínea na ausência de pressão de fármaco e transmissão através do mosquito vector. 
A sequência nucleotídica e o número de cópias dos genes descritos como moduladores 
putativos de resistência à ART: mdr1, cg10, tctp e atp6; foi comparada entre parasitas 
resistentes e sensíveis. Não tendo sido encontradas alterações na sequência ou no número de 
cópias destes genes. 
Numa tentativa de identificar os genes encolvidos na resistância à ART e ao ATN a técnica de 
Linkage Group Selection (LGS) foi utilizada e dois cruzamentos genéticos entre os clones 
fármaco-resistentes; AS-ART e AS-ATN e o clone geneticamente distinto dos anteriores e 
sensível aos fármacos em estudos; AJ; foram realizados. Foram encontrados sobre selecção 
em ambos os cruzamentos genéticos quatro loci; cromossomas de P. chabaudi 1, 2, 6 e 8. 
Atendendo a que, a selecção no cromossoma 2 era mais forte, este locus foi submetido a 
análises genéticas subsequentes. Tendo sido encontradas duas mutações diferentes (V739F e 
V770F) num gene que codifica para um enzima de desubiquitinação (ubp-1). As implicações 
destes resultados serão discutidas.  
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CHAPTER I  
INTRODUCTION 
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1.1 Malaria: general features  
 
Malaria parasites are micro-organisms that belong to the genus Plasmodium. There are more 
than 100 species of Plasmodium, which can infect many animal species such as reptiles, birds, 
and various mammals. Only four species of Plasmodium infect humans; Plasmodium 
falciparum, Plasmodium vivax, Plasmodium malariae and Plasmodium ovale [Reviewed by: 
Aikawa M 1971; Collins WE et al. 2005; Cowman et al. 2006; Gauthier C et al. 2005; 
Mackinnon MJ et al 2004]. 
Although the symptoms of malaria were known since ancient times, the discovery of the 
causative agent of the disease had to wait until the end of the nineteenth century. Charles 
Louis Alphonse Laveran, a French army surgeon stationed in Constantine, Algeria, was the 
first to notice parasites in the blood of a patient suffering from malaria (see Figure 1). For his 
discovery, Laveran was awarded the Nobel Prize in 1907 [Anderson WK et al. 1927; Celli A 
1933; Hoeppli R 1959, Hippocrates - English translation by W. H. S. Jones 1923; Jones WHS 
1909, Lehrer S 1979, Schmidt GD et al. 2004]. 
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Figure 1 - Illustration drawn by Laveran of various stages of malaria parasites as seen on fresh blood. Dark 
pigment granules are present in most stages. The bottom row shows an exflagellating male gametocyte. 
Source: National Center for Disease Control (CDC).with kind permission of CDC 
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1.2 Malaria today 
 
Although more than 100 years have gone by since the pioneering malariologists uncovered 
the causes of the disease, malaria is today the world’s most important parasitic infection, 
ranking among the major health and developmental challenges for the poor countries of the 
world [Sachs J et al. 2002]. Although four parasite species of the genus Plasmodium infect 
human beings nearly all malaria deaths and the larger proportion of morbidity are caused by 
Plasmodium falciparum. 
More than a third of the world’s population (about 2 billion people) live in malaria endemic 
areas and 1 billion people are estimated to carry parasites at any one time (See Figure 2). In 
Africa alone, there are an estimated 200-450 million cases of fever in children infected with 
malaria each year [Breman JG et al. 2001]. Estimates for annual malaria mortality range from 
0.5 to 3 million people [Marsh K 1998], although malaria related mortality is particularly 
difficult to measure because the symptoms of the disease are non-specific and most deaths 
occur at home. Although the use of ineffective antimalarials will inevitably result in an 
increase in mortality [Trape JF 2001], the real effects of antimalarial drug resistance on 
malaria morbidity and mortality tend to be under-estimated [White NJ 1999].  
After World War II, the widespread use of DDT coupled with the covering and draining of 
breeding grounds resulted in a substantial reduction in mosquito populations. This, together 
with effective treatment, eradicated malaria in Southern Europe, Russia and some parts of 
Asia. Substantial successes were achieved in subtropical regions but control of malaria in the 
tropics proved far more challenging. The effectiveness of the control effort was undermined 
through a combination of difficulties with access to health facilities, the lack of health 
infrastructures, and the gradual development of insecticide resistance. As a consequence, 
plans for eradication of malaria through mosquito vector control had to be abandoned in the 
late 1960s. 
Nowadays, prompt and effective drug treatment is probably the most cost-effective element of 
malaria control [Goodman CA et al. 1999]. The majority of antimalarial therapy worldwide is 
oral drugs for uncomplicated P. falciparum malaria. Oral treatment prevents progression to 
severe disease and complications, and if the drugs are efficacious and applied effectively they 
reduce overall malaria morbidity and mortality. However, most people living in endemic 
areas have little or no access to correct diagnosis and treatment. Malaria treatment is 
commonly inadequate: drugs are of poor quality, effective drugs are not available or if 
available they are not taken correctly due to incorrect prescription or poor adherence.  
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P. falciparum has become resistant to almost all drug classes except the artemisinin 
derivatives. Nowadays chloroquine-resistant P. falciparum occurs across all malaria endemic 
areas. The effectiveness of sulfadoxine-pyrimethamine has rapidly declined in all regions 
where it has been introduced due to resistance, and multidrug resistance is now established in 
Southeast Asia, South America and Africa (See Figure 3) [Collins WJ et al. 2006; Green MD 
2006; Kshirsagar NA 2006; Linares GE et al. 2007].  
Drug resistance is most likely to emerge when background immunity is weak, parasite 
numbers in an individual are high, transmission is low and drug pressure is intense or very 
intense [Hastings IM et al. 2000]. 
With an increase in insecticide and antimalarial-drug resistance, the development of a malaria 
vaccine and above all new drugs or new drug combinations, using drugs already in use, 
carries huge expectations [Chatterjee S et al. 2006; Girard MP et al. 2007; Greenwood B et al. 
2007; Matuschewski K 2006, Shanks GD 2006; Stepniewska K et al. 2006].  
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Figure 2 – World geographic distribution of malaria, data from 2003.  
Source: National Center for Disease Control (CDC) with kind permission of CDC. 
 
 
 
 
 
 
 
 
Figure 3 – Malaria transmission areas and P. falciparum drug resistance distribution data from World Heath 
Organization data from 2004.  
Source: World Heath Organization (WHO) with kind permission of WHO. 
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1.3 The parasite and its life-cycle 
 
In nature, malaria parasites spread by infecting successively two types of hosts: humans and 
female Anopheles mosquitoes.  
Malaria is transmitted among humans by female mosquitoes of the genus Anopheles. Female 
mosquitoes require blood meals in order to carry out egg production, and such blood meals 
are the link between the human and the mosquito hosts in the parasite life cycle. Of the 
approximately 430 known species of Anopheles, only 30-50 transmit malaria in nature 
(“vectors”). The successful development of the malaria parasite in the mosquito (from the 
“gametocyte” stage to the “sporozoite” stage – See Figure 4) depends on several factors. The 
most important is ambient temperature and humidity and whether the Anopheles survives long 
enough to allow the parasite to complete its cycle in the mosquito host (“sporogonic” or 
“extrinsic” cycle, duration 10 to 18 days). Malaria’s life cycle is comprised of both the sexual 
and asexual forms (See Figure 4). The sexual cycle occurs mainly in the mosquito; while the 
asexual cycle takes place in the human host after the parasites have entered the host’s blood 
stream when the mosquito bites for a blood meal. During a blood meal, a malaria infected 
female Anopheles mosquito inoculates sporozoites into the human host. Though the salivary 
glands of an infected mosquito contain thousands of sporozoites, less than 100 of these are 
transmitted in any one bite [Rosenberg R et al. 1990]. Within 30-45 minutes of the parasite’s 
sporozoites entering the bloodstream, they enter parenchymal cells of the liver; this is 
achieved by the binding of the thrombospondin domains of the circumsporozoite and 
thrombospondin-related adhesive proteins (csp and trap respectively) to the heparin sulphate 
proteoglygan on the hepatocytes [Frevert U et al. 1993]. This phase is called the pre-
erythrocytic stage lasting 5-15 days in which the parasite undergoes asexual reproduction 
(schizogony): the end products of this are the merozoites. In P. vivax and P. ovale a dormant 
stage called hypnozoites, can persist in the liver and can cause relapses by invading 
erythrocytes weeks or years later [Durante Mangoni E et al. 2003].  
Hepatocytes rupture to release merozoites that enter red blood cells. Invasion of erythrocytes 
by merozoites involve an initial low affinity interaction between proteins on the surface coat 
of the merozoite (merozoite surface protein-1 (msp-1), and apical membrane antigen-1 (ama-
1)) and the surface of the erythrocyte. Once inside the erythrocyte the merozoite initiates the 
feeding process forming the intracellular parasite, the trophozoite (erythrocytic schizogony 
stage). Mitotic divisions (asexual reproductive stage) occur in the cells giving rise to 
schizonts, which contain up to about thirty haploid merozoites. This red cell ruptures, 
releasing more mature merozoites, which invade more red blood cells, hence maintaining this 
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“asexual cycle”. Some parasites undergo gametocytogenesis within the erythrocyte, producing 
male or female micro and macrogametocytes respectively. These remain in the blood 
circulation where they are available for ingestion by a feeding mosquito. The asexual 
reproductive stage, occurring in the blood of the vertebrate host (human, primate or rodent), is 
the target of most antimalarial drugs, including artemisinin and its derivatives. Inside the 
mosquito mid-gut, female and male gametocytes undergo gametogenesis, in which the female 
macrogametocyte escapes from the erythrocyte membrane and the male microgametocyte 
undergoes the process of exflagellation which produces 8 motile microgametes. The micro 
and macro-gametes fuse to form a zygote that in turn becomes an ookinete, (the only diploid 
stage of the parasite). The ookinete crosses the gut wall and encysts on the outer wall of the 
gut beneath the basal lamella forming an oocyst or sporocyst. Division and multiplication of 
the sporocyst takes place to produce many haploid sporozoites. When the sporocyst bursts the 
sporozoites are released and then migrate to the salivary gland, waiting to re-infect again once 
the mosquito takes another blood-meal [Barnwell JW et al. 1998; Beier JC et al. 1998; Sinden 
RE 1997].  
See Figure 4 for details on the parasite life cycle.  
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Figure 4 - Life cycle of malaria parasite.  
Most of the biological work presented here occurs in the erythrocytic cycle of the parasite (presented in the 
Figure as B). The drug resistance selection process occurs on this part of the parasite life cycle.  
Briefly: the malaria parasite life cycle involves two hosts. During a blood meal, a malaria-infected female 
Anopheles mosquito inoculates sporozoites into the human host . Sporozoites infect liver cells and mature 
into schizonts , which rupture and release merozoites . After this initial replication in the liver (exo-
erythrocytic schizogony ), the parasites undergo asexual multiplication in the erythrocytes (erythrocytic 
schizogony ). Merozoites infect red blood cells . The ring stage trophozoites mature into schizonts, which 
rupture releasing merozoites . Some parasites differentiate into sexual erythrocytic stages (gametocytes) . 
Blood stage parasites are responsible for the clinical manifestations of the disease. The gametocytes, male 
(microgametocytes) and female (macrogametocytes), are ingested by an Anopheles mosquito during a blood 
meal . The parasites’ multiplication in the mosquito is known as the sporogonic cycle . While in the 
mosquito's stomach, the microgametes penetrate the macrogametes generating zygotes . The zygotes in turn 
become motile and elongated (ookinetes)  which invade the midgut wall of the mosquito where they develop 
into oocysts . The oocysts grow, rupture, and release sporozoites , which make their way to the mosquito's 
salivary glands. Inoculation of the sporozoites into a new human host perpetuates the malaria life cycle.  
Source: National Centre for Disease Control (CDC) with kind permission of CDC.  
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1.4 The genetics of malaria parasites 
 
Malaria parasites, as all members of the phylum Apicomplexa, are haploid for almost their 
entire life cycle (exo-erythrocytic and erythrocytic blood stages, sporogony and 
microgametogenesis), and in the haploid phase of the parasite life cycle they multiply by 
mitosis.  
The only phase of the parasite life cycle where the parasite genome is diploid is the zygote 
stage (ookinetes), prior to the meiotic division that results in the production of sporozoites.  
Malaria parasites have three individual genomes; an extra-chromosomal mitochondrial 
genome, a 35kb circular genome and a large nuclear genome. 
The mitochondrial genome, also known as the 6kb element contains genes encoding two 
truncated ribosomal sRNA and three proteins components involved in the electron transport 
system; cytochrome c oxidase subunits I and II and cytochrome b [Funes S et al 2004]. The 
inheritance of the 6 kb element appears to follow the same pattern as other mitochondrial 
genomes in eukaryotes meaning it is inherited from the female parent only [Creasey AM et al. 
1993]. 
The 35kb circular genome associated with the apicoplast encodes 30 proteins, mainly rRNA, 
tRNA, which are primarily involved in gene expression [Funes S et al. 2004, Gardner MJ et 
al. 2002]. The exact role of the apicoplast remains unclear, but it is known to be involved in 
the anabolic synthesis of fatty acids, isoprenoids and haem [Gardner MJ et al. 2002].  
The haploid nuclear genome of P. falciparum is where most parasite genes reside. It consists 
of 14 chromosomes and encodes approximately 5,300 genes with a total genome size of 22.8 
Mb. The parasite chromosomes have a central domain that contain conserved coding regions 
and chromosome ends that consist of telomeric repeat sequences and subtelomeric repeat 
regions, containing polymorphic gene families (for example pfemp1, stevors and rifins) 
[Lanzer M  et al. 1994].  
The P. falciparum nuclear genome is very (A+T)-rich, with an overall (A+T) content of 81%, 
rising to 90% in intronic and intergenic regions [Gardner MJ et al. 2002]. There is 
considerable chromosomal size polymorphism between strains of parasites [Corcoran LM et 
al. 1986], which could be due to unequal crossing-over of homologous chromosomes during 
meiosis, or non-meiotic chromosome breaking and healing events [Babiker HA et al. 1994, 
Gardner MJ et al. 2002, Hernandez-Rivas R et al. 1996, Scherf A et al. 1992].  
Various genetic polymorphisms can be observed when comparing different strains even 
within the same Plasmodium species. This diversity observed to the genotype level has its 
origin on either spontaneous genetic mutation, occurring at any stage of the parasite 
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development and also through genetic recombination occurring in the mosquito vector stage. 
Genetic recombination which the parasites undergo in the mosquito midgut can then result in 
independent assortment of genes on different chromosomes (See Figure 5) [Walliker D et al. 
1998].  
When a mosquito feeds on an infected host containing two genetically distinct parasites, 
gametocytes from the two parasites are taken up, and may fertilise, recombining into 
heterozygous zygotes, by meiosis, producing four genetically distinct haploid daughter cells, 
which are called the recombinant progeny (See Figure 5). In the case where there are equal 
numbers of male and female gametes present from each parental strain in the mosquito, then 
selfing will occur 50% of the time, resulting in 25% of the zygotes being genetically identical 
to one parental strain, and 25% identical to the other. The remaining 50% will be hybrid 
between the two parentals.What is meant is that if the recombinant progeny was undergoing a 
normal Mendelian segregation pattern meaning without any kind of selfing/crossing bias, thus 
in the presence of a random segregation and if there are equal numbers of male and female 
gametes present from each parental strain in the mosquito, then selfing (recombination within 
the same strain) will occur 50% of the time, resulting in 25% of the zygotes being genetically 
identical to one parental strain, and 25% identical to the other. The remaining 50% will be 
hybrid between the two parentals.  
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                           A                            B                                C                          D 
 
Figure 5 – Crossing and chromosomal events in Plasmodium. 
Clone 1 and clone 2 are gametes (haploid stage) from two genetically distinct parasites, after the blood meal 
zygotes are formed. The formation of these zygotes can result from selfing (equal to the progenitor gametes) or 
from crossing (cross between different clones and are therefore heterozygous). Through meiosis four genetically 
distinct haploid daughter cells are produced, which are called the recombinant progeny. A and D are the result of 
selfing on the other hand B and C are the product of recombination.  
From: Walliker D 2000, with kind permission of Professor David Walliker. 
 
Recombination between malaria parasites was first proven with genetic crossing experiments 
done with the rodent parasites Plasmodium yoelii [Walliker D et al. 1971], and Plasmodium 
chabaudi [Walliker D et al. 1975]. In the P. chabaudi experiments, two cloned parasites 
 56 
which differed in their response to the anti-malarial drug pyrimethamine and in the 
electrophoretic patterns of two enzymes (6-phosphogluconate dehydrogenase (6-PGD) and 
lactate dehydrogenase (LDH)) were mixed in mosquitoes and the resulting progeny were 
cloned and characterized for their enzyme type and their phenotypic response to 
pyrimethamine. It was found that not only had the two enzyme isoforms recombined, but that 
pyrimethamine susceptibility segregated independently [Walliker D et al. 1975], which 
showed that recombination between the parental characters had occurred. 
In P. falciparum the production of heterozygotes (in the oocyst) between two heterologous 
malaria parasites has also been demonstrated experimentally, by dissecting individual oocysts 
from mosquitoes that had fed on a mixed P. falciparum blood infection of clones 3D7 and 
HB3. After performing genetic typing of alleles of msp-1 and msp-2 genes, it was found that 
some oocysts contained alleles exclusively from HB3, some contained alleles only from 3D7, 
and the remainder of the oocysts contained alleles from both parents, and were therefore 
hybrids, meaning, the products of fertilization between the two different parental strains. The 
proportion of the homozygous and heterozygous forms was consistent with random 
fertilization between parents [Ranford-Cartwright L et al. 1993].  
With the objective of sequencing the genome of the human malaria parasite Plasmodium 
falciparum (clone 3D7), an International Malaria Genome Sequencing Consortium was 
formed in 1996. The genome was sequenced by three groups: The Institute for Genomic 
Research and the Malaria Program of the Naval Medical Research Center (chromosomes 2, 
10, 11 and 14), The Wellcome Trust Sanger Institute (chromosomes 1, 3-9, 13) and Stanford 
University (chromosome 12).  
In 2002, the complete genome of Plasmodium falciparum was published, triggering the “post-
genomic” age of malariology [Gardner MJ et al. 2002].  
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1.5 Antimalarial drugs and targets 
 
Antimalarial drugs are one of the most important measures to control the disease. The drug of 
choice depends on the parasite species and local conditions, drug resistance prevalence and 
specificity. Traditionally, antimalarial agents are classified as blood schizontocides, tissue 
schizonticides, gametocides and sporontocides, depending on the stages of the malaria life 
cycle which are targeted by the drug [Tracey J et al. 1996]. For details see Table 1. 
Blood schizontocides are drugs acting on asexual intraerythrocytic stages of malarial 
parasites. They suppress the proliferation of plasmodia in the erythrocytes. 
Tissue schizontocides prevent the development of hepatic schizonts. They are causally 
prophylactic because they affect the early developmental stages of the protozoa and prevent 
the invasion of the erythrocytes.  
A hypnozoiticide acts on persistent intrahepatic stages of P. vivax and P. ovale in the liver. 
Gametocides destroy the intraerythrocytic sexual forms (gametes) of the protozoa and the 
prevent transmission from human to another mosquito. Antimalarials are rarely used clinically 
just for their gametocidal action 
 
Table 1 – Classification of antimalarial agents according to their stage of action. 
 
Stage of Action Antimalarial 
Tissue 
schizontocides 
Primaquine, pyrimethamine, sulfonamides (and other 8-
aminoquinolines and other folate inhibitors) 
Hypnozoiticides Primaquine, tafenoquine 
Blood schizontocides Type 1, quick onset: Chloroquine, mefloquine, quinine, 
halofantrine, artemisinin 
Type 2, slow onset: Pyrimethamine, sulfonamides, sulfones, other 
antibiotics, atovaquone 
Gametocides Primaquine for P. falciparum 
Quinine for P. vivax, P. malariae and P. ovale 
Sporontocides Primaquine, chloroquine 
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1.6 Artemisinin and its derivatives  
 
Artemisinin, known in Chinese as Quinghaosu, is the active principle extract of the medicinal 
herb, know in Chinese as Qinghao (Artemisia annua L. also know as Sweet Wormwood, 
Annual Wormwood, Sweet Annie or Chinese Wormwood), and has been used in traditional 
medicine in China for about 2000 years [Antimalaria studies on Qinghaosu 1979; Klayman 
DL 1985].  
 
 
 
Figure 6- Schematic representation of Artemisia annua L. 
Source: www.hort.purdue.edu/hort/  
 
The effective antimalarial crystal was isolated in 1979. Qinghaosu high resolution mass 
spectrum and elemental analysis have led to the molecular formula of C15H22O5 .Its structure 
is shown in Table 2 based on the data of spectral analysis chemical reactions and X-ray 
diffraction [Antimalaria studies on Qinghaosu 1979].  
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Table 2 – Qinghaosu chemical information.  
 
 
Chemical name 
(3R,5aS,6R,8aS,9R,12S,12aR)-octahydro-3,6,9-trimethyl-3,12-
epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10(3H)-one 
Chemical formula C15H22O5 
Molecular mass 282.332 g/mol 
 
Chemically, artemisinin is a sesquiterpene trioxane lactone containing a peroxide bridge (C-
O-O-C), unique among antimalarial drugs, which is essential for its activity [Antimalaria 
studies on Qinghaosu 1979]. This peroxide bridge corresponds to a very unusual chemical 
property that may contribute to the molecule’s unique bioactivities, and it is more stable in 
general than other peroxides, for example it is poorly soluble in water and in oil and it shows 
remarkable thermal stability [Balint GA 2001, Klayman DL 1985]. The lactone that 
constitutes artemisinin can easily be reduced (with sodium borohydride), resulting in the 
formation of dihydroartemisinin (reduced lactol derivative of artemisinin), which has even 
more antimalarial activity in vitro than artemisinin itself [van Agtmael MA et al. 1999]. See 
Figure 7 for details in the molecule structure. 
Since artemisinin is poorly soluble in water or oil, water-soluble derivatives (artesunate and 
artelinate) and oil-soluble derivatives (artemether and arteether) have been synthesized and 
newer semi synthetic and synthetic derivatives are also being developed. 
Artesunate, the most widely used of the derivatives, is available in oral, parenteral and 
suppository formulations. Artemether, a methyl ether derivative of artemisinin, is available in 
ampoules for intramuscular injection or as capsules for oral administration. Arteether, another 
lipophilic ester is available for intramuscular injection. As artemisinin itself, both the 
lipophilic and hydrophilic derivatives are converted to dihydroartemisinin, the active 
metabolite. Dihydroartemisinin itself is available in an oral preparation [Lee IS et al. 1990; Li 
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WH et al. 1982; Meshnick SR et al. 1996; Woodrow CJ et al. 2005]. See Table 3 for details in 
the pharmacokinetic of artemisinin and some of its derivatives. 
 
 
 
Figure 7 – A - Chemical structure of (1) Qinghaosu or artemisinin and some of its derivatives (2) 
dihydroartemisinin, (3) artemether; (4) arteether and (5) artesunic acid or artesunate. The Chemical Abstracts 
numbering system is used. The active pharmacophore is the peroxide bridge, coloured red. The third non-
peroxidic oxygen atom, coloured magenta, appears to be important in conferring optimal antimalarial activity. 
The ensemble of peroxide and non-peroxidic oxygen atoms are incorporated into six-membered ring called a 1, 
2, 4-trioxane. 
B – Three-dimensional tube, and ball and stick representations of artemisinin. Atoms are colour coded as O red, 
C tan. H atoms are omitted for clarity.  
From: Haynes RK et al. 2004, with kind permission. 
 
The artemisinin compounds have antimicrobial activity against several parasites including 
Plasmodium spp., Schistosoma spp., Pneumocystis carinii and Toxoplasma gondii.  
In vitro pharmacodynamic experiments in P. falciparum show that these compounds are 
active against a broad spectrum of the life cycle of the parasite but are stage specific; late-
stage ring parasites and trophozoites are more susceptible to these drugs than schizonts or 
small rings [Alin MH et al. 1994; Caillard V et al. 1992; Geary TG et al. 1989; ter Kuile F et 
al. 1993]. They are also gametocytocial [Dutta GP et al. 1990; Kumar N et al. 1990, Maeno Y 
et al. 1993; Peters W et al. 1993; Posner GH et al. 1995], due to their activity against both the 
precursors of the sexual stages and early gametocytes. Liver stages of P. vivax and P. 
falciparum are not affected [Antimalaria studies on Qinghaosu 1979]. Artemisinin also 
 61
decreased the infectivity of the surviving gametocytes [Chen PQ et al. 1994; Targett G et al. 
2001]. This effect may help diminish transmission rates in areas of low transmission [Price 
RN et al. 1996]. In high transmission areas, however, this effect may not be evident, since 
rapidly re-infected individuals will continue to maintain a pool of transmissible parasites. 
This wide stage specificity of killing gives these drugs a major advantage over the 
conventional antimalarials. The activity against the later stages of parasite development 
prevents the releasing of merozoites; this removes or at least attenuates the occasional sharp 
rise in parasitaemia that normally occurs immediately after treatment. 
Artemisinin has been shown to prevent cytoadherence in vitro, probably by preventing 
development to the mature trophozoite stage [Udomsangpetch R et al. 1996].  
 
Table 3 – Some pharmacokinetic data of artemisinin and some of its derivatives. 
Adapted from Balint GA 2001, with kind permission. 
 
Drug Absorption Elimination 
half-life 
(hour) 
Peak plasma 
concentration 
(hour) 
Usual oral dose 
in adults 
(dose/Kg body 
weight) 
Artemisinin (1) Rapid and 
incomplete 
2-5 <2 20 mg 
Arthemether (2) Rapid and 
incomplete 
3-11 3 4 mg 
Arteether Rapid and 
incomplete 
>20 <2 3 mg 
Artesunate(3) Rapid and 
incomplete 
<1 <2 4 mg 
Dihydroartemisinin Rapid and 
incomplete 
3,1 0,65 4 mg 
Note:  (1) Artemisinin is the active parent compound of the plant. Its half-life is intermediate. It is also very 
safe, and can cross the blood-brain and blood-placenta barriers [de Vries PJ et al.1996].  
(2) Artemether has the longest life but, at the doses required for treatment, it is the most toxic. 
(3)Artesunate is the most active and the least toxic of this group of drugs. It also has the shortest life 
within the body  
 
The apparent primary disadvantage of artemisinin drugs is that they are characterized by a 
short half life [Krishna S et al. 2004]. Artemisinin drugs are very efficient and fast acting thus 
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treatment with artemisinin drugs causes reduction of parasite burden below detectable levels 
without eliminating all parasites and these results in a higher risk of recrudescence [Bjorkman 
A et al. 2005; Krishna S et al. 2004]. In addition, a fraction of the parasites exposed to the 
drug are thought to become dormant and unsusceptible to further dosing until reactivation 
[Hoshen MB et al. 2000]. In order to completely eliminate the parasites avoiding parasite 
recrudescence and preventing the emergence of resistant P. falciparum, combination with 
other longer-acting drugs is necessary [Olliaro PL et al. 2004; Menard D et al. 2005]. The 
combination of artemisinin or one of its derivatives with another drug is named artemisinin 
combination therapy (ACT).  
Artemisinin combination therapies (ACTs) are currently recommended by the World Health 
Organization (WHO) as the first line antimalarial treatment for P. falciparum malaria 
[Bulletin of the World Health Organization 2005; World Health Organisation. Chemotherapy 
of malaria and resistance to antimalarials: report of a WHO Scientific Group]. ACTs combine 
drugs with different modes of action which reduces recrudescences and also reduces 
considerably the risk of selecting resistant mutants in the parasite population (just the same 
rationale for combining drugs in the treatment of tuberculosis and HIV-AIDS). Several ACTs 
have been developed. These include Coartem ®, the combination of artemether with 
lumefantrine, and the combination of artesunate with amodiaquine, mefloquine or 
sulfadoxine-pyrimethamine [Balint GA 2001, Bulletin of the World Health Organization 
2005; Bunnag D et al. 1995, Burk O et al 2005, Campbell P et al. 2006, Hien TT et al. 1993; 
Olliaro PL et al. 2004, Svenson US et al. 1998, Svensson US et al. 1999].  
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 1.6.1 Artemisinin mode of action 
 
The mode of action of artemisinin-based compounds, in spite of intense scientific activity, is 
not yet completely understood. Artemisinin and its derivatives are toxic to malaria parasites at 
nanomolar concentrations, whereas micromolar concentrations are required for toxicity to 
mammalian cells [Lai H et al. 1995, Woerdenbag HJ et al. 1993]. One reason for this 
selectivity is the enhanced uptake of the drug by P. falciparum infected erythrocytes to more 
than 100 fold higher concentrations than do uninfected erythrocytes [Gu HM et al. 1984, 
Kamchonwongpaisan S et al. 1994]. This drug uptake is very rapid, reversible, saturable and 
appears to be partially dependent on metabolic energy [Gu HM et al. 1984, 
Kamchonwongpaisan S et al. 1994]. 
Artemisinin and its derivatives being highly hydrophobic localize in specific parasite 
membranes artemisinins are present in the parasite limiting membranes [Ellis DS et al. 1985], 
digestive vacuole membranes [Ellis DS et al. 1985, Maeno Y et al. 1993] and mitochondria 
[Maeno Y et al. 1993]. So the question is once inside the parasite how do artemisinin 
derivatives really act, and a lot of considerable evidences have been indicating that 
artemisinins mode of action is mediated by free radicals.  
The first clue to its mechanism came from synthetic chemists who demonstrated that the 
endoperoxide bridge that is part of the molecular structure was fundamental for its 
antimalarial activity [Brossi A et al. 1988] and since peroxides are a known source of reactive 
oxygen species like hydroxyl radicals and superoxide free radical mode of action was the 
obvious suggestion and further evidences came from the fact that free radical scavengers 
antagonised (like alfa-tocopherol, catalase, ascorbate, etc) the in vitro antimalarial activity of 
these drugs and that other free radical generators (like doxorubicin, micanazole, castecin and 
artemitin) promoted them [Krungkrai SR et al 1987] and also that artemisinin treatment of 
membranes, especially in the presence of heme can cause lipid peroxidation, hemolysis and 
lysis of infected erythrocytes [revised by Meshnick SR 2002]. 
Meshnick and collaborators [Meshnick SR et al. 1991] on an attempt to clarify artemisinins 
mode of action showed that artemisinin interacted with intraparasitic heme, and suggested that 
intraparasitic heme or iron might function to activate artemisinin inside the parasite into toxic 
free radicals [Meshnick SR et al 1991]. One reason that could explain the selective toxicity of 
artemisinin to the parasites is that the Plasmodium parasite is very high rich in heme-iron, 
derived from the proteolysis of host cell hemoglobin [Meshnick SR et al. 1996]. When 
artemisinins are incubated with heme or iron, they decompose in a fashion that suggests the 
generation of free radical intermediates also studies using electron paramagnetic resonance 
 64 
have also shown that the breakdown of artemisinin results in free radicals [Meshnick SR et al 
1996] during this artemisinin breakdown process ferryl ions (Fe[IV]=O) appear to be formed 
[Kapetanaki S et al 2000]. There are other electrochemical studies that have shown that 
heme/iron can catalyse the irreversible breakdown of artemisinin derivatives [Zhang F et 
al.1992] and also structure–activity relationship studies have shown a high correlation 
between antimalarial activities and heme-binding [Meshnick SR et al 1996] and between 
antimalarial activity and protein alkylation [Meshnick SR et al 1996]. Also, the predicted 
pharmacophore or drug receptor from several structure–activity relationship studies seems to 
resemble heme [Meshnick SR et al 1996] and also there are a lot of other theoretical studies 
that have shown that artemisinin could bind to and react with heme itself [Gu HM et al. 1984] 
furthermore, the presence of the heme polymer, hemozoin, is associated with sensitivity to 
artemisinins for example artemisinins are inactive against the RC strain of Plasmodium 
berghei [Peters W et al. 1986], and the related intraerthrocytic apicomplexan parasite, 
Babesia microti [Wittner M et al. 1996],.which both lack hemozoin, yet are most active 
against schistosomes which also produce hemozoin [Utzinger J et al.2001]. 
Though all these evidences one could not say that artemisinins act like the typical oxidating 
drugs which cause promiscuous damage to protein, nucleic acids and lipid firstly because, 
unlike most other oxidant drugs (and oxidizing agents per si), artemisinin cannot be cyclically 
oxidised and reduced causing the cascade effect typical from free radical reactions [Zhang F 
et al.1992] in a way that only one free radical can result from one drug molecule, secondly, all 
of the oxidant end products observed experimentally were only observed at very high drug 
concentrations [Berman PA et al. 1997], but the drug is effective at much lower 
concentrations. This is a very strong indication that, artemisinin derivatives must have a more 
selective toxic effect. One suggestion to the selective toxicity of artemisinins may be the 
formation of covalent adducts with parasite components, which will then serve as mediators 
for free radical intermediates. One important alkylation target is heme itself. Artemisinin–
heme adducts have been demonstrated in parasite cultures treated with therapeutic 
concentrations of artemisinin derivatives [Hong YL et al. 1994] this means that heme is both 
an activator and target of the artemisinin derivatives. 
The modification that occurs in heme via its ligation to artemisinin could kill the parasite in 
several ways, firstly, artemisinin or its heme adduct might be able to inhibit hemozoin 
biosynthesis or cause hemozoin degradation, for example Pandev and co-workers proved that 
at micromolar concentrations, artemisinin inhibits hemoglobin digestion by malaria parasites 
and inhibits hemozoin formation [Pandey AV et al. 1999] though this observation has only 
been demonstrated in cell-free conditions, artemisinin treatment of living intraerythocytic P. 
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falciparum in culture caused no change in hemozoin content [Asawamahasakda W et al. 
1994], suggesting that heme metabolism might not be the major intracellular target. But heme 
is not the only protein that artemisinin forms adducts with, artemisinins also form covalent 
adducts with other protein, but not with DNA [Yang YZ et al 1993, Yang YZ et al. 1994].  
The alkylation of specific malaria proteins by artemisinins has been demonstrated 
[Asawamahasakda W et al. 1994] and this could mediate the killing action of artemisinin 
derivatives since it occurred at therapeutic concentrations of drug. One of the major alkylation 
targets described in the literature is the malarial translationally controlled tumour protein (tctp 
protein), a protein that binds heme [Bhisutthibhan J et al. 1998], also previous microscopic 
studies had proven that some of the malarial tctp protein is present in the food vacuole 
membranes, where it is in proximity to the heme-rich food vacuole [Bhisutthibhan J et al. 
1998]. Thus, it is likely that the reaction between artemisinin and tctp protein occurs because 
of an association between tctp protein and heme, however, there is a lack of evidences of tctp 
or any other malarial protein in association with artemisinin is directly causing the parasite 
elimination though a variety of ultrastructural studies have been carried out on infected red 
cells treated with artemisinin derivatives and from those studies it was described that 
membrane-containing structures, such as the plasma membrane, endoplasmic reticulum, 
nuclear envelope, food vacuolar membrane and mitochondria appear to be most sensitive to 
the action of artemisinins [Maeno Y et al.1993] thought from these observations a variety of 
mechanisms of action might be suggested. Another very interesting observation is that when 
radiolabelled artemisinin derivatives are fed to malaria infected cells, the drug has been found 
to accumulate in hemozoin and in the membranes of the food vacuole and mitochondria 
[Maeno Y et al.1993]. These observations are consistent with the role of heme in the 
mechanism of action. 
Thought there are as described before many theories to explain artemisinin mode of action 
one cannot even say what is the cellular target for artemisinin. Tctp protein for the reasons 
stated before was one of the suggested targets and more recently Krishna and co-workers have 
indicated that artemisinins might inhibit the sarco–endoplasmic reticulum Ca2+-ATPase 
(SERCA) of P. falciparum (Pfatp6) and, therefore, also SERCAs of other Plasmodium 
species because thapsigargin a chemical component that is a potent and selective inhibitor of 
SERCAs and share some chemical similarities with artemisinins [Eckstein-Ludwig U et al. 
2003]. Artemisinins, but not other antimalarial drugs, inhibited Pfatp6 protein activity when 
Pfatp6 was expressed and assayed in Xenopus oocytes [Eckstein-Ludwig U et al. 2003]. 
Others have carried out docking simulation studies of artemisinin derivatives to models of the 
thapsigargin binding site in Pfatp6 protein [Uhlemann AC et al. 2005]. Several potential 
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hydrophobic interactions between side chains of artemisinin derivatives and amino acids of 
Pfatp6 protein have been identified including Leu263 that seems to modulate artemisinin 
susceptibility when examined using mutagenesis experiments of malarial SERCAs [Jung M et 
al. 2005, Uhlemann AC et al. 2005]. Taken together, there are independent lines of evidence 
that have been obtained from a range of experimental techniques to suggest that Pfatp6 
protein might be the primary target of artemisinins. However, it is suggested that genetic 
studies are required to support this hypothesis. 
More recently, Li and co-workers have suggested that the electron transport chain of P. 
falciparum might be a target for artemisinins [Li W et al. 2005]. In support of this idea, when 
yeast was grown in non-fermentable media (making it dependent on mitochondrial 
respiration), sensitivity to artemisinin increases, because over expression of some 
mitochondrial-transport proteins seems to increase sensitivity to artemisinins, it has been 
suggested that the electron transport chain stimulates the activity of artemisinins, and that 
these activated artemisinins impede mitochondrial function by depolarizing mitochondrial 
membrane potential [Li W et al. 2005]. The mechanism of this inhibition is unclear but it 
might be related to the presence of an iron group in the cytochrome center that induces the 
formation of radicals [Haynes RK et al. 2006].  
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1.7 Drug Resistance 
 
The emergence and spread of parasite resistance to anti-malarial drugs has presented one of 
the largest obstacles hindering the effective treatment and control of malaria. 
The WHO’s official definition of malaria parasite resistance dates from 1973; “the ability of a 
parasite strain to survive and/or multiply despite the administration and absorption of a drug 
in doses equal to or higher than those usually recommended but within the limits of tolerance 
of the subject” [World Health Organisation. Chemotherapy of Malaria and Resistance to 
Antimalarials: Report of a WHO Scientific Group].  
The WHO 1973 definition of the level of parasite drug resistance remains in use;  
A - Sensitive (S): The asexual parasite count reduces to <25% of the pre-treatment 
level in 48 hours after starting the treatment, and complete clearance after 7 days, without 
subsequent recrudescence - Complete Recovery. 
 B - RI Delayed Recrudescence: The asexual parasitaemia reduces to < 25% of pre-
treatment level in 48 hours, but reappears between 2-4 weeks. 
 C - RI Early Recrudescence: The asexual parasitaemia reduces to < 25% of pre-
treatment level in 48 hours, but reappears within 2 weeks. 
 D - RII Resistance: Marked reduction in asexual parasitaemia (decrease >25% but 
<75%) in 48 hours, without complete clearance in 7 days. 
 E - RIII Resistance: Minimal reduction in asexual parasitaemia, (decrease <25%) or 
an increase in parasitaemia after 48 hours. 
 
Though it is important to clarify that clinical treatment failure or increased in vitro IC50 values 
alone are not sufficient to prove drug resistance. A parasite isolate should be classified as 
resistant only after analysis of treatment response parameters (parasite and fever clearance) 
and treatment success (determination of possible re-infection, in the case of apparent 
recrudescence) in correlation with the in vitro drug sensitivity. Increased IC50 values 
combined with prolonged parasite clearance and treatment failure define a case of confirmed 
drug resistance [Noedl H 2005]. One might suggest that the first step in the development of 
clinical resistance may be a decrease in parasite in vitro susceptibility, associated with a key 
mutation in a target enzyme which ultimately results in clinical failure. Thought it is also very 
important to notice that the parasite response and resistance is not only dependent on the 
parasite genotype but also involves the general health state and immune status of the patient.  
A number of factors influence the likelihood of resistance occurring and the speed with which 
it spreads. For instance, the mechanism by which the drug works against the parasite is 
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important; simple modes of action such as simple enzyme inhibition are likely to lead to rapid 
evolution of resistance, as the number of genetic mutations required to alter enzyme structure 
is low. This is the case with pyrimethamine resistance, which evolved very quickly after the 
introduction of the drug, in contrast to the pattern seen with the emergence of chloroquine 
resistance, which took much longer to evolve, as most studies described chloroquine mode of 
action has being much more complex than pyrimethamine. 
The pharmacokinetic dynamics of drugs are also important in determining the selection 
pressure for drug resistance. Watkins and Mosobo [Watkins WM et al. 1993], for example, 
showed that the long half-life of sulfadoxine-pyrimethamine was a considerable factor in the 
selection pressure for resistant mutants, as the drug was present in patients at sub-therapeutic 
levels for long periods of time. Drugs with high efficiencies of parasite killing, rapid 
achievement of levels above the minimal inhibitory concentrations and short half-lives, will 
be the most effective at minimizing the selection pressure for resistant mutants [Winstanley 
PA et al. 2002]. 
Resistance has been recorded to every anti-malarial currently in use, with the exception of 
artemisinin and its derivatives. Quinine, the first drug used specifically to treat malaria was 
used extensively. The first reports of resistance to the drug occurred at the beginning of the 
20th century, when Couto (1908) and later Nocht and Werner (1910) reported the treatment of 
patients who did not respond to quinine treatment [Peters W 1987]. Despite the appearance of 
quinine resistance, the drug remains remarkably useful today, especially as a first line drug for 
treating complicated cerebral malaria. In fact, quinine resistance is surprisingly uncommon, 
and in the few instances it has emerged, it is often associated with parasites that are already 
resistant to other drugs such as chloroquine and mefloquine [Looareesuwan S et al.1990; 
Meshnick SR 1997; Peters W 1987; Pukrittayakamee S et al. 1994]. Chloroquine, itself based 
on the structure of quinine, was developed in Germany in the early 1940s, resistance to 
chloroquine was far more forthcoming than with quinine, and the first reports of parasites 
failing to respond to the drug emerged independently from South America and South East 
Asia in the late 1950s [Moore DV et al. 1961; Young MD et al. 1961]. The spread of 
resistance from these pioneer areas was relatively rapid, and chloroquine resistance is now a 
major problem throughout the malaria affected areas of the world.  
One of the proposed mechanisms for the emergence of drug resistance is through the presence 
of a drug at sub-therapeutic levels within a population. There can be no doubt that the 
emergence of chloroquine resistance in South America was facilitated by the policy of 
distributing chloroquinated salt to the area as part of a well-intentioned control problem. This 
resulted in a large proportion of the population being exposed to the drug at sub-curative 
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doses, thus considerably enhancing the chances of selection of chloroquine resistant parasites 
[Payne D 1988]. The proliferation of chloroquine resistance resulted in the development of 
mefloquine, a drug that was effective against chloroquine resistant parasites. Initial 
indications that mefloquine resistance was likely to emerge came, however, in 1977, when 
resistance was experimentally induced in a rodent malaria parasite [Peters W et al. 1977]. 
Efforts to reduce the possibility of the emergence of resistant parasites in the field by using 
mefloquine in combination with other drugs (especially pyrimethamine) met with failure, 
however, and reports of mefloquine resistant parasites emerged throughout the 1980s [Peters 
W 1998]. Introduced as a first line treatment to Thailand in 1984, substantial resistance had 
developed within 6 years [Price RN et al. 2004].  
 
Concerning the genetic of drug resistance, two main genes have been implicated in 
chloroquine resistance; the pfmdr1 (P. falciparum multi drug resistance 1 gene) and the pfcrt 
(P. falciparum chloroquine resistance transporter gene).  
Pfmdr1 protein is a membrane protein, belonging to the sub group of ABC-type multidrug 
transport system. P. falciparum gene mdr1 is localized on chromosome 5 and according to the 
P. chabaudi synteny map the pcmdr1 (gene homologous on P. chabaudi of the pfmdr1) gene 
is localized on chromosome 12. 
Pfcrt protein is a digestive vacuole transmembrane protein, associated to chloroquine 
resistance. P. falciparum gene crt is localized on chromosome 7 and according to the P. 
chabaudi synteny map the pfcrt gene referred to as cg10 gene is localized on chromosome 6.  
It has been shown that some point polymorphisms in the pfmdr1 gene can be correlated with 
chloroquine resistance in some field isolates [Basco LK et al. 1995, Cox-Singh J et al. 1995, 
Duraisingh MT et al. 1997, Duraisingh MT et al. 2000]. Similarly, transfection work has 
suggested that the gene pfmdr1 can modulate the sensitivity to chloroquine [Reed MB et al. 
2000]. However there are other studies found in the literature with parasites collected from the 
field where no association between point polymorphisms in the gene pfmdr1 and chloroquine 
resistance was found [Chaiyaroj SC et al. 1999, Cremer G et al. 1995, Povoa MM et al. 
1998]. In addition, the analysis of a genetic cross between a P. falciparum chloroquine-
resistant clone; Dd2 and a chloroquine sensitive one, HB3, showed that mutations in the gene 
pfmdr1 did not genetically segregate with chloroquine resistance [Wellems TE et al. 1990]. 
Later detailed linkage analysis and fine chromosome mapping of the progeny clones of the P. 
falciparum Dd2 x HB3 genetic cross allowed the identification of another gene, the pfcrt 
gene, in which a particular mutation at the amino acid position 76 (K76T) a lysine to a 
threonine change, that appears to correlate complet
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field isolates of P. falciparum [Fidock DA et al. 2000]. Babiker HA and colleagues described 
that the combination of mutation in both pfmdr1 and pfcrt gene loci confer higher chloroquine 
resistance phenotypes in field populations of P. falciparum [Babiker HA et al. 2001]. 
In relation to the genetic of mefloquine resistance, in vitro studies on P. falciparum have 
shown that genetic amplification of the pfmdr1 gene may correlate with both mefloquine and 
quinine resistance [Cowman AF et al. 1994, Peel SA et al. 1994]. However, field studies on 
the association between the pfmdr1 gene and the parasite response to mefloquine have not 
provided unanimous results, while some appear to have shown an association between the 
amplification of the pfmdr1 gene and mefloquine resistance [Price RN et al. 1997, Price RN et 
al. 1999, Wilson CM et al. 1993] others as Chaiyaroj SC and co-workers have not found any 
correlation between the two events [Chaiyaroj SC et al. 1999], one possible explanation 
comes from the fact that the genotype-phenotype associations depends from the parasite 
geographical origin. In addition and as with chloroquine it has also been demonstrated 
through genetic crossing and transfection experiments that point mutations in the pfmdr1 gene 
may modulate the sensitivity to both mefloquine and quinine in P. falciparum [Duraisingh 
MT et al. 2000, Reed MB et al. 2000]. In P. chabaudi Cravo PV and colleagues [Cravo PV et 
al. 2003] shown that amplification of the pcmdr1 gene (gene homologous of the P. falciparum 
mdr1 gene) is an important event in the generation of mefloquine resistance, paralleling the 
situation observed by Cowman AF and co-workers and Peel SA and colleagues [Cowman AF 
et al. 1994, Peel SA et al. 1994] though other genes are suggested to be also involved.  
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 1.7.1 Resistance to artemisinin 
 
Clinical parasite resistance to artemisinin drugs has not yet been observed, although variations 
in sensitivity have been described [van Agtmael MA et al. 1999] for example various isolates 
of P. falciparum from Vietnam and Thailand have been found to vary in their sensitivity to 
artemisinins in vitro [Brockman A et al. 2000; Woitsch B et al. 2004; Wongsrichanalai C et 
al. 1997; Wongsrichanalai C. et al. 1999]. Differences in the sensitivity level of P. falciparum 
isolates to artemisinins can be due to genetic alterations of the parasite that confer differential 
sensitivity to these drugs or simply can be due to the natural genetic variation of the parasite 
in that particular part of the world.  
To this stage, several proteins, including a Ca2+-depending SERCA type ATPase protein that 
in P. falciparum is codified by the pfatp6 gene that is localized in P. falciparum chromosome 
1, the P. falciparum chloroquine resistance transporter protein codified by the pfcrt gene, the 
P. falciparum multidrug resistance protein-1 codified by the gene pfmdr1, and the 
translationally controlled tumor protein (tctp) that is codified by the gene pftctp in P. 
falciparum (this gene being localized in P. falciparum chromosome 5), have been implicated 
in modulation of parasite susceptibility to artemisinin drugs.  
Mutations in pfcrt gene were associated with increased susceptibility of P. falciparum isolates 
gathered in Asia, Africa and South America [Sidhu AB et al. 2002] to artemisinin.  
Measurement of the pfmdr1 gene copy by real-time PCR on filed isolates that were 
significantly more resistant to mefloquine, quinine, artemisinin and artesunate and more 
sensitive to chloroquine showed that this isolates had 3 copies of pfmdr1 gene (in normal 
conditions pfmdr1 is a single copy gene), thus, reduced in vitro sensitivity to artemisinin and 
artesunate was correlated to an increased gene copy numbers of the gene pfmdr1 [Pickard AL 
et al. 2003, Price RN et al. 2004]. Price RN and colleagues also associated polymorphisms in 
the gene pfmdr1 with an increased artemisinin susceptibility in isolates with a single copy of 
the gene pfmdr1, in this study the N86Y mutation was associated with lower IC50s to 
mefloquine than in those isolates with a wild-type pfmdr1 gene. By contrast, the presence of 
either the S1034C mutation or the N1042D mutation in isolates with single copies of the gene 
pfmdr1 was associated with a higher artesunate IC50s than was the wild-type, at both these 
loci. On the other hand other point polymorphisms of the gene pfmdr1 have been associated 
with increased sensitivity to artemisinin [Duraisingh MT et al. 2000]. Likewise, the triple 
mutation in the gene pfmdr1, S1034C/N1042D/D1246Y, highly prevalent in South America, 
was found to enhance parasite susceptibility to mefloquine, halofantrine and artemisinin 
[Sidhu AB et al. 2005]. From all these studies the gene pfmdr1 appears to be one important 
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modulator of the parasite susceptibility to artemisinin drugs. Higher copy numbers of this 
gene predict treatment failure even for chemotherapy with the highly effective combination of 
mefloquine and 3 days artesunate [Price RN et al. 2004]. It seems that there is a correlation 
between the resistance to artemisinins and to other antimalarials. Since the gene pfmdr1 has a 
general importance in antimalarial drug resistance, induction of resistance to one drug may be 
followed by resistance to other drugs that are not active by the same mechanism [Anderson TJ 
et al. 2005; Duraisingh MT et al. 2000; Ferrer-Rodriguez I et al 2004; Ngo T et al. 2003; 
Pickard AL et al. 2003; Price RN et al. 2004; Reed MB et al. 2000; Sidhu AB et al. 2005]. 
Resistance to artemisinin in P. yoelii had been previously been selected by drug pressure and 
was correlated to a high protein expression level of parasite tctp protein (Translationally 
Controlled Tumor Protein Homolog) [Walker DJ et al. 2000], which has been shown to bind 
artemisinin [Bhisutthibhan J et al. 1998], however, the resistant parasites readily lost 
resistance once drug-selection pressure was withdrawn [Peters W et al. 1999], so no clear 
association was actually made between artemisinin resistance and the protein tctp, as being a 
transient phenotype, the genetic involved on this resistance phenotype is not possible, that is 
why one of the mains objectives of this project was to select artemisinin resistance of stable 
phenotype.  
So in conclusion we can say that we think that the genetic mechanism responsible for 
artemisinin and its derivatives resistance need clarification. To start the process of 
clarification it is better to clarify that although studies made directly on P. falciparum may 
provide more incisive information, this presents several limitations starting by the fact that in 
the artemisinin case there is no artemisinin resistance yet reported, so the work in animal 
models can circumvented all the human malaria parasite limitations. There are several rodent 
malaria models available; those will be presented in the following chapter.  
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1.8 Rodent malaria parasites 
 
The host specificity of human malaria parasites represents a major constraint on the study of 
malaria as, unlike the other major tropical diseases such as trypanosomiasis and leishmaniasis, 
the actual causative organisms cannot be maintained in convenient small laboratory animals. 
The need for suitable laboratory models has resulted in the use of avian and simian parasites 
and until 1948 these models were the only ones available. 
In 1948 the situation changed with the discovery and isolation of a malaria parasite that was 
capable of infecting laboratory rats and mice [Vincke IH et al. 1948]. This parasite, 
Plasmodium berghei, soon became the most intensively studied malaria parasite.  
All experiments described within this PhD thesis were carried out using the rodent malaria 
parasite, Plasmodium chabaudi. P. chabaudi belongs to a group of four Plasmodium species 
that infect murine rodents from Central Africa the other species being Plasmodium vinckei, 
Plasmodium yoelii and Plasmodium berghei. A map of the locations from which the various 
rodent parasites were isolated is shown in Figure 8.  
 
 
 
Figure 8 The geographic origins of the rodent malaria parasites. 
From Carlton JM et al.2001 with kind permission of Dra. Jane Carlton. 
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The parasites of rodents have received a vast amount of attention both in their own right and 
as models for human malaria. There are many reasons for using rodent malaria parasites as 
models for human malaria. The most obvious of these is the ease with which the whole life 
cycle can be achieved in the laboratory. Apart from the similarities in basic biology between 
the rodent and human malaria parasites (See Table 4 for details), they share conserved 
genetics and genome organization, conserved housekeeping genes and biochemical processes, 
and there is considerable evidence for conservation of the molecular basis of drug-sensitivity 
and resistance [Janse CJ et al. 2004].  
 
 
Table 4 Some biological similarities and differences between P. chabaudi and the human malaria parasite, P. 
falciparum. 
Adapted from: Janse CJ et al. 2004. 
 
 
P. chabaudi P. falciparum 
Merozoites per schizont 6-8 8-24 
Synchronous blood infection Yes Yes 
Optimum temperature range mosquito 
transmission (sporogony) 
24-26º C >26º C 
Duration of the asexual blood stage cycle 
(hours) 
24 48 
Duration of pre-erythrocytic development 50-58 hours 5.5 - 6 days 
Sporozoites in glands at optimum temp. (days 
after infection) 
11-13 10-12 
Note: Plasmodium chabaudi preferentially parasite mature red blood cells and more closely resemble P. vinckei 
than P. berghei.  
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Figure 9 Plasmodium chabaudi parasites (trophozoite stage) in mouse peripheral blood.  
From www.culleton.org/rodent.html, with kind permission of Dr. Richard Culleton. 
 
Although studies made directly on P. falciparum provide more information, this presents 
several limitations, such as the requirement of working with chimpanzees or humans as hosts 
for infection, a fact which poses serious ethical problems, which can be circumvented by 
working with animals models, which make easier the selection of drug-resistant mutants and 
the identification of genes involved in the resistance by performing genetic crosses.  
Of all the rodent malaria models the Plasmodium chabaudi model is the most appropriate for 
studies on the genetics of drug resistance, as P. chabaudi is the rodent malaria model that 
shows most biological similarity to P. falciparum because it preferentially parasitizes mature 
erythrocytes and the schizogony is synchronous [Carlton JM et al. 2001]. In addition several 
clones of this species are already available, which have been selected for resistance to a 
variety of different drugs (see Table 5 for the P. chabaudi clones available for this work). 
These parasites present the ideal starting material for identifying drug resistance genes since 
they have been selected from cloned sensitive parasites. In this way, the mutant parasites 
should have identical genetic backgrounds to the starting sensitive forms except for the genes 
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determining resistance. Furthermore, for the P. chabaudi clones used in this work, an array of 
amplified fragment length polymorphism (AFLPs) have been previously developed which 
allows the characterization of all the progeny of genetic crosses between the sensitive and 
resistant clones and also to pinpoint relevant genes involved in resistant phenotype [Grech K 
et al. 2002]. Using genetic crosses between parents of distinct phenotypes and a recent 
developed genetic approach, named linkage group selection [Culleton R et al. 2005], genes 
which underlie a particular phenotype can be traced among the cross progeny by the analysis 
of large numbers of genome-wide genetic markers. Those markers which follow the 
expression of a phenotype in the recombinant progeny will usually be closely linked to the 
genes which determine its expression.  
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Table 5- Clones of Plasmodium chabaudi available for this project. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CLONE DRUG RESPONSE 
AS - SENS Drug sensitive 
AS - PYR 
[Walliker D et al. 1975] 
Selected from AS - SENS; pyrimethamine-resistant 
AS - 3 CQ 
[Rosário VE 1976] 
Selected from AS - PYR; low chloroquine-resistant 
AS - 15 CQ 
[Padua RA 1981] 
Selected from AS - 3CQ; intermediate chloroquine-resistant 
AS - 30 CQ 
[Padua RA 1981] 
Selected from AS - 15CQ; high chloroquine-resistant 
 
AS -SENS 
 
AS - PRY resistant 
 
AS - 3CQ resistant  
 
AS - 15CQ resistant   
 
AS - 30CQ resistant 
 
pyrimethamine 
selection 
Chloroquine selection 
Chloroquine s lection 
Chloroquine selection 
Pyrimethamine selection 
selection 
 78 
 1.8.1 The genetics of rodent malaria parasites 
 
As it is going to be described in more detail later in this thesis, for this research a rodent 
malaria model; Plasmodium chabaudi; was used.  
Rodent malaria parasites, such as P. berghei, P. chabaudi, and P. yoelii, are used as models 
for P. falciparum. Many aspects of the biology, life cycle, and morphology of rodent malaria 
parasites show a high level of similarity with the human parasites, validating their use as 
models for human infection. Both species have 14 linear chromosomes and many genes are 
conserved [Carlton JM et al. 1998, Hunt P et al. 2004]. There are so many similarities both in 
gene sequence but also in the arrangement of genes within chromosomes between rodent 
malaria parasites and P. falciparum that using comparative genomics techniques and making 
use of significant, but partial genome data of the rodent malaria parasites, the construction of 
a virtual composite rodent malaria parasites genome and its comparison with the P. 
falciparum genome was done, generating what is called a synteny map (in comparative 
genomics, synteny describes the preserved order of genes between related species) between 
rodent malaria parasites (Plasmodium yoelii, Plasmodium berghei and Plasmodium chabaudi) 
and P. falciparum [Carlton JM et al. 1998; Janse CJ et al. 1994; van Lin LH et al. 2000].  
To compose the rodent malaria - P. falciparum synteny map advances were taken on the 
release of the complete genome sequence of the human malaria parasite P. falciparum and 
also on the partial genome sequences of the Plasmodium yoelii, Plasmodium berghei and 
Plasmodium chabaudi parasites, a genome wide survey was able to be done. This survey was 
done by merging the sequenced DNA contigs of the three rodent malaria parasites to form 
composite rodent malaria parasites contigs that cover 90% of the core rodent malaria parasite 
genomes [Carlton JM et al. 2002; Hall N et al. 2005]. For rodent malaria parasites, P. yoelii, 
P. berghei and P. chabaudi this synteny map was published in 2005 [Kooji TW et al. 2005]. 
See Figure 10 for details.  
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Figure 10 – Rodent malaria genomes synteny map to P. falciparum.  
Roman numbers represent P. falciparum chromosomes numbers (I-XIV). RMP chromosomes, means, rodent malaria parasite chromosomes from 1 to 14. In different 
colours it is possible to distinguish between the different syntenic blocks, within Plasmodium species. 
From: Kooji TW et al. 2005, with kind permission of Dr. Taco Kooji. 
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1.9 Linkage Group Selection 
 
As any other living organism, in Plasmodium the identification and fully understanding of the 
genetic mechanisms involved in important phenotypes such as drug resistance is of great 
importance. In the particular case of drug resistance the knowledge of the genes involved in 
this phenotype allows epidemiological studies and other long term studies for example as the 
ones monitoring the resistance of a particular antimalarial in the field. In the case of malaria 
parasites there are nowadays mainly two genetic methods that can be used to try to locate 
genes controlling any genetic trait such as drug resistance for example; those are linkage 
analysis and linkage group selection (LGS). 
When using classical linkage analysis to identify the genetic loci involved in drug resistance, 
the resistant mutants need to be crossed with genetically distinguishable parasites (like AS 
and AJ strains for example), this genetically distinguishable parasites must differ in a number 
of genetic markers. These markers can be restriction length polymorphism (RFLPs) or 
microsatelites for example, and will distinguish the sensitive from the resistant parasites. 
When using classical linkage analysis, the progeny of the genetic cross obtained needs to be 
cloned and the resulting cloned progeny will be analysed for linkage of the phenotype, lets 
consider for the moment drug resistance, with the inheritance of any parental markers either 
resistance or sensitive. Classical linkage analyses bring to notice groups of markers whose 
inheritance is linked to the inherence of drug resistance. In the eventual case of having a 
number of markers considered sufficient a linkage map can be constructed [revised by Carter 
R et al 2007]. Classical linkage analysis has been used before with success to identify regions 
of the parasite genome that are important for drug resistance as for example the case of 
Wellems TE and co-workers, Carlton JM and co-workers and Hunt P and collaborators 
[Carlton JM et al. 1998, Hunt P et al. 2004b, Wellems TE et al. 1991] but only once has it 
lead to the actually identification of a gene responsible for a particular phenotype, in this case, 
it was the identification of pfcrt has the gene involved in chloroquine resistance [Fidock DA 
et al. 2000, Su X et al. 1997]. Due to the fact that for using classical linkage analysis a large 
number of genetic markers is indeed necessary, it is also necessary to know the position of 
these markers in the parasite genome and then involves the cloning of a large number of 
clones from the recombinant progeny and also the genetic characterization of each one, this 
technique is very laborious and time consuming.  
The other technique that enables the discovery of genes controlling biological properties in 
malaria parasites as stated before is linkage group selection (LGS). LGS is a novel approach 
developed for malaria parasites in order to identify genes responsible for selectable 
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phenotypes, as for example drug resistance. LGS was previous validated for finding genes 
involved in drug resistance by Culleton R and co-workers [Culleton R et al. 2005]. LGS can 
be applied to the genetic analysis of any malaria parasite as long as there are experimental 
means of infecting mosquitoes with gametocytes from parasites and also means of passaging 
the genetic progeny of a cross through the liver stage of development and into the blood. LGS 
has in common to the classical linkage analysis the fact that it is an approach that uses a 
genetic cross between two unrelated parasites from the same species, one of which is sensitive 
and the other one is resistant to a particular characteristic that is going to be applied as 
selective pressure [Culleton R et al. 2005], but differs from the traditional approach by 
avoiding cloning very large numbers of cloned lines from the progeny of a genetic cross 
[Carter R et al. 2007]. In LGS the uncloned progeny of a genetic cross, between a sensitive 
and a resistant parasite to a particular characteristic and that are genetically distinguishable by 
a large number of genetic markers such as AFLPs markers for example, is placed under a 
selection pressure representing the biological property of use, in the case of our project; 
artemisinin and artesunate resistance. The DNA obtained from the surviving progeny is then 
screened from the presence of a large number of molecular markers distributed throughout the 
parasite genome. Prior to the developed of the LGS technique an atlas of a large number of 
molecular genetic markers distinguishing for example the two different strains AS and AJ was 
developed [Martinelli A et al 2005]. The genetic markers from the sensitive progenitor that 
are linked to the gene of interest (for example in our case the gene conferring artemisinin 
resistance) will be under-represented or even eliminated from the progeny of the genetic cross 
after the drug selection. Finding the genetic position of the markers under selection would 
allow us an area in the genome where the gene of interest might be located. It is important to 
noticed that the intensity of reduction of any particular marker is directly proportional to the 
distance of the gene of interest thus allowing the construction of a selection valley around the 
genetic area of interest, where the target gene in supposedly located at the valley base [Carter 
R et al. 2007]. See Figure 11 for the resume of the LGS protocol. 
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Figure 11 – Schematic representation of the Linkage Group Selection protocol. 
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 1.9.1. Amplified Fragment Length Polymorphism 
LGS requires that the two parental clones are distinguished by a large enough number of 
genetic markers to ensure that some will be linked to the genes of interest. LGS was 
optimized using amplified fragment length polymorphism (AFLP) a PCR-based method for 
amplifying DNA fragments from genetically distinct cloned lines of parasites, for example AS 
and AJ. AFLP is a technique in which large numbers of markers are generated across a 
genome [Masiga DK et al. 2000]. Having a high density of these markers in the genome 
means that there is a high probability that some of them will be linked to the gene of interest. 
It has been previously shown that AFLP meets the requirements of LGS both as regards 
numbers of markers generated in different strains of P. chabaudi [Grech K et al. 2000] and 
their quantisation in a mixture of the strains [Martinelli A et al. 2004].  
The AFLP technique allows the visualization of restriction fragments of DNA. This enables 
the detection of the variation in DNA between two strains without prior knowledge of the 
nucleotide sequence. Depending upon the polymorphism between the two strains, large 
numbers of genetic markers can be produced in a relatively short time [Vos P et al. 1995]. 
AFLP involves cutting genomic DNA into a large number of DNA fragments with two 
different restriction enzymes (an enzyme called a frequent cutter and another called a rare 
cutter), thus generating optimal size fragments for visualization on polyacrylamide gels. 
Using radiation to label one of the primers allows visualization of the products. Genetic 
differences between strains occurring at a cutting site result in fragments of different sizes 
which can then be identified on a gel as being present in one strain and absent in the other 
(See Figure 12 for an example of an AFLP gel).  
Polymorphic bands can be produced as a result of polymorphisms between strains at the 
enzyme recognition sites, polymorphisms between strains at the selective bases used in each 
PCR, or as a result of insertion/deletion polymorphisms within fragments.  
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1.10 Aims of the project 
 
This project involves identifying and characterizing genes involved in resistance to 
artemisinin using the rodent malaria specie P. chabaudi, starting by selecting stable 
artemisinin drug resistance. 
To select artemisinin and artesunate mutants using the rodent model, P. chabaudi, though 
prolonged exposure of drug-sensitive lines to low and increasing levels of the drug in mice. 
Attempts of selecting artemisinin and artesunate mutants in P. chabaudi would be carried out 
though prolonged exposure of drug-sensitive lines to low and increasing levels of the drug in 
mice; so that the surviving parasites of one lower dose of artesunate and artemisinin would 
receive an increasing dose of the same drug. These results will be presented on chapter III. 
After selecting mutant clones resistant to artemisinin and artesunate the objective would be, as 
a first approach, to study the involvement of P. chabaudi gene orthologues pfmdr1, pfcrt, 
pftctp and pfatp6, in the selected mutant clones, previously described as being putative genetic 
modulators for artemisinin. These results will be presented on chapter IV. 
The last objective was to perform genetic crosses in mosquitoes with the previously selected 
and cloned artemisinin and artesunate mutants in P. chabaudi (AS-ART and AS-ATN 
respectively) and the genetic distinctive sensitive parasite line of P. chabaudi AJ, and to 
perform linkage group selection (LGS) on the genetic crosses using artemisinin and 
artesunate; these results will be presented on chapter V
 85
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER II 
MATERIALS AND METHODS 
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2.1. Mice 
 
Inbred female CD1 (Mus musculus) from Harlan-Tekld Iberica were used for drug tests and 
selection experiments. Inbred female CBA/CA and C57B1/6J mice (Mus musculus) from the 
University of Edinburgh were used in the rest of the experiments described in this work. All 
mice used were 4-6 weeks old at the start of the experiments. They were housed in 
polypropylene cages with sawdust as bedding, and were provided with 41B rat and mouse 
maintenance diet (Harlan-Tekld) ad libidum. Drinking water was supplemented with 0.05% 
paraminobenzoic acid (PABA), an essential element for the parasite growth, and given ad 
libidum. The cages were kept in a room where temperature was maintained at a constant 25º C 
± 3 º C, on a 12-hour light/dark cycle. 
 
2.2. Mosquitoes 
 
Anopheles stepehensi mosquitoes were used for all experiments. Insectaries were maintained 
on a 12-hour light/dark cycle at 25-27º C temperature and 75-86 % humidity. Larvae were fed 
on Liquifry™ until 2nd instar and thereafter on ground Tetramin™ fish food, Adult 
mosquitoes were kept on 10% glucose and 2% PABA-supplemented water solution. Stock 
adults received weekly rat-blood feeds, which are essential for the production of eggs. 
 
2.3. Parasites 
 
All parasites used in the experiments described here were Plasmodium chabaudi chabaudi 
(referred to as P. chabaudi hereafter). See Table 5 and also Table 6.  
 
Table 6 - Parasite clones and lines used in the present work. 
CLONE DRUG RESPONSE 
AJ Drug sensitive, genetically different and distinguishable from AS line 
AS-PYR Derived from AS-SENS; pyrimethamine-resistant 
AS-15CQ  Derived from AS-3CQ; resistant to 6 daily doses of chloroquine at 
5mg/kg mouse body weight 
AS-30CQ  Derived from AS-15CQ; resistant to 6 daily doses of chloroquine at 
30 mg/kg mouse body weight 
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2.4 Preparation of 107 standard parasite inocula 
 
107 iRBC was established as the standard parasite number to be infected into individual mice 
at the time of the drug tests, during selection experiments and during preparation of inocula 
for the production of mixed infections. 
The preparation of the inocula for drug tests and for the selection experiments was as follows: 
the parasitaemia and red blood cell density (RBC/ml) were calculated in the donor mouse, 
after which the required amount of blood was collected from the mouse tail by calibrated 
capillary pipette and diluted to a final concentration of 107 iRBCs/0.1 ml in a solution of 
heparinised 1:1 calf serum/mammalian Ringer’s solution (Appendix 1). Preparations were 
kept on ice at all times and an aliquot of 0.1 ml was inoculated into mice. 
For the preparation of inocula for the production of mixed infections containing equal 
proportions of two parasite clones, infections of both clones into a single mouse were induced 
as described above. 
 
2.5 Cloning 
 
Dilutions for cloning were prepared as in 2.4 except that each mouse was infected either with 
a mean of 0.5 or 1 parasite. Groups of 50 mice were inoculated in these experiments. If 
approximately 30% of mice became infected, it could be predicted that 75% of the infections 
had resulted from a single parasite; a lower percentage of infected mice would indicate higher 
proportion of pure clones. Cloning was done once drug resistance stability was verified.  
 
2.6 Preparation and administration of artemisinin and artesunate 
 
Artemisinin powder was obtained as a gift from African Artemisia.  
Artesunate powder was obtained as a gift from Daphra Pharma. 
In the initial tests artemisinin was dissolved in dimethyl sulphoxide (DMSO) and corn oil, and 
artesunate was dissolved in DMSO, Na2CO3 or corn oil, but for further analysis DMSO was 
always used. 
Both artemisinin and artesunate were freshly diluted daily in dimethyl sulphoxide (DMSO) 
and were kept at room temperature protected from the light. Both drugs were administered to 
mice by gavage using a lubricated catheter adapted to a 1 ml syringe. Drug doses were 
expressed as milligrams of drug per kilogram (Kg) of mouse body weight per day. Both drugs 
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were diluted to a concentration such that the amount of drug corresponding to the desired dose 
was present in 0.1 ml when given to a mouse weighing 20 grams. At the time of drugging, 
mice were individually weighed so that the amount of drug given could be adjusted.  
 
2.7 Drug tests  
 
Initially, artemisinin and artesunate drug test trials were carried out on four P. chabaudi 
clones (AS-PYR, AS-15CQ and AS-30CQ), to establish the appropriate drug regimen and a 
standard test to distinguish between resistant and sensitive parasites as well as parasites with 
intermediate levels of resistance. 
Mice received 107 iRBC each by intra-peritoneal (i. p.) injection.  
Groups of five mice were prepared; one group was untreated and used as a control for the 
infection, while the remaining group was drugged three hours after injection, to allow 
parasites to reach the blood stream. Depending on the particular drug regimen the drug dose 
was repeated every 24 hours for the desired number of days. 
Blood smears from control and artemisinin or artesunate treated mice in the single dose, in the 
three-day suppressive test and in the five-day suppressive test, were taken on day five post 
infection and every day thereafter, until the infection peaked or it was clear that no parasites 
were going to appear. The parasitaemias and number of days for recrudescence of the 
different parasite lines were compared. 
 
2.8 Artemisinin and artesunate selection experiments: general procedure 
 
Two groups of five (4-6 week old) CD1 mice were inoculated with 107 parasites of the clone 
to be used for selection for increased artemisinin or artesunate resistance. 
Three hours after inoculation one of the groups were treated orally with the required doses of 
artemisinin or artesunate for a total of five days. The remaining group was left untreated and 
served as a control. Both controls and parasites that survived drug treatment were passaged 
weekly from the mouse exhibiting the highest parasitaemia into uninfected mice and the 
treatment repeated. The drug doses were increased according to the parasite response to 
treatment in the previous passage. To address the possibility that potential increases in drug 
tolerance could be to due to increased virulence attributed to multiple sub-inoculations, an 
untreated and unselected parasite line was maintained in parallel and passaged in untreated 
mice the same number of times as the drug selected line. Following these passages in the 
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presence of increasing drug concentrations, drug selected parasites showing a significant 
increase in drug tolerance in comparison with unselected control lines were cloned by the 
method of limiting dilution described in section 2.5. Cloned parasites were re-tested for their 
responses to both artemisinin and artesunate. 
 
2.9 Tests to evaluate the stability of drug-resistance 
 
To assess whether artemisinin or artesunate resistance was a genetically stable feature, drug-
resistant parasite clones were re-tested for their drug responses after each of three different 
procedures:  
i) Freeze-thaw cycles in liquid nitrogen,  
ii) After 12 blood sub-inoculations in mice in the absence of drug treatment and  
iii) Transmission through Anopheles stephensi mosquitoes. 
A measure of resistance in the drug-selected parasite clones was established in the following 
way. The minimum curative dose (MCD) of each drug was first assessed in drug-selected 
parasites and untreated control lines. MCD was defined as the minimum dose of each drug 
that would prevent re-appearance of parasites in all five mice within each treated group at any 
time during the first 10 days of the follow-up period.  
A resistance index was determined using the following equation: 
 
N-fold resistance = MCD drug selected parasites/ MCD drug unselected parasites 
 
2.10. Transmission through Anopheles stephensi  
 
For each clone a 30cm³ mosquito cage was set up containing ≈ 200 female Anopheles 
stephensi mosquitoes, 5-7 days old.  
Mosquitoes were maintained on glucose and water solution, which was removed 24 hours 
prior to infective mouse feeds. Blood smears were taken from all infected mice on day 6 post 
infection, and the presence of gametocytes was confirmed. Mice were then anaesthetized with 
rohypnol solution (Appendix 1), and attached to cork boards placed on top of the mosquito 
cages. Mosquitoes were allowed to feed for 30 minutes before the mice were removed. Mice 
were then killed before awakening from the anaesthesia. Glucose and water solution was 
placed back into the cages, and egg bowls were provided 2 days post feed. 10 mosquitoes 
were dissected from each cage 7 days after the feeds, to check for the presence of oocysts. 
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Fourteen days after the infective feed, mosquitoes from each cage were dissected, and the 
salivary glands examined for the presence of sporozoites. If the presence of sporozoites was 
confirmed, the mosquitoes were allowed to feed on a group of two uninfected anesthetised 
mice. Starting on day 8 and onwards the mice were checked for the presence of parasites in 
blood.  
 
2.11. DNA extraction  
 
Parasite genomic DNA was extracted when required as follows: parasitized RBCs were 
harvested from mice under general anaesthesia, when trophozoite stages were most prevalent, 
into citrate saline (pH 7.2) and passed through a column of fibrous cellulose powder twice 
(CF11®, WhatmanTM) to remove mouse leukocytes [Homewood CA et al. 1976]. The 
resulting RBC pellet was washed twice in PBS and parasite DNA extracted by overnight 
incubation in lysis solution (10 mM Tris [pH 8.0], 50 mM EDTA, 0.1% sodium dodecyl 
sulfate [SDS], proteinase K [1 mg/ml]) at 42ºC. After phenol extraction, DNA was 
precipitated using propan-2-ol and ammonium acetate (3M) and dissolved in TE buffer (10 
mM Tris-Cl, 1 mM EDTA, pH8.0). DNA samples were stored at –20ºC. 
 
2.12. Identification of the P. chabaudi tctp and atp6 genes 
 
The DNA sequences of the P. falciparum and P. yoelii tctp and atp6 genes were available 
online at the NCBI/NIH (National Institute of Health) database (www.ncbi.nih.gov) with the 
following accession numbers: pctctp NP_703454, pytctp AF124820, pfatp6 AB121053 and 
pyatp6 AABL01001880. To obtain the P. chabaudi orthologues of these genes, these 
sequences were retrieved and used in BLAST searches against the available P. chabaudi 
sequences (shot gun clones and genomic contigs), deposited at the P. chabaudi genome 
database (www.sanger.ac.uk). The two sequences giving significant hits were retrieved and 
used to design P. chabaudi-specific oligonucleotide primers to amplify overlapping DNA 
fragments spanning the coding region, introns and both 5’- and 3’-non-coding sequences. 
These were then used in PCR amplifications containing either P. chabaudi genomic DNA or 
cDNA templates.  
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2.13. Amplification and sequencing of the mdr1, cg10, tctp and atp6 genes of 
P. chabaudi 
 
Genomic DNA was used as template in 50µl PCR reactions, containing 0.2µM of each 
oligonucleotide primer, 1x PCR buffer (Promega), 2.5 mM MgCl2, 0.2mM dNTPs and 
0.025U/µl of Taq DNA polymerase. For amplification of the pcmdr1 and pccg10 genes, 
oligonucleotide primers and PCR amplification conditions previously published were used 
[Cravo PV et al. 2003; Hunt P et al 2004], based on DNA sequences characterised prior to 
this study (pcmdr1 AY123625 and pccg10 AY304549). These were used in PCR 
amplifications of AS-15CQ, AS-30CQ, AS-ATN and AS-ART. Negative controls were also 
prepared, which contained 1µl of sterile distilled water in place of template DNA. Positive 
controls were prepared using a previously amplified DNA template.  
The oligonucleotide primers used for pcmdr1, pccg10, pctctp and pcatp6 are listed in 
Appendix 2. 
All PCR reactions were carried out using a UNO-Thermoblock machine (Biometra).  
PCR products were run on a 2% agarose gel in TBE solution and visualized under UV. 
Products were purified using the QIAquick PCR Purification Kit from QIAGEN and 
sequenced using BigDye chain termination v3.1 (Applied Biosystems). The sequencing 
reactions were analysed by Macrogen®. The primers used in sequencing reactions were those 
used for the initial amplification of the fragments.  
Gene and predicted amino-acid sequences were manually compiled, and then compared 
between drug selected and unselected clones using an internet-based interface denoted 
Multiple Sequence Alignment with hierarchical clustering [Corpet F et al. 1998], using 
default alignment parameters (http://prodes.toulouse.inra.fr/multalin/ multalin.html).  
 
2.14. Estimation of copy numbers of the pcmdr1, pctctp and pcatp6 genes 
 
Gene copy number was assessed by RTQ-PCR. We used sequences within a fragment of the 
Merozoite Surface Protein of P. chabaudi gene (msp1) (accession no. L22982), [McKean PG 
et al. 1993] as an internal calibrator, since msp1 is a single copy gene in P. chabaudi. 
Real-Time Quantitative PCR (RTQ-PCR) was performed using a Roche LightCycler 
[Meshnick SR 2002].  
Ten microliter reactions in LightCycler capillaries (Roche) using FastStart DNA Master 
SYBR Green I kit reagents (Roche) were used according to the manufacturer’s instructions. 
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Magnesium chloride, primer concentration, denaturating, annealing and elongation rates and 
times were varied to determine the optimum conditions under which only the specific 
amplicon was produced. The average amplification efficiencies of the reactions were closely 
matched because small differences can result in large errors in quantification between 
samples. The average amplification efficiency, E, was determined from the slope of the 
standard curves produced in each experiment using the equation E=10-1/slope. PCR reactions 
where the amplicon doubles at every cycle have an optimal efficiency of 2.0 compared to 
reactions where no amplification occurs and efficiency is 1.0. All samples were analysed in 
replicate within each LightCycler run. The fluorescence signal produced from the amplicon 
was acquired at the end of the polymerisation step at 72ºC.  
The gDNA samples used were the same as those used for gene amplification and sequencing. 
The purity and quantity of DNA was determined by fluorimetry, UV spectrophotometry and 
electrophoresis of serially diluted ethidium-bromide stained samples on agarose gels. 
Standards consisting of 10-fold serial dilutions of parasite genomic DNA in the range of 60-
0.006 ng were used as quantification standards for the LightCycler calibration curve for each 
RTQ-PCR experiment. 
Maximum recovery filter tips (AXYGEN Scientific) and “No Stick” microtubes (Alpha 
Laboratories) were used in these experiments. 
The analysis of relative gene expression data was performed using the 2-∆∆Ct method described 
in detail by Livak and Schmittgen [Livak KJ et al. 2001].  
Thus, the average Cycle threshold (Ct) was calculated for both control (pcmsp1) and target 
genes and the ∆Ct (Ct target gene – Ct msp-1) was determined. ∆∆Ct was calculated for the relative 
quantification of the target gene; ∆∆Ct= (Ct target gene - Ct msp-1)α - (Ct target gene - Ct msp-1)β, where 
α = resistant sample and β = sensitive sample. After validation of the method, results for each 
sample were expressed in N-fold changes in α target gene expression, normalised to msp-1 
relative to the expression of β, according to the following equation: amount of target = 2-∆∆Ct.  
The oligonucleotide primers used for pcmsp1, pcmdr1, pctctp and pcatp6 are listed in 
Appendix 3 together with the PCR conditions used to amplify the fragments. 
 
2.15 Production of cross progeny - Overview of procedure 
 
To produce a genetic cross between two strains, the two parental clones are inoculated into 
mice to produce a mixed infection. Infections of both AS-ART/AS-ATN and AJ clones were 
induced in mice. Absolute numbers of parasites per volume of blood were worked out at peak 
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parasitemia for both infections by multiplying the parasitaemia recorded by thin blood smear 
against the numbers of red blood cells per volume of blood of each mouse (calculated by flow 
cytometry; Beckman Coulter). A volume of blood containing known parasite numbers was 
then taken from both AS-ART/AS-ATN and AJ infected mice by incision of the distal portion 
of the tail, and collected in glass capillaries. This blood was then mixed to produce a 50/50 
mixture of the two clones by parasite number, and diluted to a concentration of 1 x 107 
parasites per 0.1 ml with 50% ringers solution, 45% heat-inactivated calf serum and 5% 200 
units/ml heparin solution. This solution was kept on ice, and administered intra-peritoneally to 
each experimental mouse in 0.1 ml aliquots.  
The mixed infections were followed by microscopy for the presence of gametocytes. When 
gametocytes are present in the infection, mosquitoes are allowed to feed on the mice, and the 
sporozoites present in the salivary glands of infected mosquitoes 14 days later are inoculated 
intra-peritoneally into mice. 
Previous work determined the optimum day post mouse inoculation to achieve infections in 
mosquitoes. The results of this work showed that feeding mosquitoes on mice at day 6 post-
inoculation produced the greatest number of infected mosquitoes. All mosquito feeds in this 
experiment, therefore, were carried out at day 6 post mouse-infection.  
 
 2.15.1 Mosquito feeds 
 
Six 30cm³ mosquito cages were set up containing ≈ 200 female Anopheles stephensi 
mosquitoes, 5-7 days old. Mosquitoes were maintained on glucose and water solution, which 
was removed 24 hours prior to infective mouse feeds. Blood smears were taken from all 
infected mice on day 6 post infection, and the presence of gametocytes was confirmed. Mice 
were then anaesthetized with rohypnol solution (Appendix 1), and attached to cork boards 
placed on top of the mosquito cages. Mosquitoes were allowed to feed for 30 minutes before 
the mice were removed. Mice were then killed before awakening from the anaesthesia. 
Glucose and water solution was placed back into the cages, and egg bowls were provided 2 
days post feed. 7 days after the feeds 10 female mosquitoes from each cage were dissected, to 
check for the presence of oocysts. 
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 2.15.2 Infection of mice from sporozoites 
 
Fourteen days after the infective feed, mosquitoes from each cage were dissected, and the 
salivary glands examined for the presence of sporozoites. If the presence of sporozoites was 
confirmed, all the female mosquitoes from the cage were dissected, and the salivary glands 
removed. These were placed in a glass tube containing 50% Ringer’s solution (Appendix 1), 
45% heat-inactivated calf serum and 5% 200 units/ml heparin solution. The glands were then 
gently crushed using a pestle and mortar in order to release the sporozoites. This solution was 
kept on ice, and injected intra-peritoneally into mice in 0.1 ml aliquots. Thin blood smears 
were taken from infected mice daily, and parasitaemias recorded.  
 
2.15.3 Preparation of artemisinin and artesunate 
 
Artemisinin and artesunate solutions were prepared by dissolving artemisinin and artesunate 
powder in dimethylsulfoxide (DMSO), the exact same way has during the selection 
procedure. This was administered to mice orally in 0.1 ml volumes using a lubricated catheter. 
The dose of artemisinin used was 25 mg/kg for five days and the dose of artesunate used was 
5 mg/kg for five days. At the time of drugging, mice were individually weighed so that the 
amount of drug given could be adjusted accurately to each mouse.  
 
2.16 Linkage Group Selection  
 
2.16.1 Selection of cross progeny 
 
When the sporozoite-induced infections reached peak parasitaemia (10%–15%), the parasites 
were harvested, pooled, and inoculated into a group of mice (designated the “non-passaged” 
group containing 3 -5 mice depending on the experiment). Each mouse in the group received 
1 x 107 parasites. This initial experimental group was left untreated, and the parasites were 
harvested at peak parasitaemia for AFLP analysis to provide a reference point for markers 
analyzed in the subsequent treatment groups.  
For the AS-ART x AJ cross, parasites were pooled and sub-inoculated from the “non-
passaged” group into two further groups of mice, one of which was treated with artemisinin 
(“ART treated” group), and the other left untreated (“untreated” group).  
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For the AS-ATN x AJ cross, parasites were pooled and sub-inoculated from the “non-
passaged” group into two further groups of mice, one of which was treated with artesunate 
(“ATN treated” group), and the other left untreated (“untreated” group). These two groups 
provided the material for the comparison of markers between drug-treated and untreated 
parasite populations. Artemisinin was administered orally at a dose of 25 mg/kg of mouse 
body weight daily at 24-h intervals for 5 days, starting 3h after parasite challenge. Artesunate 
was administered orally at a dose of 5 mg/kg of mouse body weight daily at 24-h intervals for 
5 days, starting 3h after parasite challenge. Both the artemisinin-treated and artesunate-treated 
and the untreated blood-stage cross progeny were allowed to grow to peak parasitaemia 
(30%–40% for untreated, and 20%–30% for treated), at which point the blood was harvested. 
Two samples of parasite DNA were prepared for AFLP and other molecular analyses by 
pooling separately the blood from the treated and untreated mice.  
 
2.16.2 Amplified Fragment Length Polymorphism (AFLP) analysis 
 
2.16.2.1 Preparation of parasite DNA from experimental groups 
 
When infections reached peak parasitaemia, blood was extracted from all mice in each group 
by severance of the brachial artery, pooled, and prepared for DNA extraction. Blood was 
filtered in order to remove any mouse lymphocytes or other nucleated cells, by passing it 
twice through a 5 ml column of powdered cellulose (Sigma) washed with citrate saline. Blood 
was then filtered through Plasmodipur™ filters (Euro-Diagnostica) twice. The filtrate was 
centrifuged for 5 mins at 3000 rpm and the supernatant removed, leaving a pellet of packed 
cells. 0.15% saponin in Phosphate Buffered Saline (PBS) was added to promote cell lysis 
cells. After lysis of erythrocytes occurred (associated with a change in colour of the solution 
from bright red to burgundy colour), PBS was added in excess to prevent parasite lysis. This 
solution was then centrifuged again at 4000 rpm for 5 minutes and washed twice in PBS. 
Supernatant was discarded and pellets stored at -70°C. Three thick blood smears were taken, 
one prior to filtration, one after cellulose filtration and one after Plasmodipur™ filtration in 
order to determine the efficiency of host cell removal at each stage.  
The frozen pellet was re-suspended in 0.4 ml buffer A (Appendix 1), and 10 µl of 10% SDS 
and 50 µg Proteinase K (Sigma) were added. The pellet was left at 37°C overnight after which 
an equal volume of 1:1 phenol/chloroform mixture was added, mixed for 3 min, and 
centrifuged at 5,000 g for 1-2 minutes. The upper aqueous layer was transferred to a fresh 
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tube. The step was repeated 2-3 times. Then an equal volume of chloroform was added, and 
the tube was centrifuged as before for 1-2 minutes. The upper aqueous layer was removed to a 
fresh tube. This procedure was repeated once before an equal volume of ether was added, the 
solution centrifuged as before for 1-2 minutes and the upper layer removed. The remaining 
ether was left to dry in the air. Three volumes of absolute ethanol (0º C) and 1/10th volume of 
3M sodium acetate (pH 5.2) were added to the dried pellet, and the tube was mixed and 
placed on ice for 15-45 minutes to precipitate the DNA.  The tube was then centrifuged at 
10,000 g in a Speed Vac (Savant) for 10 minutes and the ethanol mixture removed. The tube 
was again centrifuged at 10,000 g for 5-10 minutes to remove final traces of ethanol and the 
pellet was resuspended in 100-200 µl of TE buffer (pH 8.0) (see Appendix 1) and left at 37°C 
for 10 minutes before storage at -20º C. 
 
2.16.3 AFLP analysis 
 
0.5µg of parasite genomic DNA was cut using two enzymes. Firstly, 10 U of EcoRI (MBI 
Fermentas, recognition sequence: G↓AATTC) were added and DNA incubated at 37°C for 1 
h, then 5 U of TruI/MseI (MBI Fermentas, recognition sequence: T↓TAA) were added and 
DNA incubated for further 3 h at 65°C.  
The digestion stage was performed in a 40 µl solution containing 2X Y+/ Tango buffer 
(Promega). The fragments were then ligated with adapters matching the cut ends produced by 
the enzymes.  
All primers used were provided by MWG-Biotech UK Ltd. Adapters disrupted the cutting site 
recognised by the enzymes in order to prevent cutting of the adapters from the DNA 
fragment.  
These adapters also provided a recognition site for primers. 
 
-MseI adapters: MeI.a1 and MeI.a2  
 -MeI.a1: 5’-GACGATGAGTCCTGAG-3’ 
 -MeI.a2: 3’-TACTCAGGACTCAT-5’ 
 
-EcoRI adapters: EoI.a1 and EoI.a2 
 -EoI.a1: 5’-CTCGTAGACTGCGTACC-3’ 
 -EoI.a2: 3’-CATCTGACGCATGGTTAA-5’ 
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Bold letters indicate base substitution to disrupt enzyme cutting site. 
Adapters were prepared by adding equimolar amounts of both strands and then performing the 
following procedure: 
 
 - Heat adapters at 94°C for 5 mins, then cool to 21°C for 5 mins 
 - Heat adapters at 72°C for 60 s., then cool to 21°C for 5 mins 
 - Heat adapters at 65°C for 60 s., then cool to 21°C for 5 mins. 
 
Adapters were then diluted to 50 pmol/µl. 10 µl of ligation mixture were then added to 40 µl 
of digested DNA and this incubated at 37°C for 3h, then overnight at 15°C. Ligated material 
was diluted 1:10 in TE buffer (pH 8.0) (Appendix 1) and stored at -20°C. 
A preliminary PCR amplification was performed involving the use of “non-selective” primers 
(meaning primers with no extra nucleotides added at their 3’ ends extending beyond the 
adapters sequence) matching the adapters: 
 
 - Non-selective EcoRI primer: 5’-GACTGCGTACCAATTC-3’ 
 - Non-selective MseI primer: 5’-GATGAGTCCTGAGTAA-3’ 
 
A 20µl PCR solution containing 0.32 µM of each of the non-selective primers, 1 µl template 
DNA, 0.4 U Taq polymerase (Promega), 1X Mg-free PCR Buffer (Promega), 1.5 mM MgCl2, 
and 0.2mM of all 4 dNTPs was set up. The following cycles were performed: 
 
 - 94°C for 60 s., then 
 - 94°C for 30 s. 
 - 56°C for 60 s. 
 - 65°C for 60 s. 
repeat the three steps for 20 cycles 
 
The resulting PCR material was diluted 50-fold in TE buffer (pH 8.0) and stored at - 20°C. 
Selective amplification was performed using radiolabelled primer (EcoRI-primer) and 
selective primers (meaning primers with a selective extension at the 3’-end, in order to reduce 
the number of fragments amplified). For radiolabeling, 2.5x Kinase buffer (Promega), 20U T4 
polynucleotide Kinase (Promega), 100 µCi [γ-33P] ATP / [γ-32P] ATP (ICN) and 500 ng of 
oligonucleotide primer were incubated in a 20 µl solution at 37°C for 60 min. The reaction 
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was stopped by adding 1 µl of 0.1 M EDTA pH 8.0 and heating at 70°C for 10 min. The 
mixture was then made up to a volume of 50 µl by adding sterile, distilled water. 
Primer purification was performed using TE Micro Select-D, G-25 microcentrifuge spin 
columns produced by Eppendorf-5 Prime Inc. 
Hot PCR with the radiolabelled primer was performed as follows: 0.32 µM of the selective 
MseI primer, 0.05 µM of the labelled selective EcoRI primer, 1 µl template DNA, 0.4 U Taq 
polymerase (Promega), 1X Mg-free PCR Buffer (Promega), 2.5 mM MgCl2, and 0.2mM of 
all 4 dNTP’s were added to a 20µl total volume PCR solution.  
PCR conditions for this stage were: 
 
 - 94°C for 60 s., then 
 - 94°C for 30 s. 
 - 65°C for 60 s., annealing temperature is reduced at each cycle by 0.7°C for the next 12 
cycles, then remained at 56°C for the remaining 23 cycles 
 - 65°C for 60 s. 
repeat the preceding three steps for 35 cycles 
 
The PCR products were mixed with 20 µl of loading dye specific for poly-acrylamide 
sequencing gels (Anachem), then heated at 99°C for 3 min and immediately cooled on ice. 
5µl of each sample was loaded onto a 5% denaturing polyacrylamide gel (5% acrylamide, 
0.25% methylene bisacryl, 7.5 M urea in 50mM Tris/50mM Boric acid/1mM EDTA). 500 µl 
of a 10% Ammonium Persulfate solution (APS) and 100µl of TEMED (Sigma) were added to 
100 ml of gel solution and the gel cast using a SequiGen 38x50 cm gel apparatus (BioRad). 
Electrophoresis was performed at 110 W for 2 h in 1x TBE buffer. Gels were then dried in a 
vacuum gel drier (model 583, Bio Rad) and exposed overnight in phosphorimager screens 
(Fuji) at -70°C. Results were visualised on an autoradiography film (Kodak XAR-5). They 
were developed in an automatic autoradiographer developer (Exograph). 
As an example of an AFLP gel and the band nomenclature see Figure 12. 
Thus, and just as an example, the marker AJAG02CA denotes the second largest (that is 
where the 02 cames from) AJ-specific band (thus beginning with AJ) obtained using EcoRI 
primers with AG (the first pair of nucleotide letters, like the forward primer) as additional 
“selective” 3’-nucleotides, and CA as “selective” nucleotides on the MseI primers (the second 
pair of nucleotide letters, like the reverse primer). 
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Figure 12 - An example of an AFLP gel.  
In this particular gel we can see the results of bands generated with Mse1 (CA selective bases, so called forward 
primer) + EcoR1 (AG selective bases, so called reverse primer). One of the markers of the sensitive parent 
(AJAG02CA) was absent in the treated population and is then presumably closely linked to the locus conferring 
resistance. 
Each one of the lanes is labelled as followed; 
AS: denotes DNA extracted from single AS-SENS clone infection (in our project the AS alleles are the 
resistant ones). 
AJ: denotes DNA extracted from single AJ clone infection (in our project the AJ alleles are the 
sensitive ones). 
1: denotes DNA extracted from the unpassaged pooled group. 
2: denotes DNA extracted from the treated pooled group (in the case of our project the AS-ART x AJ 
cross was treated with ART and the AS-ATN x AJ cross was treated with ATN). 
3: denotes DNA extracted from the untreated pooled group. 
Each lane represents a DNA sample obtained from the pooled DNA of all mice on each experimental group. 
Polymorphic markers are bands that are different for AS or AJ. AS specific markers (thus resistant) are marked 
with a broken arrow (), and AJ specific markers (thus sensitive) with an open arrow (), bands marks with an 
arrow () represent a non-polymorphic marker (there are no differences between AS and AJ within this marker). 
Adapted from Culleton R et al. 2005 with kind permission of Dr Richard Culleton. 
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2.16.4 Measurement and comparison of the intensity of AFLP 
markers 
 
This technique makes uses of a large number of molecular genetic markers distinguishing two 
strains of malaria parasites, the AFLP markers. These markers can be visualised as bands on a 
polyacrilamide gel. Most of the bands that will appear on a gel will be present in both the 
parasites and are called non-polymorphic bands and some are unique of one of the clones in 
our case either AS - resistant or AJ - sensitive. Once the selection pressure is applied in the 
genetic progeny of a cross, in the case of this project, artemisinin or artesunate pressure, the 
parasites that carry the allele that is sensitive (in this case the AJ allele) will be removed, and 
from an experimental point of view this disappearance is visible by the decrease in intensity 
or complete disappearance of an AFLP band specific for the sensitive allele (AJ band). Thus 
the progeny after selection is then screened for markers. Specially those from the sensitive 
parent that would either be significantly reduced or absent because these markers should be 
linked to the locus or loci under selection, in our case under artemisinin or artesunate 
selection. Polymorphic markers (between AS-ART and AJ and between AS-ATN and AJ, 
here simplified to AS and AJ), meaning those that are different between AS and AJ, were 
named and placed in the AFLP map, to denote specificity of the polymorphic band meaning 
the size of the band (relative to other polymorphic bands in the same gel lane) and the 
selective bases used, this would make it very straightforward the identification of a particular 
band to the AFLP map already developed by Martinelli A and collegues [Martinelli A et al. 
2005]. As stated before we were looking for the disappearing of AJ sensitive markers on the 
treated group (meaning artemisinin or artesunate treated group) in comparison of the 
untreated group, each one of these markers decreased in intensity or disappeared is predicted 
to lay in what we call a selection valley that can then be associated to a particular gene 
underling the resistant phenotype or at least responsible for given so type of selective 
advantage over the sensitive parasites. An example of an AFLP gel is represented in Materials 
and Methods Figure 12.  
As described in the materials and methods chapter, each marker band intensity was measured 
with PhosphorImager and IMAGEQUANT software (Molecular Dynamics). For each marker 
of interest, either AS or AJ, an intensity index (II) was calculated by taking the intensity of a 
polymorphic marker (either AS or AJ) and compare it to a no polymorphic marker, making 
sure that this is done using the same PCR material applied in the same polyacrilamide gel. 
Each II is then converted to a relative intensity index (RII) either unselected RIIu or selected 
RIIs. The RIIu is calculated by making a ration between the II obtained for the unselected 
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material and the II obtained for the parental (either AS if we are looking at an AS specific 
markers or AJ is we are looking for an AJ marker). The RIIs is calculated by making the ratio 
between the II obtained for the selected material and the II obtained for the parental (either 
AS or AJ) [Martinelli A et al. 2004]. 
To compare between different markers a comparative Intensity (CI) of the polymorphic 
markers was calculated. This comparative intensities are defined as the RII of an AFLP 
marker in the cross progeny selected in “treated” mice (RIIt), divided by the RII of the marker 
of the cross progeny grown in a parallel “untreated” group of mice (RIIut), and expressed as a 
percentage: 
 
CI = (RIIt/RIIut) x 100. 
 
Keeping in mind that the objective is to identify the genomic loci under drug selection either 
by artemisinin or artesunate that would correspond to a selection valley associated to the 
resistant phenotype, AFLP markers with low CIs were identified and their position according 
to the previously define genetic linkage map [Martinelli A et al. 2005] were noted. 
 
2.16.5 Assignment of AFLP markers to locations in a P. chabaudi 
genetic linkage map. 
 
Markers had previously been ordered on a genetic linkage map of P. chabaudi [Martinelli A 
et al. 2004, Martinelli A et al.2005] obtained from previously generated crosses between AS-
derived clones and AJ strains of P. chabaudi [Carlton JM et al. 1998; Rosario VE 1976; 
Walliker D et al. 1975].  
A total of 674 AFLP markers were typed for each uncloned progeny analysed in this work, 
and were subsequently assigned to linkage groups using the previously generated map 
[Martinelli A et al. 2005]. 
A total of 674 AFLP markers were typed for each of 28 cross-progeny clones, and were 
subsequently assigned to linkage groups using the Map Manager QTX software [Manly KF et 
al. 2001]. A total of 44 RFLP markers characterized in a previous study [Carlton JM et al. 
1998] were used as genetic anchors to allow the assignment of the various linkage groups to 
chromosomes. In total, 11 chromosomes could be identified, while 12 linkage groups of as yet 
unknown assignment remain, which include the three remaining chromosomes (chromosomes 
2, 4, and 14).  
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2.16.6 Sequencing of AFLP markers, and their location on the 
Plasmodium falciparum genome 
 
AFLP bands that appeared to be under selection were excised from acrylamide gels using a 
sterile scalpel. The gel fragments were then soaked in an Eppendorf tube in 50 µl of 
autoclaved, distilled water (sdH2O) overnight.  
Gel slices were centrifuged at 12000g prior to removal of the liquid phase containing the 
DNA. DNA was precipitated using 1/10 volume of 3M sodium acetate (pH 5.2) and 3 
volumes of ice-cold absolute ethanol. The solution was placed at -20°C for at least 1 h. 
Thereafter the tubes were spun for 30 minutes at high speed. The liquid phase was removed 
and the DNA pellet washed twice in 70% ethanol, before air drying. The pellet was then 
dissolved in 50 µl TE buffer (pH 8.0).  
The extracted DNA fragment was amplified by PCR, using the same selective AFLP primers 
and PCR conditions that produced it.  
Sequencing reactions were carried out using the protocol described, below in section 2.16.7. 
The sequences of markers were then physically mapped in the P. falciparum genome 
(sequence data for P. falciparum were obtained from the Sanger Centre website, which can be 
accessed at www.sanger.ac.uk_Projects_P_falciparum), using BLAST searches. 
 
2.16.7 AFLP band sequencing and purification of PCR products 
 
Sequencing PCR reactions were set up using the ABI PRISM Big DyeTM Terminator Cycle 
Sequencing Ready Reaction Kit, (PE Applied Biosystems). PCR reactions were prepared to a 
final volume of 10µl, containing the following reagents: 4µl template DNA (100-250ng), 4µl 
Terminator Ready Reaction Mix, 1µl primer (3.2pmol), 1µl sterile distilled water  
 
Sequencing PCR conditions were as follows;  
 
Denaturing 95°C for 30 seconds 
Annealing 50°C for 20 seconds 
Extension 60°C for 4 minutes 
 
Following the sequencing PCR, the products were purified by precipitation with sodium 
acetate and 95% ethanol, and washed in 70% ethanol. 
x 25 cycles 
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For sequencing of purified PCR products, internal primers covering the extreme 5’ and 3’ 
ends of the fragments were used. All fragments were sequenced in opposite directions. 
 
Sequencing results were analysed using the SeqED V 1.0.3 software (Applied Biosystems 
Inc., 1992). The programme allows the visualisation of chromatograms of the sequenced 
DNA.  
 
So as a summary: traditional linkage analysis of individual cross progeny clones, is labour-
intensive and expensive, as it involves the genotypic and phenotypic characterization of 
individual clones from a cloned progeny of a genetic cross. Without the generation of an 
extremely large number of recombinant clones it has a poor resolution, which makes the 
actual identification of the underlying genes extremely difficult unless strong candidates are 
already suspected. There is an inverse relationship between the size of the locus within which 
possible target genes may be located and the number of recombinant clones that must be 
generated [Wellems TE et al. 1991]. 
LGS, used in this project, has enabled the discovery of genes controlling biological properties 
in malaria parasites to be greatly accelerated [Culleton R et al. 2005; Martinelli A et al. 2005]. 
LGS differs from the traditional approach to genetic analysis of malaria parasites by not 
requiring individually characterisation of very large numbers of clones from the progeny of 
the cross [Carter R et al. 2007]. LGS characterises the uncloned progeny of a genetic cross 
(between a resistant and sensitive parasite to the particular parasite characteristic in study) by 
measuring the proportion of parental polymorphic markers at genome-wide loci (AFLP), 
before and after drug treatment. Markers from the sensitive parent that are linked to the gene 
underlying the resistance phenotype will be under-represented or eliminated after drug 
treatment, forming a “selection valley”. In the case of this project, the AJ markers correspond 
to the markers from the sensitive parent; those markers will be under represented or 
eliminated after artemisinin and artesunate treatment.  
As Carter R and colleagues so clearly summarise [Carter R et al. 2007], LGS analysis 
depends upon several distinct experimental components.  
A) The crossing of two genetically distinct lines of malaria parasite by preparing a mixed 
infection of gametocyte-producing blood-stage parasites in a mouse, allowing 
mosquitoes to feed upon the mixture, with consequent parasite development and 
invasion of sporozoites to salivary glands; 
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B) The subjection of the progeny of the cross to a selection pressure (in the case of this 
research, ART or ATN pressure). This drug selection is applied to the blood stage 
parasites in mice infected with the cross progeny sporozoites. 
C) The screening of the uncloned, selected cross progeny with quantitative markers, such 
as quantitative real-time PCR, quantitative AFLP and proportional sequencing. So 
before the LGS technique could be applied the development of quantitative markers 
covering as much the parasite genome as possible is necessary. Prior to this project 
quantitative AFLP were optimized and developed for being use with AS and AJ 
parasite lines from P. chabaudi [Culleton R et al. 2005; Martinelli A et al. 2005]. 
The location of the genetic markers in a Plasmodium genome database with the expectation 
that markers linked to genes controlling the target of drug selection will form a selection 
valley containing the locus of the selected genes. A genetic linkage map, in the case of this 
project already previous developed by Martinelli A and co-workers [Martinelli A et al. 2005], 
a genome sequence database, in the case of our model P. chabaudi sequence though not fully 
complete with a big coverage and a complete syntenic map developed prior to this project 
[Kooij TW et al. 2006] allowed us to map genes and markers genetically and physically, thus 
allowing identification of loci under selection. Then mutations in suspected candidate genes 
within the locus can be identified by comparative sequencing of genes from both the resistant 
mutant and its sensitive progenitor [Carter R et al. 2007]. 
 
2.17 Experiments with genetic crosses of AS-ART and AJ or AS-ATN and 
AJ 
 
To analyse the efficacy and composition of each of the genetic crosses and the progression of 
the drug selection proportional sequencing was used. Proportional sequencing was used with 
DNA samples from sporozoites and mice blood samples before and after drug selection.   
 
 2.17.1 Blood collection for Proportional sequencing analyses 
 
5 µl of blood were removed from each infected mice daily using a glass capillary. The blood 
was placed in an Eppendorf tube which contains 2 drops of citrate saline solution. The 
samples were then spun in a microcentrifuge at 10,000 rpm for 2 minutes, and the supernatent 
removed. The resulting pellet was frozen at -70°C. 
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 2.17.2 Extraction of parasite DNA from blood or sporozoites 
 
Frozen blood pellets and frozen sporozoites crushed were thawed at room temperature, and 
the DNA extracted using the InstaGene™ Matrix (Bio-Rad), following the manufacturers 
handbook protocol. 
 
 2.17.3 Determination of the proportions of clones in genetic crosses by 
proportional sequencing 
 
2.17.3.1 Principle of proportional sequencing 
 
The blood and sporozoite samples taken from each mouse or from the mosquitoes salivary 
glands were analysed using Proportional Sequencing. This technique allows the determination 
of the percentages of each parasite in a mixture on a given day of the infection. By applying 
this technique it was possible to determine the proportions of two parasites in mixed 
infections over the course of an infection.  
To directly quantify the proportions of the sensitive (AJ) and resistant (AS-ART and AS-
ATN) parasites present in the selected and unselected mixed infections, DNA was amplified 
by nested PCR at the dhps locus using primers common to non-polymorphic sequences from 
both parental alleles. The resulting PCR products were purified and sequenced. Sequencing 
results were analyzed using the SeqED v 1.0.3 software (Applied Biosystems, Inc., 1992), 
which allows the visualization of chromatograms of sequenced DNA and the quantitation of 
individual fluorescent peaks.  
The relative heights of peaks at the polymorphic sites in these genes can be used as an index 
of the relative proportions of the AJ and AS-ART and AS-ATN parasites in each sample. 
With five replicate samples, and with reference to a calibrated series of mixtures between AS 
and AJ [Cheesman SJ et al. 2003], it is possible to estimate the percentage of parasites 
carrying the AS or AJ alleles of each gene with a standard error of <3% [Hunt P et al 2005].  
A detailed description of the Proportional Sequencing technique is available elsewhere [Hunt 
P et al. 2005]. Briefly, the technique exploits the fact that during a PCR reaction, DNA is 
amplified in proportion to the initial template. If DNA containing a mixture of both AS and 
AJ type alleles is amplified in the same reaction, then the proportions of these clones will 
remain constant throughout the PCR. This means that the amplified PCR product will contain 
the same proportions of AS-ART or AS-ATN and AJ DNA as the template DNA that was 
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amplified. When this DNA is sequenced, it is possible to determine the proportions of the 
clones in a population by measuring the proportions of a single base that differs between 
them. 
For example it is possible to distinguish AJ and AS-ART or AS-ATN parasites by 4 single 
nucleotide polymorphisms on the pcdps gene. As an example the gene and the polymorphisms 
will be presented on Figure 13. 
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Figure 13- The four polymorphisms on the pcdhps gene that allowed differentiating between strains AS and AJ. 
Numbers 1-4 correspond to the polymorphisms. Primers are presented in bold. 
From Hunt P et al. 2005, with kind permission of Dr. Paul Hunt. 
 
When both these parasites are present in an infection, both bases will be present at positions 
indicated in Figure 13 with numbers 1-4 in the sequence. By measuring the proportions of 
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each base (by comparing the size of the peaks on a sequence chromatograph) it is possible to 
determine the proportions of each parasite in the mixture.  
 
2.17.3.2 Proportional sequencing - PCR reagents and reaction 
conditions 
 
Extracted parasite DNA was subjected to a nested PCR, amplifying a portion of the dhps gene 
that contains single nucleotide polymorphisms between AS-ART and AS-ATN and AJ. The 
oligonucleotide primers used were as follows: 
 
pcdhps: 
Outer PCR  
pcdhps –11 : GTACGCAGAATATTTCAAATG 
pcdhps –12 : CTTTTTATTGGGTATTCAAGG 
 
Inner PCR  
pcdhps –07 : CTTTTGTTTCTCATAATCCAG 
pcdhps –08 : GGTTTAGGTTTTGCAAAGAA 
 
Individual PCR reactions were carried out in 50µl volumes containing 10pM of both 
oligonucleotides, 1 X PCR buffer, 1 X dNTP solution, 1 unit Taq DNA polymerase 
(Boehringer Mannheim), and 20µl of extracted DNA solution from for the outer PCR and 1µl 
of the resulting PCR product for the inner PCR. Negative controls were also prepared, which 
contained 1µl of sterile distilled water in place of template DNA. Positive controls were 
prepared using a previously amplified DNA template.  
PCR reactions were carried out using an UNO-Thermoblock machine (Biometra), under the 
following standard conditions;  
 
Denaturing 95°C for 1 minute 
Annealing 52°C for 1 minute 
Extension 65°C for 1 minute 
 
x 30 cycles 
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PCR conditions were the same for both rounds of the nested reaction.  
PCR products were run and visualized on a 1.5% agarose gel in TBE solution. The resulting 
PCR products were then purified using the QIAGEN QIAquickTM PCR purification kit, 
following the manufacturer’s instructions. 
 
2.17.3.3 Proportional sequencing – Sequencing and purification 
of PCR products 
 
Sequencing PCR reactions were set up using the ABI PRISM Big DyeTM Terminator Cycle 
Sequencing Ready Reaction Kit, (PE Applied Biosystems). PCR reactions were prepared to a 
final volume of 10µl, containing the following reagents: 4µl template DNA (100-250ng), 4µl 
Terminator Ready Reaction Mix, 1µl primer (3.2pmol), 1µl sterile distilled water  
Sequencing PCR conditions were as follows;  
 
Denaturing 95°C for 30 seconds 
Annealing 50°C for 20 seconds 
Extension 60°C for 4 minutes 
 
Following the sequencing PCR, the products were purified by precipitation with sodium 
acetate and 95% ethanol, and washed in 70% ethanol. 
For sequencing of purified PCR products, internal primers covering the extreme 5’ and 3’ 
ends of the fragments were used. All fragments were sequenced in opposite directions. 
 
2.17.3.4 Proportional sequencing – Analyses of sequencing 
results 
 
Sequencing results were analysed using the SeqED V 1.0.3 software (Applied Biosystems 
Inc., 1992). The programme allows the visualisation of chromatograms of the sequenced 
DNA. The relative proportions of the two strains in each sample were determined by 
measuring the two peaks associated with the single nucleotide polymorphism that confers 
pyrimethamine resistance. It was possible, therefore, to calculate the percentages of each 
allele of a gene in each sample. For an example of a gel for proportional sequencing for the 
gene pcdhps see Figure 14. 
x 25 cycles 
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Figure 14 – Example of an electropherogram for proportional sequence analysis of two polymorphisms on the 
pcdhps gene. Numbers 1 and 2 represent a polymorphism number; both numbers correspond to the 
polymorphism number on Figure 13. 
From: Hunt P et al. 2005 with kind permission of Dr. Paul Hunt.  
1 2
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2.18. Amplification and sequencing of the ubp-1 gene of P. chabaudi 
 
The amplification and sequencing of ubp-1 gene has done using the same protocol as the one 
described for mdr1, cg10, tctp and atp6 genes, and this protocol is already described in 2.13. 
Genomic DNA was used as template in 50µl PCR reactions, containing 0.2µM of each 
oligonucleotide primer, 1x PCR buffer (Promega), 2.5 mM MgCl2, 0.2mM dNTPs and 
0.025U/µl of Taq DNA polymerase. These were used in PCR amplifications of AS-15CQ, 
AS-30CQ, AS-ATN and AS-ART. Negative controls were also prepared, which contained 1µl 
of sterile distilled water in place of template DNA. Positive controls were prepared using a 
previously amplified DNA template.  
The oligonucleotide primers sequence is presented in Appendix 4. 
All PCR reactions were carried out using a UNO-Thermoblock machine (Biometra).  
PCR products were run on a 2% agarose gel in TBE solution and visualized under UV. 
Products were purified using the QIAquick PCR Purification Kit from QIAGEN and 
sequenced using BigDye chain termination v3.1 (Applied Biosystems). The sequencing 
reactions were analysed by Macrogen®. The primers used in sequencing reactions were those 
used for the initial amplification of the fragments.  
Gene and predicted amino-acid sequences were manually compiled, and then compared 
between drug selected and unselected clones using an internet-based interface denoted 
Multiple Sequence Alignment with hierarchical clustering [Corpet F et al. 1998], using 
default alignment parameters (http://prodes.toulouse.inra.fr/multalin/ multalin.html).  
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The results of the present work are divided into three chapters:  
 
• Chapter III describes the results of experiments designed to select artemisinin and 
artesunate resistant parasites. These experiments also involved evaluation of certain 
resistance features such as stability. 
 
• Chapter IV describes the results of experiments designed to analyse the involvement of 
previously described putative genetic modulator for artemisinin and artesunate resistance, 
the P. chabaudi genes mdr1, cg10, tctp and atp6.  
 
• Chapter V is concerned with the results of experiments on genetic crosses between an 
artemisinin resistant (AS-ART) and a sensitive (AJ) cloned strain of P. chabaudi and an 
artesunate resistant (AS-ATN) and a sensitive (AJ) cloned strain of P. chabaudi. 
Presented here are also the results of LGS experiments conducted with the uncloned 
recombinant progenies of the genetic crosses. 
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CHAPTER III 
 
EXPERIMENTS FOR DRUG SELECTION OF ARTEMISININ 
AND ARTESUNATE RESISTANCE  
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This chapter presents the results of experiments to select artemisinin and artesunate resistance 
in P. chabaudi, of stable phenotype, of cloning the parasite lines obtained and in the 
characterization of the resistance obtained, including its stability. 
 
3.1. Introduction 
 
The objective of this part of the project was to select artemisinin and artesunate mutants in the 
rodent malaria P. chabaudi, through prolonged exposure of drug-sensitive lines to low and 
increasing levels of the drug, administered to mice. 
Table 7 depicts the maximum doses tolerated by the progenitor parasite lines as established in 
preliminary work. 
 
Table 7 – Maximum doses tolerated by the progenitor parasite lines used to select for resistance. 
 
P. chabaudi  Maximum dose for 
artemisinin (mg/kg/day) 
Maximum dose for artesunate 
(mg/kg/day) 
AS-15CQ 1.2 2 
AS-30CQ 4 1.6 
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3.2 Artemisinin drug selection 
 
P. chabaudi clone AS-30CQ was exposed to gradually increasing concentrations of 
artemisinin, during several consecutive passages in mice, starting with a drug dose of 4 
mg/kg/day, previously determined to be subcurative for these parasites (data not shown). See 
Table 7. 
The drug selection procedure is described in more detail in the Materials and Methods 
Chapter (see Point 2.8) and summarized in Figure 15.  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Figure 15 – A schematic representation of the artemisinin selection procedure. AS-ART* is uncloned. 
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Figure 16 represents the stepwise increase in drug dose during the artemisinin selection 
procedure.  
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Figure 16 – The increase of the artemisinin dose (mg/kg/day), tolerated by AS-30CQ clone, during 15 blood 
passages.  
 
Figure 16 shows the stepwise increment on the artemisinin dose during selection, starting by a 
4 mg/kg/day dose of artemisinin, this dose being the maximum dose tolerated by the initial 
parasites, AS-30CQ.  
The drug resistance selection process lasted for approximately 27 weeks (approximately 7 
months); meaning that during this period the P. chabaudi parasite clone AS-30CQ was kept 
under increasing drug pressure until a concentration of 60 mg/kg/day, at the end of which 
resistance seemed to have been selected. Due to time constrains the selection process was 
finished at this stage where stability of resistance was assayed.  
In the first four passages under drug pressure, the total increment on the artemisinin dose was 
of only 6 mg (from first passage to passage number 10) only from passage number five 
onwards we were able to increase 5mg of ART on each passage. 
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Figure 17 – The day of recrudescence on each passage under selection and artemisinin dose (mg/kg/day). 
 
Figure 17 shows the stepwise increment on the artemisinin dose during selection, and time of 
recrudescence.  
The day of recrudescence was considered during the selection procedure as an indication on 
the parasite sensitivity to artemisinin. However, after the five passages, it was noticed that the 
time of parasite presence under pressure remained roughly the same; though drug pressure 
was increased a few fold.  
At the end of the selection procedure, assays were carried out to confirm that a parasite 
resistant line to artemisinin was obtained. This was established by the determination of the 
minimum curative dose (MCD) of each drug from the selected and original sensitive parasite 
populations.  
MCD was defined as the minimum dose of each drug that would prevent recrudescence 
within each treated group at any time during the first 10 days of the follow-up period.  
A resistance index was determined using the following equation: 
 
N-fold resistance = MCD drug selected parasites/ MCD drug unselected parasites 
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Table 8 – N-fold resistance, using the equation above and calculated for each passage under artemisinin 
pressure. The MCD drug pressure for the 1st passage is 4 mg/kg/day, which was the initial drug dose tolerated by 
the AS-30CQ clone used for drug selection. 
 
Number of blood 
passage under 
artemisinin pressure 
MCD drug selected 
parasites 
(mg/kg/day) 
N-fold resistance  
(MCD drug selected parasites/ 
MCD drug unselected 
parasite) 
1 4 1 
2 6 1.5 
3 6 1.5 
4 8 2 
5 10 2.5 
6 15 3 
7 20 3.5 
8 25 3.8 
9 30 4 
10 35 4.5 
11 40 5 
12 45 7.5 
13 50 10 
14 55 12.5 
15 60 15 
 
At the 15th passage, when due to time constrain limitations the selection procedure was 
stopped, the parasite line obtained, denoted AS-ART*, (* uncloned parasite population). AS-
ART* has an N-fold resistance of 15 when compared to the initial parasite clone and was 
cloned by the method of limiting dilution [Rosario V, 1976]. See Section 3.4. 
Cloned parasites were re-tested for their responses to artemisinin. 
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3.3 Artesunate drug selection 
 
To select for artesunate resistance, P. chabaudi clone AS-15CQ, was exposed to gradually 
increasing concentrations of artesunate during several consecutive passages in mice, starting 
with a sub curative drug dose of 2 mg/kg/day. See Table 7. 
The procedure was the same as for artemisinin drug selection and is described in more details 
in materials and methods (See Section 2.8) and previous on Section 3.2 and a schematic 
representation of the protocol can be seen on Figure 18. 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Figure18 – A schematic representation of the artesunate selection procedure. AS-ATN* is uncloned. 
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Figure 19 represents the stepwise increase in drug dose during the artesunate selection 
procedure.  
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Figure 19 – The increase of the artesunate dose (mg/kg/day), tolerated by AS-15CQ clone, during 14 blood 
passages.  
 
Figure 19 shows the stepwise increment on the artesunate dose during selection, starting by a 
2 mg/kg/day dose of artesunate, this dose being the maximum dose tolerated by the initial 
parasites, AS-15CQ.  
The drug resistance selection process finished at the 14th passage when the parasite tolerance 
had increased to 12 mg/kg/day, due to time constrains the selection process was finished at 
this stage where stability of resistance was assayed.  
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Figure 20 – The day of recrudescence under selection and artesunate dose (mg/kg/day). 
 
Figure 20 shows the stepwise increment on the artesunate dose during selection versus the day 
of recrudescence.  
As stated before the time of recrudescent parasites appearing in the blood of treated mice was 
used during the selection procedure as an indication on reduced susceptibility to artesunate. 
Here, and in a different fashion from artemisinin, the selection of artesunate resistance was 
carried out in a more consistent increase of the drug pressure within roughly the same period 
of time. It is speculated that this is related to the metabolism of the drug. Thus, being a second 
generation derivative of artemisinin, it is more active than artemisinin itself in the process of 
eliminating the parasites.  
The minimum curative dose (MCD) for artesunate was calculated the same way as for 
artemisinin.  
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Table 9 – N-fold resistance calculated for each passage under artesunate pressure. The MCD drug unselected 
parasites is 2 mg/kg/day, which was the initial drug dose tolerated by the AS-15CQ clone initially used for drug 
selection. 
 
Number of blood 
passage under 
artesunate pressure 
MCD drug selected parasites 
(mg/kg/day) 
N-fold resistance  
(MCD drug selected 
parasites/ MCD drug 
unselected parasite) 
1 2 1 
2 2.5 1.2 
3 3 1.5 
4 3.5 2 
5 4 2.2 
6 5 2.5 
7 6 2.5 
8 7 3 
9 8 3.5 
10 9 4 
11 10 4.5 
12 10 5 
13 11 5.5 
14 12 6 
 
At the 14th passage at the end of the selection procedure, the parasite line obtained, denoted 
AS-ATN*, (* uncloned parasite population). AS-ATN* has an N-fold resistance of 6 when 
compared to the initial parasite clone and was cloned by the method of limiting dilution 
[Rosario V, 1976]. See following Section 3.4. 
Cloned parasites were re-tested for their responses to artesunate. 
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3.4 Cloning of resistant parasites 
 
At the end of the selection procedure, it was considered that a significant level of resistance to 
both to artemisinin and artesunate had been obtained. The N-fold level of resistance was 
calculated. The artemisinin resistant parasite line AS-ART* was 15 fold more resistant than 
the initial clone AS-30CQ; the artesunate resistant parasite line AS-ATN* was 6 fold more 
resistant to ATN than the initial clone AS-15CQ. 
Both parasite populations were cloned by the limiting dilution method. (See Section 2.5 for 
details). The cloning procedure is extensively described at Rosario V 1976. 
From the cloning procedure of the parasite line AS-ART*, from the 50 mice inoculated, five 
mice developed patent parasitemias (10 % infection rate ) from which parasites were 
harvested and frozen in liquid nitrogen  
From the cloning procedure of the parasite line AS-ATN*, from the 50 mice inoculated, seven 
mice developed patent parasitemias (14% infection rate) from which parasites were harvested 
all frozen in liquid nitrogen. 
Of these, one clone from each line was chosen on the basis of their faster growth rate, for 
further studies, including stability assays and genetic crosses and analysis. The artemisinin 
and artesunate resistant clones were designated P. chabaudi AS-ART and AS-ATN 
respectively. See Figure 21 for details. 
 
 
 
 
Figure 21 – A schematic representation of the clones and parasite lines of Plasmodium chabaudi used in this 
project. 
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AS-ART and AS-ATN were tested for their response to artemisinin and artesunate 
respectively, immediately after cloning. AS-ART and AS-ATN clones were inoculated into 
naïve CD1 mice and then re-tested for their susceptibility to artemisinin and artesunate, by 
comparing their response to each drug with that of non-treated and passaged the same number 
of times as the parasites under selection, control parasites, AS-30CQ and AS-15CQ 
respectively.  
AS-ART and AS-ATN were shown to retain the same phenotype as that of the drug-resistant 
population from which they had been derived, under the same drug pressure of respectively 
60 mg/kg/day treatment for 5 days with artemisinin, or a 12 mg/kg/day treatment for 5 days 
with artesunate. These parasites were then used in subsequent studies to investigate further 
whether the observed drug resistance was stable. These results will be presented on Section 
3.5. 
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3.5 Drug resistance stability tests  
 
Once resistance to artemisinin and artesunate were selected and cloned stability of the 
resistant phenotype, under absence of drug pressure was assayed.  
Drug-resistant parasite clones, AS-ART and AS-ATN were re-tested for their drug responses 
after each of three different procedures: 
i) Freeze-thawing cycles in liquid nitrogen,  
ii) 12 continuous sub inoculations in mice in the absence of drug treatment and  
iii) Transmission through Anopheles stephensi mosquitoes into new mice. 
N-fold resistance index was calculated as it has been previously described. 
 
 3.5.1. Resistance stability after liquid nitrogen preservation (deep-
freezing) 
 
To check for resistance stability after liquid nitrogen preservation, resistant clones were 
frozen down in liquid nitrogen and then thawed, and re-tested for resistance.  
Briefly infected blood is drawn, when the majority of asexual parasites are at the ring stage of 
development, into heparinised syringes. The red blood cells are pelleted by centrifugation 
(2000 rpm for 5 minutes) and the majority of the plasma is removed, two volumes of deep-
freeze solution (Appendix 1) are added to one volume of the packed red blood cells with 
constant mixing in a drop wise fashion. Such material, inoculated i. p. into a mouse, after any 
period of storage, induced an infection, which became patent from 7-14 days after 
inoculation. The parasites growing in this fashion were evaluated for their response to 
artemisinin or artesunate in comparison with unselected control parasites, the same way as 
during the drug resistance selection.  
AS-ART and AS-ATN parasite clones phenotypes drug resistance remained unchanged in 
both cases. The two cloned lines retained a 15 and 6 times N- fold resistant phenotype 
respectively. The parasites response to the drug was the same after freezing and thawing. 
Stability of resistance was therefore, confirmed. 
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 3.5.2. Resistance stability after blood passages in the absence of drug 
pressure 
 
AS-ART and AS-ATN cloned parasites were subjected to 12 passages in untreated mice, after 
which they were tested for their drug responses.  
Briefly, 107 infected red blood cells were established as the standard parasite number to be 
infected into individual mice. Infections in the absence of drug pressure were maintained by 
passaging resistant parasites twelve times in CD1 mice i. p. route. Treatment was 60 
mg/kg/day for 5 days for ART and as 12 mg/kg/day for 5 days for ATN.  
Once drug tests were preformed after the twelve passages in the absence of drug treatment, it 
was verified that the resistant phenotype maintained because resistant parasites recrudesced as 
expected while sensitive parasites did not. 
Resistant clones retained resistance to the corresponding drug.  
 
3.5.3. Resistance stability after cyclical transmission through 
mosquitoes 
 
After confirming the stability of the resistance phenotype after cloning, freezing and thawing 
of these clones, in the absence of drug pressure, it was necessary to demonstrate that this 
genetic trait was transmissible through mosquitoes. 
The procedure for cyclical transmission through mosquitoes was previously described by 
Landau and colleagues [Landau I et al. 1966].Briefly, infected splenectomised rats, in which 
gametocytes were present, were exposed to mosquitoes, which had been starved for 24-48 
hours. The infected rodents were exposed to mosquitoes for a varied length of time (1-2 
hours) depending on the feeding performance of the mosquitoes. Seven to ten days later a 
small number of mosquitoes were dissected in order to count the number of oocysts, which 
had developed on each midgut. Fifteen and, eventually, seventeen days after the blood meal, 
when sporozoites were present in the salivary glands, an uninfected mouse was exposed to the 
mosquitoes for transmission of the malaria infection. Patent blood infections could be 
detected after 4-8 days in blood smears from the mice. Resistant clones successfully 
transmitted in this fashion were tested for their response to artemisinin or artesunate in 
comparison with unselected control parasites.  
Mice infected with AS-ART or AS-ATN were used to feed A. stephensi mosquitoes. AS-ART 
was successfully transmitted through mosquitoes on two separate occasions, and the resulting 
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blood forms that developed in mice were renamed AS-ARTA and AS-ARTB. The N-fold 
resistance index of AS-ARTB were then assessed in parallel to the, untreated but passaged 
control line, AS-30CQ (this line was also transmitted through mosquitoes at the same time, as 
a control). AS-ARTB showed an N-fold resistance index of 15-fold to artemisinin relative to 
AS-30CQ. Thus, artemisinin resistance remained stable after transmission of the resistant 
parasites through mosquitoes. AS-ARTA was not tested and the parasites where deep-frozen. 
For simplicity and clarity on further analysis during this project, AS-ARTB clone was 
renamed AS-ART. 
In a similar fashion, AS-ATN was also subjected to mosquito transmission and showed a 6-
fold increase in the N-fold resistance to artesunate relative to sensitive control; therefore we 
also consider artesunate resistance to be stable after mosquito transmission. See Figure 22 for 
a summary of the drug selection / stability tests procedure. 
 
 
 
 
 
 
 
 
 
 
 
Figure 22 – A schematic representation of the artemisinin and artesunate selection procedure.  
Clone AS-30CQ and parasite line AS-15CQ were passaged in the absence and presence of gradually increasing 
doses of drug (artemisinin and artesunate, respectively). Initial drug sensitivities (4 mg/kg/day or 2 mg/kg/day) 
decreased (to 60 or 12 mg/kg/day) after 15 or 14 passages, respectively. The drug responses after cloning, 
passage in the absence of drug (“untreated”) and transmission through mosquitoes remained unchanged. Control 
selection procedures in the absence of drug are also shown.  
Adapted from: Afonso A et al. 2006. 
 
The artemisinin and artesunate resistance phenotypes were unaltered after passaging in the 
absence of drug pressure, after freezing and thawing and after transmission through laboratory 
mosquitoes (Figure 22). Thus artemisinin and artesunate resistance obtained in our rodent 
model P. chabaudi is stable, indicating that resistance is likely to be genetically encoded. 
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3.6 Test for cross-resistance between artemisinin and artesunate clones  
 
In order to evaluate whether the mechanisms of resistance to artemisinin and to artesunate 
share similar features, the responses of AS-ART to artesunate and AS-ATN to artemisinin 
were tested, resistant clones were cross tested with each other’s selective drugs. Artemisinin 
at chosen dose was given to the artesunate resistant clone (AS-ATN) and artesunate at chosen 
dose was given to the artemisinin resistant clone (AS-ART).  
For these tests several drug doses were initially tested for both resistant clones, the maximum 
dose of artemisinin tolerated by the artesunate resistant clone (AS-ATN) is 32 mg/kg/day for 
five days and the maximum dose of artesunate tolerated by the artemisinin resistant clone 
(AS-ART) is 8 mg/kg/day (data not shown). AS-ART showed a five-fold increase in the 
MCD to artesunate relative to AS-30CQ while AS-ATN showed a greater than ten-fold 
increase in the MCD to artemisinin, relative to AS-15CQ. These tests therefore revealed that 
both clones showed cross-resistance and that in both parasites there were greater increases in 
artemisinin resistance (15–26 fold) than for artesunate resistance (5–6 fold). The 
demonstrated cross-resistance suggests some sharing of genetic or pathways features in the 
parasites clones described here. Thought the existence of cross-resistance suggests that 
resistance to artemisinin and artesunate do share similar features, at least in the parasites 
clones described in this project. 
 
Table 10 - N-fold resistance of P. chabaudi AS-ATN and AS-ART. The absolute and relative (N-fold) drug 
sensitivities of AS-ATN and AS-ART after blood passage in the absence of treatment, freeze/thaw and mosquito 
transmission are given. MCD – minimum curative dose.  
From: Afonso A et al. 2006. 
 
P. chabaudi MCD ATN 
(mg/kg/day) 
MCD ART 
(mg/kg/day) 
N-fold ATN N-fold ART 
AS-15CQ 2 1.2 - - 
AS-ATN 12 32 6 26 
AS-30CQ 1.6 4 - - 
AS-ART 8 60 5 15 
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3.7 Discussion 
 
Drug resistance genetic basis can be study using various methodologies. A correct and 
complete method to study drug resistance genetics depends on firstly selecting drug resistance 
mutants of stable phenotype, because only the presence of a stable phenotype guarantees that  
resistance is genetically encoded and not a physiological adaptation to the constant presence 
of drug pressure. Drug resistance can be selected in vitro using for example chemical 
mutagenesis or in vivo by drug pressure either using a single very high dose like the method 
used to select PYR resistance or by progressively increasing the drug concentration. The latter 
situation is the one that most closely mimics the actually scenario taking place in natural 
parasite populations. Therefore, an appropriate method that has been used for selecting and 
understanding drug resistance is the utilization of genetically stable resistant mutants selected 
through drug pressure, originated from cloned sensitive parasite lines. Both the original drug-
sensitive and the selected drug-resistant parasites should be genetically identical, (or 
isogenic), except for any mutations involved in resistance; such mutations can then be 
pinpointed using different approaches.  
This project represents the first study where malaria parasites with genetically stable and 
transmissible resistance to the antimalarial drugs artemisinin and artesunate were selected and 
used in genetic crosses. 
The reasons for obtaining stable resistance where others have previously tried unsuccessfully 
are not clear. One reason could be the use of the rodent model P. chabaudi, which had been 
used before to select for pyrimethamine, chloroquine and mefloquine resistance. The 
existence of parasite clones with an accumulation of drug resistance genetic markers may 
create a favourable background for the selection of artemisinin and artesunate resistance. 
Two parasite lines were selected and cloned: AS-ART is 15 times more resistant to 
artemisinin than its progenitor parasite line, AS-30CQ and AS-ATN which is 6 times more 
resistant to artemisinin than its progenitor parasite line, AS-15CQ.  
In this work the utilization of approximately the same number of blood passages, during a 
similar time period under drug pressure, produced an N-fold resistance for artesunate inferior 
to the N-fold resistance for artemisinin and this is not explainable.  
Metabolization differences between the two drugs may have had an intrinsic difference in the 
selective pressure within the host, but drug concentration studies were not carried out. 
A very interesting finding during this part of the project was the cross resistance between the 
selected resistant clones, giving a very strong indication that resistance to ART and ATN 
share similar features. 
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The successful selection of these parasites and the fact that they can be transmitted through 
Anopheles sp. mosquitoes is a significant achievement for two main reasons: a) these 
observations demonstrate that malaria parasites are genetically and biologically capable of 
sustaining stable resistance to artemisinins which had been selected through drug pressure. 
Consequently, it is also conceivable that, in human malaria, artemisinin resistance may appear 
in the future due to extensive and/or inappropriate drug usage; once it does, it may spread in 
the parasite population and become established; b) the resistant P. chabaudi parasites reported 
here could then be used to investigate the genetic determinants of resistance to these drugs.  
It was possible to generate ART or ATN resistance from two different parasite clones, AS-
30CQ and AS-15CQ which were already resistant to chloroquine and pyrimethamine. Efforts 
to generate ART or ATN resistance from the very original chloroquine sensitive clone (AS-
PYR), were abandoned, because this clone showed, under the same drug pressure 
methodology, high susceptibility to the treatments (data not shown). As stated before, this 
may be a result of a genetic ability, if not potentiation of the parasite ability to generate 
mutations in response to drug treatment (called the “Accelerated Resistance to Multiple 
Drugs” (ARMD) phenotype) [Rathod PK et al. 1997] which might have occurred during the 
generation of previous drug selective methods, including chloroquine. 
Alternatively, it is possible that the ART resistance phenotype is only expressed in 
chloroquine resistant clones, almost as resistance to CQ is required for the selection of ART 
and ATN.  
This suggests the presence of functional interactions between the pathways underlying 
chloroquine and artemisinin resistance or that resistance to cloroquine genetically creates 
genetic conditions which facilitate the appearance of ART and ATN resistance. These 
questions have significant relevance to the practical lifetime of a drug in areas where 
resistance to other drugs (or to chloroquine specifically) is prevalent. 
The inspection of mutation or mutations underlying resistance to ART and ATN, will be 
described in Chapter IV (known or suspected mutations) and in Chapter V using high-
throughput comparative genomic studies based on genome-wide approaches, Linkage Group 
Selection (LGS) (new mutations) [Culleton R et al. 2005].  
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4.1. Sequencing of P. chabaudi mdr1, cg10, tctp and atp6 genes, in the 
selected mutant clones. 
 
The first objective of this research work was the selection resistant parasites in the rodent 
malaria model, P chabaudi, to artemisinin and artesunate and this was achieved. At this stage 
in order to see if there were differences in the previously described putative genetic 
modulators for artemisinin and artesunate resistance, P. chabaudi genetic homologues of the 
P. falciparum mdr1, crt, tctp and atp6, between the sensitive and the resistant parasites, DNA 
was extracted was extracted from the parasites AS-15CQ and AS-30CQ, and from their 
related artemisinin (AS-ART) and artesunate (AS-ATN) resistant clones.  
 
4.1.1 Isolation of the mdr1, cg10, tctp and atp6 P. chabaudi orthologues 
 
Prior to the present work, the P. chabaudi homologues of the P. falciparum genes pfmdr1 and 
pfcrt, which are respectively pcmdr1 and pccg10 had been identified by Cravo PV and 
colleagues and Hunt P and co-workers [Cravo PV et al. 2003; Hunt P et al 2004]. Thus, for 
PCR amplification of the pcmdr1 and pccg10 genes, oligonucleotide primers and PCR 
amplification conditions previously published were used [Cravo PV et al. 2003; Hunt P et al 
2004], based on DNA sequences characterised prior to this study (pcmdr1 AY123625 and 
pccg10 AY304549).  
The DNA sequences of the P. falciparum and P. yoelii tctp and atp6 genes were available 
online at the NCBI/NIH (National Institute of Health) database (www.ncbi.nih.gov) with the 
following accession numbers: pctctp NP_703454, pytctp AF124820, pfatp6 AB121053 and 
pyatp6 AABL01001880. To obtain the P. chabaudi orthologues of these genes, these 
sequences were retrieved and used in BLAST searches against the available P. chabaudi 
sequences (shot gun clones and genomic contigs), deposited at the P. chabaudi genome 
database (www.sanger.ac.uk). The two sequences giving significant hits were retrieved and 
used to design P. chabaudi-specific oligonucleotide primers to amplify overlapping DNA 
fragments spanning the coding region, introns and both 5’- and 3’-non-coding sequences. 
These were then used in PCR amplifications. 
Pcmdr1 gene has a nucleotide sequence identity of 75.0% to P. falciparum and 78.1% amino 
acid identity to P. falciparum. [Hunt P et al. 2004]. Its accession number is AY123625 and it 
encodes a protein of 1416 amino acids and its coding region is of 4248 base pairs.  
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For the P. chabaudi cg10 gene, there is a nucleotide sequence identity of 68.6% and amino 
acid sequence identity of 75.1% within the predicted coding region when compared to P. 
falciparum crt gene. [Hunt P et al. 2004].  
To investigate whether the P. chabaudi orthologue of Pftctp gene play a role in the resistance 
to artemisinin derivatives in our model, P. chabaudi specific database sequences 
(www.sanger.ac.uk/cgi-bin/blast/submitblast/p_chabaudi) were used to design oligonucleotide 
primers for amplifying pctctp. Pctctp gene has an 84% identity with pftctp gene in relation to 
nucleotides and a 90 % identity to pftctp in relation to amino acid. This high degree of 
identity is a confirmation that the gene has been corrected isolated from the database. [Afonso 
A et al. 2006].  
PCR amplifications were initially carried out using genomic DNA from the drug-sensitive 
parasite clone AS-SENS, according to the gene sequence and primer sequence presented at 
the appendix 2, the P. chabaudi tctp gene was first characterised in the drug-sensitive parasite 
AS-SENS (Genbank accession number AY304545).  
In AS-SENS, the gene is encoded by a continuous open reading frame containing 516 b.p., 
which translates into a predicted peptide of 171 amino acids [Afonso A et al. 200].  
In order to identify possible point mutations in tctp gene, in artemisinin (AS-ART) and 
artesunate (AS-ATN) resistant parasites, in comparison to progenitors, DNA from AS-15CQ, 
AS-30CQ, AS-ART and AS-ATN was used to sequence the entire coding region of the pctctp 
gene. See Figure 25 for details in the extent of DNA sequence analysed. 
Pcatp6 gene has a 72% identity with pfatp6 gene in relation to nucleotides and a 72 % identity 
to pfatp6 in relation to amino acid. This high degree of identity is a confirmation that the gene 
has been corrected isolated from the database. [Afonso A et al. 2006]. The atp6 gene has a 
Genbank accession number of DQ171938. In P. chabaudi the gene was verified to be 
constituted of 3539 nucleotides, comprised of three exons interrupted by two introns one of 92 
nucleotides and the other of 90 nucleotides. 
The pcatp6 gene has two introns (intron 1: 92 bps; intron 2: 90 bps) located near the 3´end of 
the gene and in identical positions to the predicted introns in the P. falciparum gene (See 
Figure 26 for details). The full coding sequence translates into a predicted protein of 1118 
amino acids. . Due to the fact that pfatp6 has been pointed as the target for artemisinin the 
non-coding region that lay in the proximal region of the gene was also checked for gene 
mutations, because in the case of existing these mutations could eventually affect the level of 
transcription. However, no differences in nucleotide sequence between the resistant clones 
and their sensitive progenitors were found in 4kb of nucleotide sequence upstream or in 1 kb 
downstream of the gene.  
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The gene sequence and the primers used for amplification of all of the above genes are 
presented in Appendix 2. 
 
 
 
 
 
 
 
 
Figure 23 – Extent of sequence analysed for the gene pcmdr1 for the clones AS-15CQ, AS-30CQ, AS-ART and 
AS-ATN. Numbers refer to nucleotides 5’ to ‘start’ codon ATG (negative) or 3’ to termination codon (positive). 
Adapted from Afonso A et al. 2006 
 
 
 
 
 
 
 
 
 
 
 
Figure 24 – Extent of sequence analysed for the gene pccg10 for the clones AS-15CQ, AS-30CQ, AS-ART and 
AS-ATN. Numbers refer to nucleotides 5’ to ‘start’ codon ATG (negative) or 3’ to termination codon (positive). 
Adapted from Afonso A et al. 2006.  
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Figure 25 – Extent of sequence analysed for the gene pctctp for the clones AS-15CQ, AS-30CQ, AS-ART and 
AS-ATN. Numbers refer to nucleotides 5’ to ‘start’ codon ATG (negative) or 3’ to termination codon (positive). 
Adapted from Afonso A et al. 2006.  
 
 
 
 
 
 
 
 
 
 
Figure 26 – Extent of sequence analysed for the gene pcatp6 for the clones AS-15CQ, AS-30CQ, AS-ART and 
AS-ATN. Numbers refer to nucleotides 5’ to ‘start’ codon ATG (negative) or 3’ to termination codon (positive). 
Adapted from Afonso A et al. 2006. 
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4.1.2. Sequence comparisons of P. chabaudi mdr1, cg10, tctp and atp6 
in the selected mutant clones and their sensitive progenitors. 
 
AS-ATN, resistant to artesunate and its progenitor parasite line AS-15CQ and AS-ART, 
resistant to artemisinin and its progenitor clone AS-30CQ were all sequenced twice in both 
directions (sense and antisense) for all genes described above. Pairwise comparisons were 
made between sensitive and resistant clones as well as the sequence published in the P. 
chabaudi database. The result revealed that the sequence of all genes was identical between 
all parasites and between the database sequences, showing that no mutations had occurred 
during the selection of drug resistance. In other words, the genes do not appear to be involved 
in chemoresistance in the rodent malaria model P. chabaudi. 
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4.2. Estimation of gene copy numbers of the pcmdr1, pctctp and pcatp6 
genes, in the selected mutant clones. 
 
Besides gene mutations, changes in copy numbers may also be responsible for drug 
resistance. Therefore, gene copy number of pcmdr1, pctctp and pcatp6 on the previously 
selected and cloned artemisinin and artesunate mutants in P. chabaudi (AS-ART and AS-
ATN respectively) were studied. At this stage the gene pccg10 was not analysed for gene 
copy number change due to the fact that there were no references found in the literature that 
account for changes in the gene copy number of either pfcrt or its P. chabaudi homologue 
pccg10.  
The gene copy number can be analysed by various methods, the method of using real-time 
quantitative PCR (RTQ-PCR) has been extensively validated for the use in malaria parasites. 
We found that the most robust method for copy number determination by real-time PCR is the 
comparative Ct (2-∆∆Ct) method [Livak KJ et al. 2001]. While requiring an endogenous control 
and a calibrator, meaning a gene from which previous knowledge is needed for the exact gene 
number (for example msp-1 gene that is known for sure to be a single copy gene in P. 
chabaudi) and a sample that is use as a control for that gene, it differs from relative standard 
method by relying on equal PCR efficiencies with the target and the endogenous control 
genes. The 2-∆∆Ct method is described in detail by Livak and colleagues [Livak KJ et al. 2001]. 
Briefly for the ∆∆Ct calculation to be valid, the efficiency of the amplification of target and 
reference gene must be approximately equal. The control gene was msp-1 and the target genes 
were mdr1, tctp and atp6 genes. The average Ct was calculated for both control and target 
genes and the ∆Ct (Ct target gene – Ct msp-1) was determined. Different plots of the log DNA 
dilution versus ∆Ct were made and whenever the slope was close to zero the efficiencies of 
the target and reference genes were similar, the ∆∆Ct was calculated for the relative 
quantification of the target gene; ∆∆Ct= (Ct target gene - Ct msp-1)α - (Ct target gene - Ct msp-1)β, where 
α = ART or ATN resistant sample and β = AS-30CQ or AS-15CQ samples respectively.  
After the method was validated the results for each sample were expressed in N-fold numbers 
in α gene copy number with normalization to the msp-1gene copy number according to the 
equation: gene number of target = 2-∆∆Ct [Livak KJ et al. 2001]. 
After optimisation of all the RTQ-PCR conditions we aimed to investigate if ART and ATN 
resistance could be related to changes in the gene copy number of mdr1, tctp and atp6 genes. 
For this the N-fold gene number was evaluated and mdr1, tctp and atp6 genes were 
normalised to msp-1 gene, in artemisinin resistant parasites P. chabaudi AS-ART relative to 
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artemisinin sensitive P. chabaudi AS-30CQ from which this parasite line was obtained and 
artesunate resistant P. chabaudi AS-ATN relative to artesunate sensitive P. chabaudi 
AS15CQ from which this parasite line was obtained. Three independent experiments were 
carried out; the mean N-fold values of the experiments are presented in Figure 27. There were 
no changes in the gene copy number of mdr1, tctp and atp6 genes detected (Figure 27), 
meaning that during the selection for artemisinin and artesunate resistance the genes pcmdr1, 
pctctp and pcatp6 did not suffer any gene copy number change.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27 – Relative differences (N-fold) in gene copy number between artemisinin (AS-ART) and artesunate 
(AS-ATN) resistant parasites and their sensitive progenitors, AS (30CQ) and AS (15CQ) respectively.  
The y-axis represents the mean N-fold of gene number (grey bars) and standard deviations (vertical lines) at 95% 
confidence interval of each of the genes under study normalised against msp-1, generated after three independent 
assays. 
From: Afonso A et al 2006. 
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4.3. Discussion 
 
4.3.1. Summary 
 
The previously described putative genetic modulators for artemisinin and artesunate drug 
resistance, pcmdr1, pcg10, pctctp and pcatp6 that are P. chabaudi gene homologues of P. 
falciparum mdr1, crt, tctp and atp6, respectively, were fully isolated and analysed for their 
coding regions. In the case of the gene atp6 gene an area of 4kb upstream and 1 kb 
downstream was also analysed, in both the resistant clone lines, AS-ART and AS-ATN in 
relation to their sensitive progenitors AS-30CQ and AS-15CQ respectively and found to be 
not mutated.  
Collectively, the above data allowed us to conclude that in our model P. chabaudi the 
pcmdr1, pcg10, pctctp and pcatp6 genes are not involved in artemisinin or artesunate 
resistance by gene point mutation.  
Besides looking for point mutations, the genes pcmdr1, pctctp and pcatp6 were also 
investigated for their involvement in artemisinin and artesunate resistance by inspecting 
putative changes in gene copy number. This allowed us to conclude that the phenotype of 
artemisinin and artesunate resistance in our model, P. chabaudi, is also not associated with an 
increase in the gene copy number of the same genes. 
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4.3.2. General Discussion 
 
This study has shown that no changes in nucleotide sequence or copy number for pcmdr1, 
cg10, tctp or atp6 genes were found in the artemisinin or artesunate resistant parasites when 
compared to their sensitive progenitors.  
We consider, however, that other genetic mechanisms such as protein turnover and/or post-
translational modifications of the gene products may account for the involvement of these 
genes in the resistance phenotype. However the investigation of these putative mechanisms 
was not contemplated in this study.  
In malaria, the genetic mechanisms underlying drug resistance have been extensively studied 
for most antimalarials, but are not fully understood, except for resistance to pyrimethamine. 
Resistance to this drug has been to shown to be conferred by cumulative single nucleotide 
mutations in the dhfr gene [Sirawaraporn W et al. 1997] in P. falciparum and in all rodent 
malaria models analyzed. Artemisinin has been used in the field for centuries without 
resistance ever being registered, so one might expect a complex mechanism for resistance, not 
as simple as that for pyrimethamine. 
In our study in a rodent malaria model, we selected for high levels of drug resistance, which 
suggests the involvement of more than one gene.  
The evidences supporting the role for pfatpase6 protein in artemisinin sensitivity in P. 
falciparum arise from the interaction of artemisinin in an ex vivo heterologous system 
(Xenopus oocytes) [Eckstein-Ludwig U et al. 2003] which may reflect a histological, 
physiological and biochemistry point of view which may be difficult to interpret in light of the 
human malaria parasite. Evidence for the involvement of this gene in modulating artemisinin 
susceptibility also came from the fact that recent evidence indicates that mutations in the 
pfatpase6 gene may correlate with varying degrees of in vitro responses of P. falciparum to 
artemisinin derivatives [Jambou R et al. 2005]. In this case the pfatpase6 protein S769N, 
A623E and E431K polymorphisms were associated with an increased mean in the IC50 for 
artemisinins [Jambou R. et al. 2005]. The importance of these findings is unclear however, 
since: i) the correspondence between reduced sensitivity of the field isolates to artemisinins 
and the presence of the different polymorphisms was incomplete and ii) there was a region-
specific association of these polymorphisms with varying degreees of susceptibility 
correlating highly (but not completely) with the S769N mutation in French Guiana but not in 
Senegal or Cambodia. In addition, later studies found no association between mutations in the 
pfatpase6 gene and the sensitivity of field isolates to artemisinins from Tanzania [Mugittu K 
et al. 2007] and São Tomé and Principe [Ferreira ID et al. 2007].  
 148 
Interestingly, it may be possible that another gene closely link to the atp6 gene may be 
involved in the resistance to this drug, which could explain the strong but incomplete 
association observed in French Guiana [Jambou R. et al. 2005]. In actual fact, a similar 
scenario has already been described before with the chloroquine resistance determinant in P. 
falciparum which had been mapped by linkage analysis to a segment on chromosome 7 where 
two candidate genes cg1 and cg2 with complex polymorphisms initially linked to the 
chloroquine resistance phenotype where found [Duraisingh MT et al. 2000a, Fidock DA et al. 
2000a]. More detailed analysis within that region later revealed a different, but closely linked 
gene, pfcrt, to be the major determinant of chloroquine resistance.  
Finally, it is relevant to mention that, if pfatpase6 turns out to be the major modulator of 
artemisinin responses in P. falciparum, it is conceivable that the rodent malaria P. chabaudi 
may reveal alternative mechanisms of resistance to those of P. falciparum, as is the case with 
chloroquine resistance [Hunt P et al. 2004]. 
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5.1 Introduction 
 
As described in the previous chapter (Results – Chapter IV) sequence analysis of genes with 
potential involvement in modulating parasite responses to artemisinin derivatives, was carried 
out for the P. chabaudi orthologues of pfatp6 [Eckstein-Ludwig U et al. 2003; Jambou R et 
al. 2005; Uhlemann AC et al. 2005], pfcrt [Sidhu AB et al. 2002], pfmdr1 [Ferrer-Rodríguez I 
et al. 2004; Price RN et al. 2004; Reed MB et al. 2000; Sidhu AB et al. 2005], and pftctp 
[Bhisutthibhan J et al. 1998; Walker DJ et al. 2000]. Sequencing of AS-ART and AS-ATN 
and their progenitors showed that there were no mutations or copy number changes in these 
genes (data published Afonso A et al. 2006). 
This chapter describes the application of Linkage Group Selection (LGS) as an approach to 
identify the genetic locus or loci involved in artemisinin and artesunate resistance in P. 
chabaudi. 
Some of the results described below have been accepted for publication [Hunt P et al. in press 
at the Molecular Microbiology]. 
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5.2 Production of cross progeny 
 
The procedure to obtain a cross progeny have been already described (See Chapter II - 
Materials and Methods).  
Three independent genetic crosses were obtained using AS-ART and AJ and two independent 
genetic crosses were obtained using AS-ATN and AJ. 
One of the conditions for a correct and useful utilization of LGS for identifying genetic locus 
involved in a particular phenotypic trait, is that large numbers of recombinant progeny clones 
are present both in the progeny prior to the selection, and post selection. For that reason and in 
order to increase the number of recombinants, the uncloned progeny from these crosses 
(called “unpassaged”) were pooled in equal proportions (equal number of parasites) and 
passaged through the two treated and untreated groups. See Figure 28 for details on the 
experimental groups. 
For further analysis pooled crosses were used. Those pooled crosses were named super 
crosses. The three genetic crosses obtained between AS-ART and AJ were pooled together in 
a super cross that for clarity was named AS-ART x AJ. The two genetic crosses obtained 
between AS-ATN and AJ were polled together in a super cross that for clarity was named AS-
ATN x AJ.  
Each cross was not analysed individually during this project. 
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5.3 Selection of cross progeny 
 
5.3.1 General procedure 
 
When the sporozoites-induced infections (so called “unpassaged”) reached parasitaemias of 
between 10%–15%, the parasites were harvested for AFLP analysis (providing a reference 
point for markers analysed in the subsequent treatment groups), pooled, and inoculated (each 
mouse in each group received 1 x 107 parasites) into two groups of mice, one drug treated 
with either artemisinin or artesunate (so called “treated”) and the other left untreated (so 
called “untreated”). See Figure 28 for details. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28 - Schematic representation of the selection of the pooled cross progeny (LGS) experiment using 
previously generated individual crosses between AJ and AS-ART 
For the pooled cross AS-ATN x AJ only two individual crosses were used. 
Adapted from Culleton R, 2005 with kind permission from Dr. Richard Culleton. 
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 5.3.2 Results 
 
We passaged the pooled uncloned cross progeny in the presence and in the absence of drug 
treatment. The dose of artemisinin used for LGS in the treated group of the cross AS-ART x 
AJ was 25 mg/kg of mouse body weight daily for 5 consecutive days, starting 3h after parasite 
challenge. The dose of artesunate used for LGS in the treated group of the cross AS-ATN x 
AJ was 5 mg/kg of mouse body weight daily for 5 consecutive days, starting 3h after parasite 
challenge. These doses were chosen as a likely compromise between a very good selection, 
that would eliminate most sensitive progeny and a dose that allowed the maintenance of a still 
high number of recombinants. 
Both the artemisinin or artesunate treated and the untreated blood-stage cross progeny were 
allowed to grow to peak parasitaemia (30-40 % for untreated approximately day 8 post 
infection and 20-30% for treated approximately day 10 post infection), at which point the 
blood was harvested, and DNA was extracted for future analysis. See Figures 29 and 31: each 
point on these figures corresponds to a group of five mice; means were calculated and 
standard deviations are presented in the graphs.  
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  5.3.2.1 Selection of the pooled AS-ART x AJ cross 
 
Parasitemias of ART treated and untreated uncloned progeny of pooled cross AS-
ART x AJ
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Figure 29 - Parasitaemia curves for the “untreated” and “artemisinin treated” uncloned cross progeny of the AS-
ART x AJ cross. Each point corresponds to a mean parasitemia of an experimental group of five mice and the 
vertical bars are standard deviations. 
The dose of artemisinin used for LGS of the cross AS-ART x AJ was 25 mg/kg of mouse body weight daily at 
24-h intervals for 5 consecutive days, starting 3h after parasite challenge.  
 
Parasitaemia curves for both artemisinin treated and untreated groups are shown in Figure 29. 
The ART treated group show a delay in the parasite grow due to drug administration, though 
it does not show a very marked inhibition of parasite growth when compared to the untreated 
group, meaning there is not a very big delay on the parasite recrudescence of the treated group 
indicating presence of relative high amounts of parasites carrying the resistant allele (AS 
allele) in the polled cross used AS-ART x AJ.  
Before engaging in the genome wide analysis using AFLP, the proportions of AS and AJ 
alleles were measure to get information on the quality and genetic composition of the cross 
relative to the number of sensitive and resistant alleles, 
Quantitation of the proportion of each allele on the genetic crosses allowed us to evaluate the 
quality of the selection by calculating the percentage of the resistant allele (AS allele). 
Proportional Sequencing [Hunt P et al. 2005] estimates the proportions of alleles of a gene in 
a mixture by measuring the heights of the peaks in DNA sequence gel electropherograms 
which correspond with the nucleotides at the polymorphic sites under study (See example 
Figure 13, 14 and 30). 
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For analysing the composition of the progeny of the genetic cross AS-ART x AJ (the 
unpassaged, ART treated and untreated experimental groups), proportional sequencing of 
alleles of the dhps gene was performed.  
Each DNA sample (one from AS-ART x AJ and other from AS-ATN x AJ untreated group) 
was prepared with the blood of all mice in each experimental group pooled together. Each 
individual measurement was repeated 5 times from the PCR stage (meaning 5 different PCR 
amplifications using the same DNA sample) and a mean %AS (AS concentration in the 
mixture) was calculated for each polymorphism and for each different PCR amplification for 
the dhps gene. On Table 11 we can se the mean %AS for each one of the four polymorphism 
(named for simplicity 1-4 see Figure 13 and 30 for correspondence) obtained from the 
quintuplicate analysis for each experimental group (unpassaged, untreated and ART treated) 
and for each group another mean was calculated using each mean value obtained for each 
polymorphism each will then gives us the mean %AS on each experimental group. These 
values serve the purpose to quickly evaluate the quality of the genetic cross and its selection, 
prior the extended AFLP analysis. The approximate %AS composition for each 
polymorphism was calculated by the relative peak height corresponding to the nucleotide 
from the AS DNA sequence, normalized with a non polymorphic allele. The data normalised 
treatment is described in detail by Hunt P and colleagues [Hunt P et al. 2005].  
Proportional sequencing protocols are described before (see Materials and Methods - Chapter 
2) and in great detail in Hunt P et al, 2005. 
 
 
 
 
 
 
 
Figure 30 – Detail of the pcdhps gene sequence with indication of polymorphisms in red and bold, 1-4 numbers 
in blue are the numbers used in Tables 11 and 12 to indicate each one of the polymorphism between AS and AJ. 
For entire sequence of the gene please check Figure 13. 
AS – AATCGAGAAACAGAATGATAAATTAAATCAAAATAACCTATCTTTAC 
AJ - --------------------------T-----------------------G--------------------------------------------- 
1  2                                                    
                        3                                                          4 
     AS –AAACAAAAACATCAACTATTTATAAACCGCCTATAAGTATAGATACCA 
    AJ - -------A-------------------------------------------G--------------------------------------------- 
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Table 11 – Proportional sequencing results for each group of the selection procedure for the genetic cross AS-
ART x AJ (“unpassaged”, “untreated” and “artemisinin treated”) for all the polymorphisms of the dhps gene 
analysed. There are four polymorphisms between AS and AJ strains for the gene dhps, the mean %AS coming 
from the quintuplicate measurements was calculated for each polymorphism and finally a mean %AS was 
calculated as a mean between the four %AS means. 
 
 dhps gene 
(%AS) 
%AS for the dhps locus 
1 2 3 4 Mean 
Unpassaged group 43.4 42 31.4 30.4 36.8 
Untreated group 13.4 15.8 25.8 16.3 17.8 
ART treated group 42.8 39.8 37.9 36.4 39,2 
 
From the results presented on Table 11 we can observe that though the unpassaged group was 
not submitted to any kind of drug selection, the %AS does not correspond to the 50% initially 
inoculated (the initial inoculum was 50% AS and 50% AJ parasites, calculated by parasite 
numbers), which can be explained by the fact that in previous experiments (data not shown) 
AJ parasites overgrew AS, AJ is a faster grower in comparison to AS. 
As expected under drug treatment, and due to the selective pressure applied, AS overgrows 
AJ which carried the sensitive alleles, this was an expected result and gives us an indication 
that the selection pressure is being efficient. 
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  5.3.2.2 Selection of the pooled AS-ATN x AJ cross 
 
Parasitemias of ATN treated and untreated uncloned progeny pf the pooled cross 
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Figure 31 - Parasitaemia curves for the “untreated” and “artesunate treated” uncloned cross progeny of the AS-
ATN x AJ cross. Each point corresponds to a mean parasitemia of an experimental group of five mice and the 
vertical bars are standard deviations. 
The dose of artesunate used for LGS of the cross AS-ATN x AJ was 5 mg/kg of mouse body weight daily at 24-
h intervals for 5 consecutive days, starting 3h after parasite challenge.  
 
Parasitaemia curves for both artesunate treated and untreated groups for the AS-ATN x AJ 
pooled cross are shown in Figure 31. The ATN treated group show a delay in the parasite 
grow due to drug administration, thought it does not show a very marked inhibition of parasite 
growth when compared to the untreated group, meaning there is not a very big delay on the 
parasite recrudescence of the treated group indicating presence of relative high amounts of 
parasites carrying the resistant allele (AS allele) in the polled cross used AS-ATN x AJ.  
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Table 12 – Proportional sequencing results for each group of the selection procedure for the genetic cross AS-
ATN x AJ (“unpassaged”, “untreated” and “artesunate treated”) for all the polymorphisms of the dhps gene 
analysed. There are four polymorphisms between AS and AJ strains for the gene dhps, the mean %AS coming 
from the quintuplicate measurements was calculated for each polymorphism and finally a mean %AS was 
calculated as a mean between the four %AS means. 
 
 dhps gene 
(%AS) 
%AS for the dhps locus 
1 2 3 4 Mean 
Unpassaged group 21.9 13.4 24.8 31.7 22.9 
Untreated group 30.5 23.5 21.6 17.9 23.4 
ATN treated group 7.6 11.4 17.5 16.8 13.3 
 
As expected under drug treatment, and due to the selective pressure applied, AS overgrows 
AJ which carried the sensitive alleles, this was an expected result and gives us an indication 
that the selection pressure is being efficient.  
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5.4 AFLP analysis 
 
5.4.1 General procedure 
 
Once the selection pressure is applied in the genetic progeny of a cross, the parasites that 
carry the allele that is sensitive (in this case the AJ allele) will be removed, and from an 
experimental point of view this disappearance is visible by the decrease in intensity or 
complete disappearance of an AFLP band specific for the sensitive allele (AJ band). Thus, we 
were looking for the disappearing of AJ sensitive markers on the treated group (artemisinin or 
artesunate treated) in comparison to the untreated group (an example of an AFLP gel is 
represented in Materials and Methods Figure 12).  
Keeping in mind that the objective is to identify the genomic loci under drug selection either 
by artemisinin or artesunate that would correspond to a selection valley associated to the 
resistant phenotype. AFLP markers with low CIs were initially identified and positioned 
according to the previously defined genetic linkage map of Martinelli A et al. 2005. 
Subsequently, markers under selection were sequenced in order to confirm their location 
though comparative genomics, making use of a rodent malaria genetic sinteny map. 
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 5.4.2 Results 
 
We determined the CIs of 206 AJ specific AFLP markers and 119 AS specific AFLP markers.  
A table showing raw data from all markers (AS and AJ specific markers) comparative indices 
(CI) between all treatment groups is included in Appendix 5. 
When in the genetic cross AS-ART x AJ, the ART treated group was compared to the 
untreated group, 36 of the 206 AJ specific markers showed CIs of less than 0.5 (meaning a 
reduction of more than 50 % on the band intensity when comparing selected and unselected). 
These are shown in Table 13, along with their derived positions as located on the genetic 
linkage map, assigned by Martinelli A and colleagues [Martinelli A et al. 2005]. Those 
positions only correspond to their localization on the genetic map, prior from sequencing of 
each individual band, which then will eventually allowed a physical position on the parasite 
chromosome. The markers that were further analysed are represented in grey in the table.  
By assigning AFLP markers to the P. chabaudi genetic linkage map, it was possible to 
generate graphs showing the change in marker intensities between treatment groups as they 
appear across the P. chabaudi genome. 
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  5.4.2.1 AFLP analysis for the AS-ART x AJ 
 
Table 13 - CI of AJ specific AFLP markers under selection in the ART treated group, compared to the untreated 
group for the AS-ART x AJ genetic cross, and their P. chabaudi chromosomal locations according to the genetic 
linkage map.  
Group 2, 12, 16 and 38 are linkage groups that could not be assigned to any particular chromosome. No data 
means there is not any data for the chromosomal position of this marker.  
Unlinked means a marker that is not linked to any chromosome or group. The marker name, when a marker 
shows reduction in both crosses AS-ART x AJ selected with ART and AS-ATN x AJ selected with ATN is 
coloured in orange. In grey, AJ specific AFLP markers that showed high reduced CI that were sequenced. 
 
 
Marker name Comparative intensities (CI) 
P. chabaudi chromosomal location in genetic 
linkage map according to Martinelli A et al. 
2005 
AJAC03TA 0.4797 Chromosome 1 
AJTT05AT 0.1252 Chromosome 6 
AJTA01CA 0.4483 Chromosome 7 
AJGA03AC 0.4496 Chromosome 7 
AJTG02AT 0.4702 Chromosome 7 
AJAG03AG 0.3000 Chromosome 8 
AJTT02AT 0.1500 Chromosome 8 
AJAT01TA 0.3230 Chromosome 8 
AJTG03AA 0.4667 Chromosome 8 
AJAC03AT 0.3185 Chromosome 8 
AJGA01TT 0.2667 Chromosome 10 
AJAG03AC 0.2500 Chromosome 10 
AJAC02AC 0.3077 Chromosome 10 
AJAC02AA 0.1667 Chromosome 10 
AJGA03AG 0.2195 Chromosome 10 
AJGA01CA 0.2027 Chromosome 10 
AJGA02CA 0.2797 Chromosome 10 
AJTT03AT 0.1538 Chromosome 11 
AJTT04AT 0.1364 Chromosome 12 
AJAT02CT 0.4141 Chromosome 12 
AJTA01AG 0.3622 Chromosome 13 
AJAA01TA 0.4000 Group 2 
AJAG02AT 0.3333 Group 2 
AJGA01GA 0.3770 Group 2 
AJAC05AT 0.4903 Group 2 
AJTA03AC 0.3617 Group 2 
AJAC01TT 0.4379 Group 2 
AJGA02AC 0.4398 Group 12 
AJTG04AT 0.4706 Group 16 
AJTT01AT 0.1488 Group 33 
AJTA02AG 0.2857 Group 38 
AJAC01TG 0.4528 Group 38 
AJGA01TA 0.3182 Group 38 
AJAC04.5AT 0.3600 No data 
AJTC02AG 0.4528 No data 
AJGA03AT 0.4505 Unlinked 
 
Figure 32 shows the CI of AJ specific AFLP markers between the ART treated and the 
untreated group. It was found that all of the AJ markers which were most reduced under ART 
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pressure lie in chromosomes 8 and 10 (in the graph with a red arrow) of P. chabaudi and 
groups 2 and 38 (unassigned).  
Figure 33 shows the same graph but for the AS specific AFLP markers. No markers showed 
significant reductions in the CI between the ART treated and untreated group, except in the 
case of three markers (represented in the graph by a red arrow) which seeme to be found 
under selection, although the reason for this is unclear.  
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Figure 32 - Comparative Intensities (CI) of AJ (sensitive parent) specific AFLP markers in the ART treated 
group compared to the untreated group, for the AS-ART x AJ cross. 
P. chabaudi chromosome numbers (Chromosome number *) correspond to the markers chromosomal location in 
genetic linkage map according to Martinelli A et al. 2005 (prior to individual band sequencing). 
Markers are positioned on the X axis according to their positions in cM along the chromosomes. Each point 
corresponds to an AJ-AFLP specific marker and their position along the chromosome. The gaps correspond to 
areas without any marker. 
The two red arrows indicate the chromosomes where there is a bigger AJ specific marker selection thus a bigger 
drug selection. 
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Figure 33 - Comparative Intensities (CI) of AS (resistant parent) specific AFLP markers in the ART treated 
group compared to the untreated group, for the AS-ART x AJ cross. 
P. chabaudi chromosome numbers (Chromosome number *) correspond to the markers chromosomal location in 
genetic linkage map according to Martinelli A et al. 2005 (prior to individual band sequencing). 
Markers are positioned on the X axis according to their positions in cM along the chromosomes. Each point 
corresponds to an AS-AFLP specific marker and their position along the chromosome. The gaps correspond to 
areas without any marker. 
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  5.4.2.2 AFLP analysis for the AS-ATN x AJ 
 
Once AFLP analysis was done for the AS-ART x AJ cross we wished to investigate whether 
similar loci were involved in the selection of the pooled AS-ATN x AJ cross after artesunate 
treatment. 13 of the 206 AJ markers showed CI of less than 0.5 (meaning a reduction of more 
than 50 % on the band intensity when comparing the treated and the untreated groups). These 
are shown in Table 14, along with their derived positions as located on the linkage map.  
Only four markers were reduced on both the pooled AS-ART X AJ selected with ART and 
this one, pooled AS-ATN x AJ selected with ATN, those were: AJAG03AC located on P. 
chabaudi chromosome 10, AJTA01AG located on P. chabaudi chromosome 13, AJAC05AT 
a marker that belongs to group 2 and finally AJGA03AT a marker that is unlinked 
(represented in orange in Tables 13 and 14). 
Though only one marker on chromosome 10 (AJAC02AC) was significantly reduced in this 
cross, all the AFLP markers from this chromosome are represented in Table 14 in grey, due to 
the fact that although their CI indices in this pooled AS-ATN x AJ were reduced to border 
line values to the cut level of 0.5 of CI those same markers on P. chabaudi chromosome 10 
were significantly reduced in the pooled cross AS-ART x AJ. 
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Table 14 - CI of AJ specific AFLP markers under selection in the ATN treated group, compared to the untreated 
group for the AS-ATN x AJ genetic cross, and their P. chabaudi chromosomal locations according to the genetic 
linkage map.  
Group 2 and 20 are linkage groups that could not be assigned to any particular chromosome.  
Unlinked means a marker that is not linked to any chromosome or group. 
The marker name, when a marker shows reduction in both crosses AS-ART x AJ selected with ART and AS-
ATN x AJ selected with ATN is coloured in orange. 
In grey, AJ specific AFLP markers that showed high reduced CI that were sequenced. 
 
Marker name Comparative intensities (CI) 
P. chabaudi chromosomal location in genetic 
linkage map according to Martinelli A et al. 
2005 
AJTC01TG 0,4549 Chromosome 8 
AJGA01TT 0,6667 Chromosome 10 
AJAG03AC 0,5556 Chromosome 10 
AJAC02AC 0,3571 Chromosome 10 
AJAC02AA 0,6667 Chromosome 10 
AJGA03AG 0,6667 Chromosome 10 
AJGA01CA 0,5316 Chromosome 10 
AJGA02CA 0,6866 Chromosome 10 
AJTT02GA 0,4545 Chromosome 11 
AJTT01CT 0,0313 Chromosome 12 
AJTA01AG 0,4097 Chromosome 13 
AJAG02TT 0,4444 Group 2 
AJAC05AT 0,4419 Group 2 
AJGA01GA 0,3684 Group 2 
AJTC02TA 0,4885 Group 20 
AJAT02CT 0,4426 Group 20 
AJGA03AT 0,4865 Unlinked 
AJTC01AT 0,4750 Unlinked 
AJTT03GA 0,4362 Unlinked 
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Figure 34 - Comparative Intensities (CI) of AJ (sensitive parent) specific AFLP markers in the ATN treated 
group compared to the untreated group, for the AS-ATN x AJ cross. 
P. chabaudi chromosome numbers (Chromosome number *) correspond to the markers chromosomal location in 
genetic linkage map according to Martinelli A et al. 2005 (prior to individual band sequencing). 
Markers are positioned on the X axis according to their positions in cM along the chromosomes. Each point 
corresponds to an AJ-AFLP specific marker and their position along the chromosome. The gaps correspond to 
areas without any marker. 
 
1        5        6         7           8       9     10         11          12             13 
 
CI 
AJ 
Marker 
 
Chromosome number * 
 
 168 
 
 
 
0,01
0,1
1
10
0 200 400 600 800 1000 1200
 
 
Figure 35 - Comparative Intensities (CI) of AS (resistant parent) specific AFLP markers in the ATN treated 
group compared to the untreated group, for the AS-ATN x AJ cross. 
P. chabaudi chromosome numbers (Chromosome number *) correspond to the markers chromosomal location in 
genetic linkage map according to Martinelli A et al. 2005 (prior to individual band sequencing). 
Markers are positioned on the X axis according to their positions in cM along the chromosomes. Each point 
corresponds to an AS-AFLP specific marker and their position along the chromosome. The gaps correspond to 
areas without any marker. 
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  5.4.2.3 AFLP analysis comparison between pooled crosses AS-
ART x AJ and AS-ATN x AJ 
 
As summary of the AFLP analysis on the two pooled crosses: 
A – There is a general reduced pattern of selection in the AS-ATN x AJ pooled cross 
in relation to the AS-ART x AJ that may potentially be attributed to a reduced number of 
recombinants in the AS-ATN x AJ cross; 
B – There are four main genetic loci under strong selection, according to the P. 
chabaudi genetic linkage map defined by Martinelli A and colleagues [Martinelli A et al. 
2005] on chromosomes 8 and 10 and two unlinked groups 2 and 33. The AFLP bands from 
these loci were sequenced and results will be presented in the next section. 
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5.5 Sequencing and mapping of AFLP bands under selection 
 
5.5.1 General procedure 
 
The genetic linkage map [Martinelli A et al. 2005] shows the position of markers upon the P. 
chabaudi genome as determining from the characterisation of 28 clones of a cross between 
AS and AJ. 
The way the genetic linkage map was prepared and published by Martinelli A and colleagues 
[Martinelli A et al. 2005] may not reflect exactly the correct physical linkage in the genome, 
thus and to be absolutely sure about the genetic and chromosomic position of these markers 
sequencing is necessary. In this context, with the objective of obtaining the exact correct 
physical position of those markers in the genome and mapping their physical 
chromosomal/gene position all AFLP markers were sequenced. The strong synteny between P 
falciparum and the rodent malaria parasites [Carlton JM et al. 1998; Hunt P et al. 2004] and 
the synteny map compiled by Kooij TW and colleagues [Kooji TW et al 2006], allowed us to 
physically localize the markers in relation to genes closely linked.  
AFLP bands that appeared to be under selection were sequenced and the corresponding 
sequences in the P. falciparum genome were identified [Hunt P et al. 2004b]. The sequences 
obtained in the P. falciparum database were then used in BLAST searches against the P. 
chabaudi database in addition to the genome-wide previously described syntenic map [Kooij 
TW et al. 2006]. See Table 15 for details. 
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 5.5.2 Results 
 
All the data from AFLP markers sequencing is summarized in Table 18. Though there were 
other markers under selection either by artemisinin or artesunate (see Tables 16 and 17), their 
sequences are not presented there due to the fact that they were either not possible to assigned 
unambiguously to any particular area in P. chabaudi genome or due to poor sequence quality.  
So as a result summary from the AFLP sequencing analysis: 
A – Three AJ specific markers were found to be under selection on P. falciparum 
chromosome 6 that are allocated, using the P. falciparum rodent malaria synteny map, on P. 
chabaudi chromosome 1; 
B – Two AJ specific markers were found to be under selection on P. falciparum 
chromosome 12 and one on P. falciparum chromosome 13 that are all allocated, using the 
P.falciparum rodent malaria synteny map, on P. chabaudi chromosome 14;  
C – Two AJ specific markers were found to be under selection on P. falciparum 
chromosome 9 that are allocated using the P. falciparum rodent malaria synteny map, on P. 
chabaudi chromosome 8; 
D – Four AJ specific markers were found to be under selection on P. falciparum 
chromosome 7 and one on P. falciparum chromosome 1 all of them are allocated using the P. 
falciparum rodent malaria synteny map, on P. chabaudi chromosome 2 (see also Figure 36). 
 
Mostly due to the evidence presented above that all AJ specific AFLP markers on P. chabaudi 
chromosome 2 were under strong selection further analysis was only done on this 
chromosome. The other P. chabaudi loci under selection; chromosome 1, 8 and 14 will be 
analysed within the scope of other projects. 
 172 
Table 15 - Physical and genetic mapping of the AFLP markers with low CI.Most of the AJ specific AFLP 
markers that were found to have CIs under 0,5 are presented. Their names, CIs and physical localization 
according to Martinelli A et al. 2005, and the gene annotation got from the P. chabaudi database is also 
presented. Their chromosomal position in the P. falciparum genome and their correspondence after using the 
correspondences facilitated by the use of the synteny map are also presented.Pfxx means the chromosome 
number in P. falciparum. Na – Not possible to assign. Adapted from: Hunt P et al. in press at the Molecular 
Microbiology, 2007, with kind permission of Dr. Paul Hunt. 
 
AFLP Marker Comparative 
Intensities  
(CI) 
P. chabaudi 
linkage group 
according to 
Martinelli A et al. 
2005 
Gene name P. falciparum 
genomic locus  
P. chabaudi 
chromosome 
location 
according to 
synteny from 
Kooij TW et al. 
2006 
AJAT01TA 0.3230 Chromosome 8 hypothetical Pf09 8 
AJAC03AT 0.3185 Chromosome 8 hypothetical Pf09 8 
AJGA01TT 0.2667 Chromosome 10 hypothetical Pf07 2 
AJAG03AC 0.2500 Chromosome 10 
Insufficient 
sequence for 
analysis 
Na Na 
AJAC02AC 0.3077 Chromosome 10 
Insufficient 
sequence for 
analysis 
Na Na 
AJAC02AA 0.1667 Chromosome 10 
Ubiquitin 
carboxy-
terminal 
hydrolase 
Pf07 2 
AJGA03AG 0.2195 Chromosome 10 hypothetica Pf07 2 
AJGA01CA 0.2027 Chromosome 10 hypothetical Pf01 2 
AJGA02CA 0.2797 Chromosome 10 hypothetical Pf07 2 
AJAA01TA 0.4000 Group 2 hypothetical Pf12 14 
AJAG02AT 0.3333 Group 2 
Translation 
initiation 
factor-2, 
putative 
Pf13 14 
AJAC05AT 0.4903 Group 2 hypothetical Pf12 14 
AJGA01TA 0.2857 Group 38 hypothetical Pf06 1 
AJAC01TG 0.4528 Group 38 hypothetical Pf06 1 
AJTA02AG 0.3182 Group 38 hypothetical Pf06 1 
 173
5.6 Further investigation of markers under selection on chromosome 2 
 
From a detailed observation of the synteny map in Figure 10, it is clear that P. chabaudi 
chromosome 2 is syntenic with two blocks of the P. falciparum genome, on chromosomes 1 
and 7 [Kooij TW et al. 2006]. One should also note that the fragment from P. falciparum 
chromosome 1 in inverted on P. chabaudi chromosome 2. See Figure 36 for details. 
When we joined the syntenic P. falciparum block of approximately 330 kb from chromosome 
1 with the syntenic P. falciparum block of approximately 220 Kb from the end portion of P. 
falciparum chromosome 7 we obtained a region of 550 Kb in P. falciparum that is expected to 
be most similar in size in P. chabaudi due to the big similarities already published between 
genome sizes of P. falciparum and rodent malaria parasites [Carlton JM et al. 2002]. The 
approximately 150 Kb difference between the described 700 Kb size of P. chabaudi 
chromosome 2 and the 550 Kb obtained by the synthenic map can be due to the fact that 
telomeres and genes from the chromosomes extremities due to the fact that are very variable 
are not included in the syntenic map between P. falciparum and P. chabaudi. 
An interesting finding concerning the genetic localization of the markers found to be under 
selection and their position on P. falciparum genome is that the gene that has been mostly 
suggested and described as the target for artemisinin, the SERCA-type Ca2+-dependent atpase 
gene [Eckstein-Ludwig U et al. 2003] is genetically localized very near the markers under 
selection. 
The AJ specific marker AJAC02AA annotated as an ubiquitin carboxyl-terminal hydrolase, 
putative gene, for simplicity named ubp-1, was sequenced and two major mutations were 
subsequently detected between different parasite clones as described in the ensuing sections.  
Briefly, ubiquitin hydrolases promote the catalysis of the hydrolysis of non terminal peptide 
linkages in oligopeptides or polypeptides. Ubiquitin hydrolases are involved in the hydrolysis 
of esters, including those formed between thiols such as dithiothreitol or glutathione and the 
C-terminal glycine residue of the polypeptide ubiquitin [Hall N et al. 2002]. 
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Figure 36 - P. chabaudi chromosome 2 with syntenic blocks represented, P. falciparum chromosome 1 and P. 
falciparum chromosome 7. 
In red (A) the Ca2+-ATPase-serca type gene. 
In green the AFLP markers that were sequenced. 
Legend for AFLP markers: 
B – AJGA01CA 
C – AJAC02AA 
D – AJGA03AG 
E – AJGA02CA 
F – AJGA01TT 
See Table 18 for details on the AJ specific AFLP markers. 
Note (1): The dimension of P. chabaudi chromosome 1 is approximately 750 Kb. This result was obtained from 
pulse-field gel electrophoresis analysis of P. chabaudi clones AS and AJ by Carlton JM [Carlton JM, personal 
communication]. 
Note (2): 330 Kb is the dimension of the P. falciparum synthenic block. The published size of this chromosome 
is 644 Kb. 330 Kb does not include telomeres and the chromosome extremities where genes like strevor, rifins 
and cir are found.  
Note (3): 1220 Kb approximately the dimension of the P. falciparum chromosome 7 defined by the synteny map 
the first synthenic block is approximately 1000 Kb long and the second synthenic block is approximately 220 Kb 
long. The published size of this chromosome is 1352 Kb. 
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 5.6.1 Identification of ubp-1 gene mutation on P. chabaudi 
chromosome 2 
 
The entire sequence, primers used for its amplification, predicted protein sequence and gene 
and protein alignments relative to the ubp-1 gene are presented in Appendix 4. 
Due to the fact that a mutation was found between the DNA sample from the clone AS-ART 
and the one from the clone AS-ATN, the other clones and parasite lines were fully sequenced; 
those were AS-SENS, AS-15CQ and AS-30CQ.  
The full ubp-1 gene sequence and alignments can be seen found in Appendix 4. For a question 
of simplicity and interest for the discussion, the portion of the alignments where mutations are 
to be found is presented in Figure 37. A summary of gene/protein analysis of the changes 
found in the ubp-1 gene is depicted in Table 16.  
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            2211                                                                                                                          2340 
    AS15CQ  AGATGTTACAGAATTATTTAGATATACATTTGAACAATTAGGAGGATCAGAAAAAAAATTTCTAAGATTAATATTTTCAGGAGTTGTTATACAAAAAGTTCAATGCCAAAAATGTTTTTTTATTTCAAAG 
    AS30CQ  AGATGTTACAGAATTATTTAGATATACATTTGAACAATTAGGAGGATCAGAAAAAAAATTTCTAAGATTAATATTTTCAGGAGTTGTTATACAAAAATTTCAATGCCAAAAATGTTTTTTTATTTCAAAG 
    AS-ART  AGATGTTACAGAATTATTTAGATATACATTTGAACAATTAGGAGGATCAGAAAAAAAATTTCTAAGATTAATATTTTCAGGAGTTGTTATACAAAAATTTCAATGCCAAAAATGTTTTTTTATTTCAAAG 
    AS-ATN  AGATTTTACAGAATTATTTAGATATACATTTGAACAATTAGGAGGATCAGAAAAAAAATTTCTAAGATTAATATTTTCAGGAGTTGTTATACAAAAAGTTCAATGCCAAAAATGTTTTTTTATTTCAAAG 
 
Figure 37 – Part of the ubp-1 gene alignments where the different mutations are highlight. 
The rest of the gene alignment is represented on Appendix 4.  
 
Just to resume the gene/protein analysis of the changes found on the ubp-1 gene Table 16 was built. 
 
Table 16 – A summary of the ubp-1 gene mutations and their correspondence on ubp-1 transcript for each of the P. chabaudi clones and parasite lines analysed. 
 
P. chabaudi clone or parasite line DNA Protein 
2215 bp 2308 bp 739 aa 770 aa 
AS-15CQ G G V V 
AS-30CQ G T V F 
AS-ART G T V F 
AS-ATN T G F V 
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From Table 16 and Figure 37 it can be seen that during the process of artesunate resistance a 
mutation base 2215 of the ubp-1 gene had occurred. This was a transversion where a G was 
changed into a T. This change generates a non-synonymous substitution in the ubp-1 protein 
that results in a swap from a valine in codon 739 to a phenylalanine (V739F). 
Also, in base position 2308 of the ubp-1 gene, a difference was found between the parasite 
line AS-15CQ and the clone AS-30CQ (obtained from AS-15CQ after chloroquine pressure), 
meaning that during the chloroquine selection this gene suffered a transversion of a G to a T 
in this base. This gene change corresponds to a non-synonymous substitution in the ubp-1 
protein from a valine to a phenylalanine at residue 770 (V770F).  
As a summary from the results obtained for the mutational analysis of the ubp-1 gene: 
a) A G to T transversion occurred in DNA base 2308 from AS-15CQ, intermediate 
chloroquine resistant, to AS-30CQ, high chloroquine resistant, under chloroquine pressure.  
b) A G to T transversion occurred in DNA base 2215, from AS-15CQ to AS-ATN 
under artesunate pressure. 
c) The G2215T mutation above does not exist in the AS-30CQ nor in the AS-ART 
clone. Thus whilst this mutation may be responsible for the appearance of artesunate 
resistance in the AS-ATN clone, the gene changes responsible for the appearance of 
artemisinin resistance after artemisinin pressure on clone AS-30CQ are yet to be found. 
At this stage it seemed important to evaluate the biological and biochemical significance of 
the mutations found in the P. chabaudi gene homologue of the P. falciparum ubp-1 gene. A 
profound analysis of this significance was done by Hunt P and colleagues (Hunt P et al. in 
press at the Molecular Microbiology, 2007) and it is out of the scope of this thesis. 
For this thesis only very preliminary comparisons were made between the ubp-1 predicted 
protein of P. chabaudi and for P. falciparum. The two proteins, ubp-1 from P. chabaudi and 
ubp-1 from P. falciparum are only moderated similar, possessing a very high degree of 
identity only in a particular area of the protein, near the C-terminus of the protein. Because 
both mutations V739F and V770F are mapped to the C-end portion of the ubp-1 protein it is 
expected that these mutations occurred in parts of the protein/enzyme that are very important, 
maybe even fundamental for its biological activity. 
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5.7 Discussion 
 
Most of this chapter was devoted to present results from the use of LGS in the analysis of 
pooled genetic crosses called AS-ART x AJ and AS-ATN x AJ. LGS was chosen as a faster 
approach to identify the genetic loci involved in artemisinin and artesunate resistance. 
For the artemisinin resistant line, AS-ART, three independent genetic crosses were obtained, 
these three were not analysed individually and were pooled together in a super cross named 
AS-ART x AJ. For the artesunate resistant line, AS-ATN, two independent genetic crosses 
were obtained, theses two independent crosses were not analysed individually and were also 
pooled together in a super cross named AS-ATN x AJ. 
Four loci were found to be under selection in the uncloned progeny of the treated pooled 
crosses: P. chabaudi chromosomes 1, 2, 8 and 14. 
A note to the fact that the selection observe in the AS-ATN x AJ was much less pronounced 
than the one that we were allowed to observe in the AS-ART x AJ cross. One possible 
explanation to this fact is that in the AS-ATN x AJ pooled cross there was a limited number 
of genetic recombinants. An alternative explanation can also be that the artesunate dose given 
to the cross was higher that the one that allows a more correct discrimination between 
resistant and sensitive progeny.  
Due to the fact that all markers on P. chabaudi chromosome 2 were under strong selection, 
further analysis was only done on P. chabaudi chromosome 2. Within this chromosome 2 a 
gene encoding a deubiquitinating enzyme (ubp-1 protein) was found to be mutated twice. A 
transversion of a G to a T was found in DNA base 2215 of the ubp-1 gene, in the clone AS-
ATN in relation to its parasite line progenitor AS-15CQ, corresponding to a protein change of 
V739F. The same gene was also found mutated in base 2308 in the clone AS-30CQ when 
compared to its progenitor AS-15CQ. Thus the V739F change occurred from AS-15CQ to 
AS-ATN under artesunate pressure, independently from the V770F change that occurred from 
AS-15CQ to AS-30CQ under chloroquine pressure. From the very preliminary alignments 
done between the P. falciparum and P. chabaudi proteins it was possible to observe that the 
changes occurred in the most conversed area of the protein thus for that reason supposedly 
important maybe even fundamental for the enzyme function. 
The analysis of this gene and these two mutations is most incomplete and the physiological 
significance of these mutations is still to clarify. Plus the fact that there were no mutation 
found in any of the genes analysed so far that could explain or justify the artemisinin resistant 
phenotype. 
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The failure to find a new mutation in the AS-ART clone can be explained by the fact that 
there may still be a gene, lets call it gene A, different from ubp-1 gene but still on P. chabaudi 
chromosome 2, which is indeed mutated and which mutation arose during artemisinin drug 
selection. If on future further analysis of this chromosome 2 other gene is found to be 
mutated, then the selection observed after artemisinin and artesunate treatment on the AS-
ART x AJ and AS-ATN x AJ pooled crosses can be explained. This gene A should also be 
found to be mutated on the AS-ATN clone. 
But a pendent question will then remain, if in the future another gene either on chromosome 2 
or any other chromosome, either found under selection like P. chabaudi chromosome 1, 8 and 
14 or not found under selection, is found mutated and the mutation found then could indeed 
explain or justify the resistant phenotype. The question will then be: what would be the 
importance of the mutations already found in the ubp-1 gene? One explanation is that 
mutations on the ubp-1 gene may be compensatory mutations. By compensatory mutations we 
mean a mutation that is not directly responsible for the resistant phenotype per si but on one 
hand is responsible for a change in a protein that might be involved in increasing the parasite 
general fitness, giving him proliferative and surviving advantages in relation to the ones that 
do not posses the same mutation. 
But an important note has to be made again because if another gene on another P. chabaudi 
chromosome either 1, 8 or 14 or any other not under selection on these LGS experiments is 
indeed found mutated there is still unanswered the question, why is there a selection valley on 
chromosome 2?  
A very curious finding was that two different, but at the same time similar mutations were 
found in the ubp-1 gene, that occurred during chloroquine and artesunate selection. Why this 
particular gene? Maybe the ubp-1 protein is involved in a particular cellular function involved 
in drug metabolism like for example the regulation of oxidative stress and drug detoxification 
[Krungkrai SR et al. 1987, Tilley GJ et al. 2001]. 
Artemisinin and its derivatives resistance is most likely to be a multigenic phenomenon and 
many reasons can be pointed to support this statement: first the fact that artemisinin resistance 
in the field is yet to be reported though its enormous use makes it likely, even in vitro stable 
resistance (besides this study) an though many researchers have tried is yet to be reported. 
One can even suggest evidences for the phenomenon of multigenic resistance when in our 
project four loci were found to be under drug selection (though P. chabaudi chromosome 2 
was under greater selection), might each loci correspond to a different gene involved in the 
resistant phenotype? Future studies on these four loci are necessary but before engaging in 
further analysis on P. chabaudi chromosome 1, 8 and 14 for example the recommended 
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procedure is to narrow down the selection valleys and to do that the pooled genetic crosses 
used in this project should be submitted again to another genetic cross (so called back-
crossing) and another round of LGS.  
Another future question that should be answer is what effect might be expected for ubp-1 
gene mutations on malarial parasites. This discussion is largely done in Hunt P et al. in press 
at Molecular Microbiology of which I am a co-author (this paper is in Appendix to this 
thesis). Thus I would not like to repeat Hunt P and colleague’s arguments. Ubp-1 gene allelic 
exchange transfection on P. falciparum parasites in culture and evaluation of the importance 
of the mutations found on this gene. 
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CHAPTER VI 
GENERAL CONCLUSIONS 
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A - Chapter III 
 
Stable resistance to artemisinin and one of its derivatives, artesunate, was described for the 
first time to our knowledge in a rodent malaria model, P chabaudi.  
A line was selected that was 6-fold more resistant to artesunate than the initial progenitor, AS-
ATN and other was selected that was 15-fold more resistant to artemisinin than the initial 
progenitor, AS-ART. Importantly, these results showed that malaria parasites are capable of 
developing resistance to these drugs and that this resistance can be passed on through 
generations, because it is genetically stable. 
There was full cross resistance between ART and ATN selected parasites clone lines. This is a 
strong indication that genetic mechanisms in common might be involved in drug resistant to 
ART and ATN. 
The resistant clones obtained were used downstream to investigate the putative mutations 
involved in these phenotypes. 
 
 B - Chapter IV 
 
The previously described putative genetic modulators for artemisinin and its derivatives, 
Plasmodium chabaudi homologues of the genes pfmdr, pfcrt, pftctp and pfatp6 were 
sequenced and their gene copy number calculated in relation to their progenitors. 
No changes were found, between resistant parasites and related sensitive ones allowing the 
conclusion that, at least in this model, resistance is not determined by these genes.  
 
 C – Chapter V 
 
Genetic crosses between AS-ART and AJ and AS-ATN and AJ were done. These were 
submitted to LGS and four loci were considered to be under selection. These correspond to 
areas in P. chabaudi chromosomes 1, 2, 8 and 14. 
This complex picture clearly points towards a multigenic mechanism of resistance to 
artemisinin and its derivatives. 
Detailed analyses of chromosome 2 allowed to uncover mutations in a gene denoted ubp-1 
whuich may be implicated in resistance to both artesunate and chloroquine. No novel 
mutations could be detected in artemisinin-resistant parasites however implying that 
understanding the genetic basis of resistance to this drug requires further efforts.  
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There may be many hypothetical roles for the involvement of this gene in drug resistance, 
whose study lie outside the time frame of this work. Evidence of a particular role for the 
mutations found in the ubp-1 gene in the rodent malaria parasite P. chabaudi or, eventually, in 
the human malaria parasite, P. falciparum is not yet demonstrated. In this trend, further 
investigations on the role of the mutations detected on ubp-1 gene are necessary. Allelic 
replacement experiments represent an attractive strategy to elucidade functional properties of 
the ubp-1 mutations disclosed. 
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APPENDIX 1 
 
SOLUTIONS AND BUFFERS 
 
1:1 FCS: Ringer’s Solution 
50% (v/v) heat inactivated foetal calf 
serum 
50% (v/v) mammalian Ringer’s solution 
20 units heparin/ml mouse blood 
 
Buffer A 
150 mM NaCl 
25 mM EDTA 
 
Citrate saline     
0.9% (w/v) NaCl  
1.5% (w/v) Sodium citrate 
pH 7.2 
 
Deep-freeze solution 
28% (v/v) glycerol 
3.0% (v/v) sorbitol  
0.65% (v/v) NaCl- sterilise by filtration. 
 
Mammalian ringer solution   
27mM KCl  
27mM CaCl2 
0.15M NaCl 
TBE buffer (sterilised by filtration) 
100nM Tris   
100 mM Boric Acid  
2 mM EDTA (Ethylenediaminetetraacetic Acid) 
 
TE buffer (Tris/EDTA)    
10mM Tris-HCl  
1mM EDTA 
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APPENDIX 2 
 
GENE AND PRIMER SEQUENCE FOR THE GENES pcmdr1, pccg10, 
pctctp and pcatp6 
 
 
A-pcmdr1 gene 
 
Note: Primers are underlined in the sequence.  
 
TATATTATTACAAAAAGGTCTATAGATGTTGTAAAATTTGTTGTCTTAAATATATTCAGTTATTTTATAAGTATGCATAATTTGTGTCGTTATC
CACAC(45)TATAAAATTACAGAATAAAGTAATCACATATTTTTAACGATAGACATATTTATTTATGATTGCGCTTGATAATATATACCTCATT
ATATAATTTCTTAATACCTGATTTTTCAAAATGGCGGACAAAAGAAGTAATAACAATAGTATCAAAGATGAAGTTGAGAAAG(34)AGTTAAAT
AAGCAATCCACCGTTGATCTGTTTAAAAAG(37)ATAAAGAAACAAAATATCCCACTGTTTTTGCCATTTCATTCACTACCATCCAAACACAAG
AGATTATTAGCTATATCTTTTATATGTGCGACAATATCAGGAGCTGCGTTACCCATTTTTATTTCGGTGTTTGGTCTTACTATGGCAAATATGA
ATATGGGAGAGAGCGTAAATGACATAGTTTTAAAATTAGTAATAGTTGGTATATGCCAATTTGTGATATCATCGATTTCATGTTTATGCATGGG
TACTGTTAC(29)TACAGAGATTATAAGAATGTTAAAATTAAAATATTTAAAAAGTGTTTTTCATCAAGATGGAGAATTTCATGATAATAACCC
AGGTTCTAAATTAACATCCG(30)ATTTAGATTTTTATTTAGAACAAGTAAATTCAGGAATAGGAACAAAATTTACTACAATATTTACATATAG
CAGTTCATTCTTAGGTTTGTATTTCTGGTCACTATATAAAAATGTAAGATTAACATTATGTGTTACATGTGTTTTTCCAGTAATATATATAATC
AGTACGATATGTAATAAAAGAGTTCGATTAAATAAAAAAACATCATTATTATATAATAACAATTCAATGTCTATAATTGAAGAAGCATTAGTTG
GTATTAAAACTGTTGTAAGTTATTGTGGAGAAAGTACAATATTAAAAAAATTTAAATTATCAGAACAATTTTACAGTAAATACATGTTAAAGGC
(44)AAATTTTATGGAATCGCTACATGTTGG(39)TTTTATTAATGGATTTATATTAGCTTCATATGCTATGGGATTTTGGTATGG(23)TACT
AGAATTATGATACATGATATTAAAAATCTGAGTTCACCCAGCGATTTC(25)AATGGAGGATCAGTTATATCAATTTTATTAGGAGTTCTTATA
AGTATGTTTATGCTTACTATTATATTACCAAATGTTACTGAATATATGAAAGCGTTAGAGGCAACGAACAATATACATGAAGTTATTAACAGAA
AACCAGCTGTTGACAGAAATCAAAATAAAGGTAGAAAATTAGATGATATTAAAAAAATAGAATTTAAAAATGTCAAATTTCATTATGGTACTAG
(40)AAAAGATGTTGAAATTTATAAGGATTTAAATTTTACATTAAAAGAAGGAAATACTTATGCATTTGTTGGAGAATCTGGATGTGGTAAATC
AACAATTTTAAAATTGCTTGAGCGATTTTATGATCCAACAGAAGGAGATATTGTTATTAATGGTGCACACAATTTGAAAGACGTTGACTTAAAA
TGGTGGAGATCTAAAATTGG(17)AGTAGTTAGTCAAGATCCTTTATTATTTAGCAATTCGATTAAAAATAATATTAAATATAGTTTAATAAGT
CCAAATACTTTAGAAGCAATGGAAAATGGATTCACCATGAACGGAAGTAGCGATTCTTCATTAAATAATAACAAAAATGGAAAGTCCACTAGTA
TTTTGGATGAAATATCTAAGAGAAATACAACTAATGATTTATTAGAAGTAATATCATCTATTAATTCAGTTGAAGATTCAAAAGTAGTTGATGT
ATCTAAGAAAGTGCTAATCCACGATTTTGTTGCAGCATTACCAGACAAATATGACACTTTAGTAGGTTCTAGCGCATCTAAGTTGTCAGGTGGA
CAAAAACAAAGAATATCGATAGGTAGAGCTGTTATTAGAAACCCTAAGATTTTAATACTTGATGAAGCTACATCATATCTTGATAATAAATCAG
AATATTTAGTTCAGAAAACAATTAACAATTTAAAAGGAAATGAAAATCGTATCACCATTATTATTGCTCATAGATTGAGTACTATTCGATATGC
(26)TAACCAAATTTTTGTCTTATCAAATAGAGATCAAGAATCAACAGGAATTGATGAAAAAAAACAAGGTGCTATAAATAGCAATAACGGAAG
TGTAATAGTTGAACAAGGTACTCATGATAGTTTGATGAAAAATAAAAATGGTATTTACTATTCTATGATTCAAAACCAGAAAGTATCCTCAAGT
GGAAATGGTGAAAATGGTGATGACAATAATAGTAGCGTATATAAAGACTCTAATCCAGGTGATGCTAAATCTGTTACTG(27)ATACAAATATG
GACATTGGTACAAATAAAAATCTTAATACTAAAAAAGAAAAAGAGATTGCTGATGCTGATAAACAAACTAAACCATCAATCTTTAAAAGAATGT
TTGGAAAGAAAAAGAAGAAACCTAACAATTTGAATATGGTGTATAAAGAAATATTTTCTCACAGAAAAGAGGTTGCTATTATGCTTTTAAGTAC
TATAGTAGCAGGTGGTTTATATCCATTGTTTGCTGTATTATATGCAGAATACGTTGTGACATTATTTGATATCCCGAACTTAGAATATAATTCA
AATAAATATTCTATATTCATATTGTTTATTGCTTTAGCTATGTTTATTTCTGAAACATTAAAAAATTATTACAATAATAAAATTGGAGAAAAGG
TTGAAAGCAAAA(14)TTAAATATTTATTATTCGAGAATATAATACACCAAGAAATTGCCTTTTTTGATAAAGATGCACATGCCCCTGGATTTT
TATCATCATATATTAACAGAGATGTACATTTATTAAAAACTGGTTTAGTAAATAATATTGTAATATTTACGCATTTTATTATTTTGTTTATTGT
TAGTATGATTTTGTCATTTTATTTTTGCCCAATAATAGCAGCAGCTTTAACATTAACATATACCTTTATAATGCGAGCTGTTACTGCAAGAGTA
CGAATGGAAAAATCG(18)AATAAAATAGAGAAAATCGGAGATAAAAAAGATGGATGCCTTTCATATACTACTGATGACGAAATATTTAAAGAT
CCTAACTTTTTAATTCAAGAAGCATTTTATAACATGCAGACAATTATTACATATGGATTAGAAGATTATTATTGTAAACTGATAGAAAATGCAA
TAGATCATTACAATAAAGAGCAAAGAAAATCAATTATAGTAAATTCAATATTATGGGGATTTAGTCAATGTACACAATTATTTATTAATGCATT
TGCTTATTGGTTAGGTTCCATTTTGATAAAACACAAAATTATAGTTGTTGATGATTTTATGAAATCTTTATTTACATTTATATTTACTGGTAGT
TATGGTGGTAAGTTAATGTCCTTCAAAGGAGACTCAGATAATGCTAAATTAACATATGAGAAATATTATCCTATAATGGTTAGAAAATCAAATA
TCGATGTAAGAGATGAAGGTGGTATAAGAATAAAGAATCCACATCAAATAGACGGAAAAGTAGAAGTGAAGGATGTTAACTTTAGATATTTATC
TCGACCAAATGTACCAATATATAAAGATTTATCATTTAGTTGTGATAGCAAAAAAACTACTGCTATAGTTGGAGAAACTGGATGTGGTAAATCC
ACAATTATGCATTTATTGATGCGATTTTATGATTTGAAAGATGACCACGTTTTATTAGATAATCAACATGTTGAAAAAGACAATAAAGATAAAT
CAAATGATATAGAAATGACTAATGCAACCTCTATGAACGAATTGAATGAATTGCATAAGAAAAACGCAACTGAAGAATATACTCTTTACAAAAA
TAGTGGTAAAATTTTACTTGATGGTGTAGACATTTGCGATTATAACTTAAAAGATCTAAGAAAATTATTTGCGATAGTTAACCAAGAACCAATG
TTGTTTAATATGTCTATTTATGAAAATATAAAATTCGGTAAAGAAGATGCAACATTAGAAGATGTAAAAAGGGCTTGTAGATTGGCTGCTATTG
ACGAATTTATTGAATCATTACCAAATAAATATGATACTAATGTAGGACCTTATGGAAAAAGC(5)TTATCAGGTGGTCAAAAACAACGTGTTGC
TATTGCTAGAGCCC(3)TATTAAGAGAACCTAAAATATTGTTGTTAGACGAAGCTACATCAGCTCTTGATTCACACTCAGAAAAATTAATCGAA
AAAACTATTGTTGATATTAAAGATAGAGCTGACAAAACCATCATTACTATTGCTCACAGAATTGCATCTATCAAAAGATCAAATAAAATTGTAG
TTTTTAACAACAATGATAAAAATGGATCTTTTGTTCAAGCCC(53)AAAAAACACACGACGAATTGATTCGTGATAAAGATAGTGTTTATACAA
AATATGTCAAATTAACTAAATAAACGATTGAAAGTTGGGCAAATACATAACCAGATAATAGGAATGGAAAAAAATTGTGTTGAAATTTATTATT
AGCTCACTCTTGATCTATGAC(31)TATAGAAAGAGTTCATTTTACCTTTTAATCGGCTATTGAAAAAGAACTAAAAAAAATGAATTTGCTAAT
ACAAGATGATGAGTTGATATTTGGTCATGATTTTTATATAACATATAATTATTATGAACAAATATGCTATTAAAATTATATTTTGATGTATGCT
TTTTGAAAATGTTTTATATGTTCTCTCTTTATATCTTCATATATTTTATTTTTGCATATTTTTTTGTATTCACAATATACATATTGTTTTTTTT
TTTCATTTTTCCTATAAGAGAGGGAATTTTTGTGCATAT(50)TTAGCACCCGCTAAACCCTAATAATGCGCAAAATACATATTTTGTATACAT
ACATTTCTCATTAAATTTTGTTCTTATTATCGTTTGTGTTACTGTATTTTTTTTCATATGTAATATAGTGTATGTAAAATAACACCGTTTTTTA
CCGAATATTATATTTTTATGATTATCTAAATTTTAAACTATTTTTATAAAAAAAAAATGCGATTTTTATATATAGTAAAGATAAGTAGGGATGT
TATTCCCAGGAAAATA(51) 
 
 
B-pccg10 gene 
 
Note: Primers are underlined in the sequence.  
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GTACTATAATATTATTATTATAGGGTGAATAATAAAATTGTTTGCTTTATTAGGAGTCGACCAAAAATAAATGTATTATGGAAATCACCGCATA
C(37)CAATTGATTATAAAAAAATATATATATAATATTTATTGCATTTAAAAAAAAAAAAAAAAAAAATATCCCTATATAAATAATAATTCCTA
TGTATTAGAAAATAAGACTCACCTATATCGAAATAGTGCTGATATGAATGGGAAAAAAAATTTTATGGATAATAAAATTCTAATATATGCATAT
AATAACTACTATAAGCATTCATATTGATTTCCTTATCATTTTTAAAACTATAAAAAAATCAAGGTTTATATTATTTTTATATCTTTTTTTTTTA
AACTATTATATATAGTAAAATAATAAGTTTTTATGGAAAATATTAATATTCCAGTTTGAATATCATCATATTATCCATTAATATATATATAACC
AATTATATTAATACATTATAATATTCTAATTTTTTTAATATTTATTTTAATAGTATAAGAGTTTGTGCTAATTG(35)AAATAAATATATTATA
TATATTTTCTTTAACATTAGGTTATATATATATATAATTGATAATATGAATTATTTTCATTACTTAGTTAATGATATACATTGAGAATAAAACA
ATATATTGAAAAATAATATTATATATTTAATATAAATTATACAATTATATGTAAAAAAACCAAGACATATTATTTATATATCAACTTTTTAAGA
TATACTAAATCATTGTATCAATAATGACAGGAATGAAAAAAGGAAAAAACAAAAAAAAAAATGTAAAAAATGATGAACGCTATAAAGAATTGGA
TAGTCTAATAAGCAATGATAG(15)TAATAATCAAATAAAATTAAAAATGAAAATATAAAAACAAAGGAAACAAAATAAATATGAAAATATTAA
ATAATTAAGCTCGAAGCCAAACAATAAGGGGGGATATAAGAGAAACTAATTGAAATGATAATTAGCTACTAATTTTGGAAGACAGAATAAACTA
TGATGAACTGATTATGTATTTTCACACATGATTACTGATTGTATTATAGTTTTTTTTGTCTTATTTTTCTTATAACCATTCCAAATACT(36)T
ATGTTTGAGACTTAATCGTGGCTTAATTATATTTGACAAAAGTTTCGCAAACTTAATAAAAAAAGTTAAGGGTGTAGTGATATGG(27)TAGTA
GTATTACGACTTATATAGCACTAGTTACTCTAAACTTATTATTATGTTAACGATAAAATATATAGTAATATCACACATGCCATGTATAGAAAAC
ATACATATATTTTTCCCTTATTATAATAAATATATTTGTAGGCGAAATAGGAAATAACTCAC(18)GATGGGGTGGTGCCAAAAGAATTTGCAA
ACTAATTGGAAATGAAATG(20)AGAAATAACATTTATGTTTATTTACTAAGTATATTATATTTATGCGTCAGTGTAATGAATAAAGTTTTTTC
AAAAAGAACCCTGAATAAGATTGGAAATTATAGTTTTGTTACTTCAGAAGTACATAACATGATTTGTAC(17)TATAGTTTTCCAATTATTATA
TTTTATTTACCGTAAAACATCAAATCCTGCATCTAGAAATGAGAGCCAAAAAAATTTTGGATGGCAGTTTTTCCTTATCTCATTATTAGATGCC
TCCACAGTTATAATTACTATGATTGGTATGTCAATTTTATCCCGAAAATTATATATTAAGCTTTAAAACGGCGCATGCTCGCTACTCATATGTA
TATATATGCACACACACACACACTTACGACTCTTCTCCTTTTTAAGGTCTCACAAGAACAACGGGGAACATCCAATCATTTATTATGCAACTGA
TTATTCCAGTTAACATGTATTTTTGTTTCATCTTCCTTGGATATAGGTAAAAAATCGAAATTAAAAAATGGAAACCATTACACGTATATTTATA
GCACCAAATTTTATGCATACTAAAATTTATACATTTTACTATTATCCTTTTTTTGCTACTCTTAGATATCACTTATTTAACTATTTGGGAGCTT
TCATTATACTTATTAC(32)TATAGCCGCCGTAGAAACTGTTTTATCTTATGAAACCCAAAGTGACAACTCAATC(33)ATTTTTAACTTAATT
ATGATTTTCGCCTTAATTGTAAGTTTATTAATATAATCGTCAACGAACAGTTTGCAAATTTATATGCGCCCCTTTTCC(12)TTTTTATTAATA
TTTTTCAATTTTCATTTTTCAATTTTCATTTTTCAATTTTCATTTACAGCCTTTAAGCTTTTCAAATATGACC(13)AGAGAAGTTGTCTTCAA
AAAACACAAAATAAATATCATAAGATTGAATGTAAGAAATATGTTAAAATTGCGTTTGAAAAAGATGGCAAAAAATCGTAGAATTGCAATAGGG
CAATTTATCAAACTGATTGCACCACTAATAATCACACTATGATAAAATTTTTCCAACAATTTTTCCAACAATTTTTTATTTTTATTAGGCTATG
GTCGCTTTGTTCCAATTTTTTACTTCCCTTTTAGTTTTACCAGTCTATAATATCTCATTTTTGAAAGAAAGTAATGAAAATAAGATTTCAGTTT
ATTTGAAAAAGAATAGTACCAGTTTTTAGCTATATTACTG(21)TCTGCAAAATTGTTATTTTTCATTTTTCATTTTTTCACTTTTTAGTTTAT
ATGCCATTCTCTGAAATGGGCACAAACATTAATGACGGTTT(22)AAGATGCTTATTTTATGGACAAAGCACAATCGTTGAGGTAGGACATAAT
TTTACATTCTCAAGATGAAATTCACATATTTTTATTCAGCTAATGTTTTATAACATACTTATACAATCATGTTTATTACTAATTTTGTGTATTA
TTTTTTTTACAGAATTGTGGTGTTGGTATGGTCAAAATGTGTGACCAATGTGAAGGAGCATGGGTAATTAATTTTTATAAAAAAAAAAAAAAAA
AAAATACAGAATAAAATGCATTATTCAAGTTGATATATTCAACAAAATTATCTAACTGTTTTTTATCTCTTTTTCAGAAAACCTTTATAACATA
TTCCTTTTTCAAC(11)ATATGTGACAACTTACTTGTTTGCT(26)ATGTAAGATAAAAAAAATGCACATAATATATCATTATTTAGATCAAAA
AACATATAAAATTATTATTATTTTTTTTTTCGTTTTAGATAATTGATAAATTTTCAACAATGACATATACCATTGTTAGTTGT(16)ATACAAG
GACCAGCCATAACAATAGCTTATTACTTTAAATTTCTTGCGGTAAAATATTTTATAACAGAACAAAATTCGAAATATTTTCACCTTTTTTTTAC
TTTATTTTGACAATATATGTTTTTTTTTTGTGTCTTTAGGGTGATGTTGTAAGACAACCAAGACTATTGGATTTTCTCACTTTG(24)GTAAGG
AATATGAAATAAAAATTTTTAACAATTTTGTACATAGCTAGTAATGATTTC(28)TTTTTTAATATAATTTTTTTGTTTTCTTTCTTACAGTTT
GGATACTTATTGGGAAC(29)AATAATTTACAGAATTGGAAATATCATATTAGAAAGTTAGTTTTAAAAATAGTTAAATAAAACTGGAAAATTA
TATTTATACATATATTATGTGTCTACATATG(30)TGTACAACATATTGATATTTTTTTATTCTTTTTTAATNCAGAAAAAAAAATGTTAAAGG
CACTAAACACCGATGGATCCGAAGCAGAATTAACTTCTATAGAAACATCAACAGCATAATAGATATGACAAGTTTATATGTTAAATATTTTTTT
TAAATGCCACATAAAATTGTAAAGAAG(34)AGTATGCTAATAATTAAATATATGTATTTTTTTTTGAATCAAACTACTTTATTTTGATTCATA
AATATTTATATTTTATAAAATTTGTGAATTTTTTTTTTATGAAAATTATGTGTTACATTTTGAATATTAAATATATGACTTTTTAATACATATT
TTGTAAATCTTAAAATTTGCTGATATTCTGCTATTATATATTAAT 
 
C-pctctp gene 
 
Note: Primers are underlined in the sequence.  
 
AATGATGAAGTATGCTCTGACTCA(1F)TACGCTCAAGAAGATCCATTTGGAAATCCAGAATTCCGTGAAATTGCTTTTGAAGTCAAATCAAAT
AAAAGAATAAAAGGAAATGATGACTATGGTATAGCCGATAATAGTGAAGATGCAGTAGAAGGAATGGGAGCTGATGTTGAACACGTCATTGATA
TTGTTGACTCTTTTCAATTAACATCCACTAGTTTAAGCAAAAAGGAATACAGTGCTTATGTTAAAAACTTTATGCAAAGGATTCTTAAGCATTT
AGAAGAAAAGAAACCAGATCGTGTAGAGATTTTTAAAACAAAGGCACAACCCTTAATTAAACATATTTTAACAAATTTCGATGACTTTGAATTT
TATATGGGAGAATCACTTGATATGGAAGCTGGTTTAATTTATTCATATTATAAAGGTGAAGAAATTACTCCTAGATTTGTTTACATATCA(1R)
A  
 
D-pcatp6 gene 
 
Note: Primers are underlined in the gene sequence, initiating and stop codon are presented in bold, the introns 
are highlighted in grey.  
 
AAGGATCTTTATATAGTTTATATTATATATGAAATAAAAAAATACACATGTATATATAATTATAAAAAACAAATTATCCTAATAATAAAAACAT
TTCAAACAAAAAATAGAAGAAAAGAAAAAAGAAACAATTGCTAAATATGTTTATGCTTATATGTTGATACTCAAAATTTTCTTATAATCTTAGA
AATATTCACAACTCGTTTGGTC(1F)ATTTTTATTTTTTTTTAACCAAAGATGAAATAAATCATTTGTAAAAAAAATATATATTAGCGATTTTT
TCATATAGCTAGAATTTCCCTTTAAAAAAAATATGATAAATATAGCTATTTGCAATAAGAAGTATATAAATTATAAAAAAAAACATGAACAGTT
CAGATTATTTTATCCGTTATGTATGATTTGTACATGTTTTTTTCCCCTTTTACTGAATATTTCAAAATGGTACAAAATAATTTGATATAACAAA
TGTTCATTATTCTTGTTGCTAGTGATATGTTTAATAGACAAAAGTAATTTTTATCACAGGAAAAAAAATATGTGTATATATTTGACTTATTCTG
CATACACATATGTATAGGAAATATTTAGGTTTTTCAATGAGCTTTATTTATTGAATGTCTTCTGATTCATATGAATCCGAATATGCTTGATTGG
AATCGTCCTCATCTGAATATTCGCTAGCTGAATCATCTTCTTCATCTATATCCGCTTCTTGTATTAAATTATGTTCTCTACAAGAGTTTAAATC
GGATTC(2F)TTGTATATTTCTAATTTTTTCAATCATTTCTAAATTATTGTTTTTTAAATCTTTGTACAAATCTAATATTAAATCAGAAACTTC
GATCTACAAATTGG(1R)AAAAAAAATAAAGCGTATAATTGTTAATAAATTAATATTTTTCATAGTTTTGCTTATATTTCTATTATTTATTCGT
TTGTTTGTTTATCTTACATCACTATCATCATCAAGATCCACATTAAAAAGCGTATTAATTTCATCTCTTAAGTAGTCACAAAGTTTATCTTTGG
GTCCCGTGTCTTGAGAATAGTATATGAAAAAAATAAAAAAATGCATATATATATTTTGATTATCTAAGTAATAAGAAATGGGAATGCATTTTAG
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CGGCTAATTCGGTATATGCATACACGTTAACATTTTTTGTGTGCTTACTTGATAAAACATAATTATGGACATATTCAATTAACTTTTTTTTCTT
TTCCTCTGAGGATGTTCCACCCCAATTATTTGTCACAGCTAAACGGAGCACTGTCCTATATC(3F)AATGGAAAACGAAATTTTATATTTTTTT
TATTTATTCAATCGTATGTAAATAAATATAAATTGTAGATATGCATGATGGAAGGTATAGCAATAATCCTTGTAGATGACAAATGCAGG(2R)T
TTTTGCCAAATACATAGAATATTTACATATATTAAATTGCTTTTTTTATATAATACCATTTATCAAATATTAAGTTAATCCCTTCAAGTAATAA
AGTAGATAAATTTTCACTATTCATTATTATTATTATTTTATTTAAAGTAAAATTAAAATATGTTTTTCAAAAAATAACCCGTTATATATTTTAT
AGAAACCCTGTTTCATTAATTTTTAAGCAATCCGTTTTTTTATATTTTTTTTGTCGTTGTTTTTTTTCCACTCGTTTTTTAATTACAACGATTA
CATTTTATTGTGCCCAAAAAAGGGGAAAAAGTATAAAGATACTTTTATTTTATAAAAAAAAATGTCTATATATTCCTGATTTACTATAAAATAA
ATATTATATCCAATTATATATTGCTACAAGTATTGACGTTTGCCATTCTCGTG(4F)ATGCTATTTTTATTTTTTTTATTTTTTACTAGCCAAA
TATTGTTACATATTAGGAAATAACATATAAAAAATATAATAAAAGAAAAAAATTAAAAAATTTACAAACGTAGAAAATGATAGCACGG(3R)TA
AATAAGAATAATAAAACAAGTGAACTTTGAACAACTTTAGAAAAAAGTTAAATGAAAAATATAAATTTCCCAAATAATATATTATTTCTTATTA
TTGCCCCCACCCCAATTTGTAAAATATTACTGTATATTTTTTACATGAACTGTTAATAATTAAATGGGATAATTCATAAATTTTAATTTTATTA
TTCCAAAATGAACAGGTTGAAATCGTAAGTTATCAAAAATAATGCTAATTTTTTCTTTTATTTGTCATATTTTTTATAATTATAAATGAGCATA
GATAAAATATGTGCATATGTAAGTTGGTGTTATACGTTTTTATGGATTAAACTTATAAATGGGCGTATATATTTCTCCTCTATACTTTCGGATA
GCCATATCAATATGCTAATGTTTGTATAACCTTGTTCAGTCTCATAAGGTATAGAAATGGTTATATAACAATGAGGTATAATTTAGCTTATCCA
ATTTCTTTAC(5F)ATAAATTTATTTATTTAAAGACAGAATAATATTATATATATACAAAACAATATTTTTGTATGTAGGGGTATTTTATAAAA
AATATTTTTTCCCCTTTTCTCACACACATAAAG(4R)TAAATAATTATATCCAATGTAATATAAAAAGGGTAACAAAATTAATAAGAGATATAC
TTATCATATCATCTTATGAATAATTTAACACAATGCTTACGCATATGTATGTGCATATTTATTGGGGGTAATATTTATTATTAACATTACAAAG
CAATAATTTTTTTTTCCTAATAAGACTTTTTTTATGACTGTTCATAAATATTTATCTAAAAAAATTATTAGTATAAATTTACTTTTATATCATT
ATGTGTGTTTAGTAAATGTGCTTATGAATAATTTTACACGCATAATATAGTAATACTAAATAAAAGAAAAAAATGTGTTAGTTGCCAAATATCA
TTGTCATTAATTTTATTATTCTTATGAAAGAAATAATATATCATAAAGATAAATTAGCTAAAGATATTTATAAAATAAGCGAATGGAAATATGA
GCATATTTAAAAAAGTATAATATATATTGTTGTTAATTTGCTTTTGTATATTATAAACACTATATGGTATTTACGC(6F)TTTTTCTTATACAC
ATTTTTTATTTAATTTATAATAATTTAGTATGGAATAATTAATTTTTTTTTCTTAATTGAGATATATATTTTATTTTGTGTCAGTTTTCTACAA
TGC(5R)AAATAGAAAAAAAATATATTTTTATGCATACATAACATATTATTTTAAAAATAATTGAAAATTAAGAAATAATAGCAATTTTCATGA
TATATTTTTTTCATTTATTAATCATTTCATTTATGCTTAACATGATCTCGTAACAATAAAAAATAAAAAAATAAATCGCTAAAAAGATACAAAA
ATATATAAAATGTATGGTGATTTATTTTTATAAGTGTACATATATATATATACATACACGGTATTATAAGTGCTCATTACTTAATAGCTTTAAA
ATTTATAAAATTTTTTACCATATTTGTTATGTATGTAAAATAGATACGCTTATTTATGTATACATTTTTTTTTCCTGTTTCAATAAATAAAAAT
ATATATATATATTTTATCCCTTGTTTTATATTTCTATTATTTTTATTTATTTTTCTTTTTTTTTTTAATGTGCTTTTCTTTTTGTTTTACATAA
TGCCAAAAAATGCGTAG(7F)TAAAATTAGGATTTATATATAATATATACACATATATTATTATAAGTATGCACATGAAAAGGATTATAAATAT
ATTGATTTAGGTATGTACATATAGTATAATAAAGTACGCTAATTAAGATAAAACAAACTTAAAAAAAAATTATATAAAAATAATTCTGTGGATT
TACAAAATAATTGATC(6R)CCCCAAAAGAAACAAGAGAAACACATCACGTATGTACATGTATGTATTTATGCGTATTATGTGTTAAATAAACA
TTAGAGGTGATTATATTTGTTTTTTATTTTTTTCATAATATTTTAAAAAAATAATATACAAAATTTGGAGTCACAATTATTTTAATCTATGATA
AAAGTTTATATTGAAGTGTTTGCTTTTCGTCGCAGCATATGCCCGTGAGTATATGCATATATGTATATGTGCCTATATGCATATAGATAAATAG
AAATATAATTTATGAGTAGGTTAGCCCTTTGAT(7R)TTAAAAATAAATTTTGATTTAAGATCACATTACAATTATCAAATAAAAAGATATATA
TATCGAGAGACATTTCCAGTAGATATCATTCGATGTATTTTGCCATATTGTCAATAAAATAAGCATACAAAATAATAATTGATACTGCGAAAAT
ATAATGGAAGATATTTTGAAATATGCACATGTATATAATGTAGAAGATGTTTTGAGAGCAG(8F)TAAAAGTAGATGAAAATCGGGGTTTATCC
GAAAATGAAATAAGAAAGAGAATAATGCAATATGGGTTCAACGAATTGGAAGTAGAAAAAAAAAAAGGAATTTTTGAATTGATATTGAATCAGT
TTGATGACTTATTAGTAAAGATATTGCTTTTAGCTGCTTTTGTTAGTTTTGCACTAACATTACTAGATATGAAAGATAATGAAGTAGCTTTATG
TGATTTTATAGAACCCGTTGTTATATTATTGATACTTATATTAAATGCAGCTGTTGGAGTATGGCAAGAATGTAATGCAGAAAAATCGTTAGAG
GCACTAAAACAGTTGCAGCCAACAAAGGCAAAAGTATTGAGAGAAGGTAAATGGGAAGTTATAGATAGTAAATATTTAACAGTTGGTGATATAA
TTGAATTAAGTGTTGGTAATAAAACACCAGCAGATGTTCGAATTATTAAAATATTTTCAACAAGTATTAAAGCAGAACAAAGTATGTTAAC(9F
)TGGTGAATCATGCTCTGTTGATAAATATGCAG(8R)AAAAATTAGATGAATCATTAAAAAATTGTGAAATTCAATTAAAAAAAAATATATTAT
TTTCTTCTACAGCTATTGTAGCAGGTAGATGTATAGCTGTTGTAATTAAAATAGGTATGAAAACTGAAATAGGTAATATACAACATGCAGTTAT
AGAATCAAATAATGAAGAAACAGATACACCATTACAAATAAAAATAGATTCATTTGGAAAACAATTATCAAAAATTATATTTATTATTTGTGTA
ACCGTTTGGATTATTAATTTTAAACATTTTTCAGATCCAGTACATGAATCATTTTTATATGGATGTTTATATTATTTCAAAATCAGTGTGGCAT
TAGCTGTTGCTGCAATTCCTGAAGGATTACCAGCAGTTATTACTACATGTTTAGCTTTAGGAACCAGACGAATGGTCAAAAAAAATGCTATTGT
TAGAAAGTTACAAAGTGTTGAAACATTAGGTTGTACCACTGTTATATGTTCTGATAAAACCGGAACCTTAACAACAAATCAAATGACAGCTACT
GTTTTTC(10F)ATATATTTAGAGAATCAAATACATTAAAAGAATATCAACTATGTCAAAGAGGAG(9R)AAACCTATTTCTTTTATGAAACTA
ATACTAATCAAGATGGTGAAGAAGATTCATTTTTTAAAAAATTACAAGAAGAGGAAAATAATGAATCTAATTATAAAAGACAAATAAGTAAAAA
TATAATACATGATGAAGAAGATTCAGATGATGAAAGAGCACCGTTAATGAATATGAAATCAAATGTAAATACAATTATAAGTAGAGGTAGTAGA
ATTATTGATGATAAAATAAATAAATATAGTTATTCCGATCTTGATTATCATTTTTATATGTGTTTATGTAATTGTAATGAAGCTAGTATTTTAT
GTAATAGGAATAATAAGATTATTAAAACATTTGGAGATAGTACCGAATTAGCTTTACTTCATTTCGTTCATAATTTTAATATAACTCCTAATAG
TGCAAAAAATAATAAAATGACATCTGAATATGAAAAATTAAATAGTGGAAGCAGAAAAAATAGTGACCTGGATACCGATTGTGATTCTTTATAT
AGTAGTGAAAAAAAAACAAAAGTTTCAGATAAAAAATCGGAACCATCATTCCCAAGTGAATGTATAACTGCATGGAGAAACGAATGTACAACAT
TGCGAATTATTGAATTTACTCGTGAAAGAAAACTAATGAGTGTCATTGTAGAAAATAATAAGAATGAATATATATTATATTGTAAAGGTGCACC
AGAA(11F)AATATTATTAATAGATGTAAATATTACATGTCTAAAAATGATGTACGGTCATTAACTGATTC(10R)TATGAAAAATGAAATTTT
AAATAAAATTAAAAATATGGGAAAAAGAGCTTTGAGAACTTTAAGTTTTGCATATAAAAAAGTTAAAGCCAATGATATTAATATAAAAAATGCT
GAAGATTATTATAAATTAGAATATGATTTAATATATATAGGAGGATTAGGTATAATTGATCCCCCAAGGAAGAATGTAGGAAAAGCTATTAGTT
TATGTCACTTAGCAGGCATTCGTGTTTTTATGATTACTGGTGATAATATTGATACTGCAAAAGCTATTGCTAAAGAAATCCATATATTGAATAA
TGATGATACTGATAAATATAGTTGTTGCTTTAATGGACGTGAATTTGAAGAACTACCTTTAGAAAAACAAAAATATATTTTAAAAAATTATCAA
CAAATAGTATTCTGTAGAACTGAACCAAAACATAAAAAAAATATTGTTAAAATTTTAAAAGATTTAGGAGAAACTGTTGCTATGACAGGTGATG
GTGTAAATGATGCACCTGCTCTTAAATCTGCTGATATAGGTATTGCTATGGGTATAAATGGAACTCAAGTTGCTAAGGAAGCTTCCGATATTGT
TTTAGCTGATGATAATTTTAATACTATTGTTGAAGCTATTAAAGAAGGACGATG(12F)TATATATAACAACATGAAAGCTTTTATACGATATC
TTATAAGTAGTAATATTGGAGAAGTTGC(11R)TTCGATTTTCATTACTGCTATTTTGGGTATCCCCGATAGTTTGGCTCCCGTCCAGTTACTA
TGGGTTAACTTAGTAACTGATGGTTTACCTGCCACTGCTCTCGGTAAGTTTGTGAATCTTCACATGTTTCCATTTTCTCACCTTTTCCATTTCT
TACTTTGTTTCGCTTATTTTGTCATTTCTTTACCATCGCAGGATTCAACCCCCCCGAGCACGACGTGATGAAATGCAAACCCAGACACAGGAAC
GACAACTTAATAAACGGGCTGACATTGCTTAGATACATAATTATAGGTACATATGTTGGAATAGCTACAGTGTCAATCTTTGTATATTGGTTTG
TGTTTTATCCAGATATGGATAATCACACTCTAATAAATTTTTATCAACTTTCTCACTACAATCAATGTAAAACGTGGGAAAATTTTAAAGTGAA
TAAAGTATATGGTATGTCCGAGGATCTATGCTCTTATTTTTCTGCTGGCAAAGTCAAGGTAATAAAATCATTCCGTTTTTATCATAAATTTTGT
ATGCATGCAACAATATAGTTATTCATTTGACGTTTGTTTACTTCTTTTTTTTAGGCAAGTACCTTATCATTATCC(13F)GTTCTAGTCTTGAT
CGAAATGTTCAATGCGCTTAATG(12R)CACTTAGTGAGTATAACTCATTATTTGTGCTTCCACCATGGCGAAATATGTACCTAGTATTTGCAA
CAATAGGATCTTTACTTCTTCACTGTATGATCATATATTTCCCACCACTAGCTAGAATATTTGGGGTTGTGCCACTTAATTTACACGATTGGTT
TTTAGTATTCTTGTGGTCCTTCCCTGTAATAATAATTGATGAAATTATCAAATTTTATGCAAAAAAACAATTAAACAAAGAACTCGGGTATGGT
CAAAAATTGAAGACGC(13R/15F)ACTAATGCACACATTTACTTCGCATCAAATAATTATAAACATGTTGTACATGGAAGTTTATGTCTTCTT
TCGTTTCTTTTCTTTTCTGTTTTTTTTTTTTTTTTTATTGTGATACTTTTCTAAATTAAACCCCCAAATTATGAATATGCATAATGTATACTTA
TCTCTTAATTATTTTACTTCGCTTATTTTTATTTTATTTTCTTCTTCCTATTTTATATTGTATTTAAATTAGTATAACATTATTACTATCCCAT
TTTTATTTTTTTAAATATATTATAAAAGTACAATAAAAAGAAAAATAACGAACATCAATTTTTTATATATTCCTTATTTATAAATATTTACAAT
TTTTTTTTTAAATATATATTGATGTCTTTTTCGAATAATTCTAATTTTTTTTCGACAATTTTTTTAAGTATACACATATTTGGGTATTGAAAAA
GGTGTGCGTAAAATGAGG(14F)AAAATTATACACATTCTTCCTTTTCATTATTTTTAATTTTTATAAAAAAAAATGAAAATAACAAGATATAT
AATTGGTAATTAAAAATATAAACTACGAATTTACTACTGTTTTATGTATTTTCTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTAACTTTATT
ATTTGTTACATCCCTATGCAAATGGCC(15R)ACAATGATACTACTTGACAAATAAAGAAGGGAACATAACGAAATACAGTTATTTTAAAAATT
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TTTTTATTTTATACATTTTGAGAAAAAATGGAACTAGCATACGAACATGAAGTTACAAAAAAAATAGTTTATAAAATAATAAACAATATGAACA
GCAAAAATGATGTAACATTAGAAAGGATGCAACACACCAGGTACAGTATTCATTTTGTTACCATCTTACTACTGCCTTACATGTGTATTTACTT
GAAAATATAAGAATGGTCATGAAGTAATGGCACACTTTCAAAAAGGCACAAAGCCAAAACACGTTCATACAATATGCCATATGTCATAGCACAA
AGAATAATTCATTTTGTAATATACTTTATAATTATACTTTATTTTGTACATTTTCTTGCCCTTTTTAGAAATAAGATAGTGAAATACTTTTTCG
AAGCAGAATTGTTATTTAAATACTATGACATAGGAAAGACTGGTGAG(14R)ATAGATGTAAGTCTATTCCCACAAATGGCAAGAACATTAAAA
CAAATATATGATGCAGAAGATATTAAACGGT 
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APPENDIX 3 
 
PRIMER SEQUENCE AND PCR AMPLIFICATION CONDITIONS FOR 
DETERMINING GENE COPY NUMBER OF pcmdr1, pctctp and pcatp6 
GENES 
 
Table A3-1 - Polymerase Chain Reactions for gene quantification of pcmdr1, pctctp and pcatp6 genes in 
comparison to pcmsp1. 
 
Gene Primer sequence 
5’ - 3’ 
[MgCl2] (mM) / 
[Primer] (µM) 
PCR amplification programme 
pcmdr1 
 
sense - TCT CGA CCA AAT GTA CCA ATA TA 
 
 
 
 
antisense - GCA TTA GTC ATT TCT ATA TCA TTT G 
 
 
 
 
3 mM / 0.8 µM 
40 cycles 
95ºC for 600’’, 95ºC with a 0’ hold, 
cooling at 20ºC/s to 63ºC with a 7’ 
hold, heating at 20ºC/s to 72ºC with a 
7’ hold. heating at 20ºC/s to 95ºC with 
0’ hold, cooling at 20ºC/s at 65ºC and 
heating at 0.2ºC/s to 95ºC in a 
continuous acquisition mode produced 
the melting curve 
pctctp 
 
sense - AAT GAT GAA GTA TGC TCT GAC TCA 
 
 
 
 
antisense - CAT TCC TTC TAC TGC ATC TTC AC 
 
 
 
 
4.5 mM / 0.8 µM 
40 cycles 
95ºC for 600’’, 95ºC with a 0’ hold, 
cooling at 20ºC/s to 60ºC with a 7’ 
hold, heating at 20ºC/s to 72ºC with a 
7’ hold. heating at 20ºC/s to 95ºC with 
0’ hold, cooling at 20ºC/s at 65ºC and 
heating at 0.2ºC/s to 95ºC in a 
continuous acquisition mode produced 
the melting curve 
pcatp6 
 
sense - AGG CAA GTA CCT TAT CAT TAT CC 
 
 
 
 
antisense - GTG AAG AAG TAA AGA TCC TAT TG 
 
 
 
 
4.5 mM / 0.8 µM 
40 cycles 
95ºC for 600’’, 95ºC with a 0’ hold, 
cooling at 20ºC/s to 58ºC with a 7’ 
hold, heating at 20ºC/s to 72ºC with a 
7’ hold. heating at 20ºC/s to 95ºC with 
0’ hold, cooling at 20ºC/s at 65ºC and 
heating at 0.2ºC/s to 95ºC in a 
continuous acquisition mode produced 
the melting curve 
pcmsp1 
 
sense – ACA GTA ACA CAA GAA GGA AC 
 
 
 
 
antisense – GAT ACT TGT GTT GAT GCT GG 
 
 
 
 
3.5 mM / 0.4 µM 
40 cycles 
95ºC for 600’’, 95ºC with a 0’ hold, 
cooling at 20ºC/s to 59ºC with a 6’ 
hold, heating at 20ºC/s to 72ºC with a 
7’ hold. heating at 20ºC/s to 95ºC with 
0’ hold, cooling at 20ºC/s at 65ºC and 
heating at 0.2ºC/s to 95ºC in a 
continuous acquisition mode produced 
the melting curve 
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APPENDIX 4 
 
GENE AND PRIMER SEQUENCE FOR THE GENE ubp-1 
 
A - Pcubiquitin carboxyl-terminal hydrolase gene summary (ubp-1 gene) 
 
Note: Primers are underlined in the gene sequence, initiating and stop codon are presented in bold.  
 
TTATCAAAGAGTTCAATTTTAATGATATTGTTAATGCTGAGGTGAGTTCAAAAAACCTAATGCACTCCCCTCGCGATCACAATCACGATTCCCA
CGGAACCCCCCCTCCGAATCCATTGAATCAGGTATGTTCGGCGCCCGATGCCACGCCCACCATTTGCTTGTCATGCTTGCCATGCATCGGTTTA
GGCCCACTTGTTTAGTTTCATTGCATTTTCTTTGTTTCACTTGCATTTTCTTTGTTGCACTCGTTTCGTTCTTCGCCCACTCTCACATTGACA(
1F)TTCCCATTCTCTTTGCAGCAGAAAACCGAGAGGAAATCGAACAGGCCAAGGAAAACACGATCGGAATAAAAAATATGCTTAAGTTCATAAT
CCAAAAAAGCAAAAAGGAAAAAAATATGATATGTTGTAGTGATGCTAATGAACTGAAACTGTTGGTATTTTTAGGCATATGTATAAAAATTGTC
ATATGTAGGATATCAAATTTATTAAATGCAAAAGCATGCTTAGAACAATTTTACTATTTCATAAATCATAAAATATTGGGTTTAAAAATATTTC
GACATTCTCATATCGTTTTAGTTTATTTTATTCCGTTTTTCAAAAAATATTATTTTTTATGGAAGTTTATTGAACATGAAATTGATCCAGAAAT
TATTAAACTCATAAATGCAATTATAAATAATTTAGAAAACTTACAAAATAATAAAAATATAAATAATATTGGAAGTAATCCTATGTTACATCCA
TACACTCGTAGTAATACATCATTACCTGAAGTAGATCATTTCTCTTTCCCTTCAAAAGATAAGAATCTAAATCATACTTTTAATAATTTTTCTA
CCCAATATAACCCACATGATTATAAAACAAGCTTCTCTCACAGCATATC(2F)AATAGAAAATAACAATTCAAAACAAAACTTTTTTAAACATA
AACAGAATGATTTATCATTAGATTCTGATTTGCCAACACCAG(1R)ATTTATTTAACCCAAAAAATAAAAAAAAAAAAAAAAAAAATTCTGAAA
AATTTGAAGATTCACATAATAAAAATCAGCAACATCCTCATGATTATTCCGAATTTGATTCACATAATAATTTTCACAAAAATATAATTAATAA
TATTAATAATATTAATTATTTTAGACCTAGCTCTTTATTTAATACAAATGAAAATTGTGATCACGGTATTACTTATGATGACATGTTTAGAGAT
AATGACAATAGCAGTGATGATAATTATTTTGATAAAGGTAAAAATAAAATTTGTAATGTTAAAGAATATATTACAAACTTACATTTTAATAATT
TACCGGACTATCCTACTTCTTTG(3F)AAAAATAGTGATGAAAATAAAAAATCGGAAGATAAAAAAAAAAAAAAAAAAAAAATAAAAAATGAAA
ATCAAAATAGTAAAGAAGAACAAGATAATGGG(2R)GAAGAAGAAAATCATAGTAATAAAACTCAACATAAAGAAAATAATAATATTTCAAAAG
TCAATGAGCAAAATGAAAATATTTTACTTTATAATATACAAGATAATGAAAATGCAGAAAACAAAATATCCAAAAATTCTAACACTACTCGAAA
ATATATGATTGATGAAAACCTTAATGAATATAAAATTGAAAACAAAAAAGATGTATCAAACAATTATAATAATAAAGAAGGATCACCAACTTTT
GAAGAAGATAAGTATAGACATAATAATCGATCAAGCACTCCTCAAAACAATGGAATTAAAAAATTTCCTACTGTTTCCTATGAAGATGCTGATA
ATTCAAATAATATGGTGGATAAAAAATCACAAAAGAATTATATAAATTTAGAATTAGATAGAGAGAAAAAAGAAAATTTTGGATCCTCAAAAAA
GTTAACTAACATTGAAAGTGCTAAAGGAATGAATAATGATGACAATTATAATAGCAATAATGAAATATTAAATAATCGTAGAACAATTCAAACC
AATGG(4F)ACATACTGTTAACTACAACAGAAATAATAACAATATGAGACCAGATGAATATGAAAACT(3R)TTGTAAAAGATAAAAAAAACGA
TTTAGATATTATACAAAGAAAAGGAATATCTCTTGTTAATGCTACAACAAATAATAATTATGAAGAAATAAATATAGTTAATAATCCTATAGAA
AAAAATAAACATGTTAGTTCAGATAAGTTAATACAAAAACGACCCAAATATTTAATGTTACCAATTGATACGACTGAATTAAAAAAAATGCAAA
AAGGAAAATTACGACACCCACCTGTTGGTTTGATAAATTTAGGAAATACTTGCTACTTAAATAGTTTATTACAAGCATTATATAGTACTGTTTC
ATTTGTTGTTAATTTATACATTTTTAATATTGATGATAATAAAGAATTAAAACACATAAATAATAAAAATATCTCTAACGAAATGCCCATCAA(
5F)AAATAAATTATCATTTAACCTGAACAATACAAACATGAATAATAATAATAATAATGCAAACTTACTTTCAAAACGATTTTTATATGAGTTG
AAAATATTATTTAAATTAATGACTACAACAAATAAAAAATATGTTTCACCAGATAATATTTTAGGTATACTACCTCAAGAACTTAACAATAGAA
ATCAACAAGATGTTACAGAATTATTTAGATATACATTTGAACAATTAGGAGGATCAGAAAAAAAATTTCTAAGATTAATATTTTCAGGAGTTGT
TATACAAAAAGTTCAATGCCAAAAATGTTTTTTTATTTCAAAGAAAGAAGAAATTATCCACGATTTATCATTTCATGTTCCTGCAAAGTCAAG(
4R)TAAAAAACAGTCTATCCAAAAATTCTTTGATACATATATTCAAAAAGAAAAAATTTATGGAAACAATAAATACAAATGCTCGAAATGCAAC
AAAAGGCGAAATGCCCTCAAGTGGAACGAAATCATATCCCCCCCCTGCCACCTCATACTAATTCTGAACAGGTAAACCAAAAAATGCAAAAAAA
TCCAAAAAAATCCAAAAAAATCCAAAAAAATCCAAAAAAAAGCAAAAAAAAATATTTTTCACTTCGTCAATTTTTCATTTTTCAATTTTCCATT
TCGTCAATTTTTCACTTCGTCAATTTTTCACTTCGTCATTTTTCCATTTTCCACTCCTTCCCACTTTCAGGTACAACTGGTCGTTTAGCTCCAA
CGAAAAGAAGAAAATAAAAACGCACGTCAAGATCAACAAAAAGATAGTTGTAAACAATTTTGATTACCGATTGTATGGAGGAATAATTCACAGT
GGCGTGTCAGCATC(6F)ATCAGGTCATTATTATTTTATCGGAAAGAAATCCGAAAAAGGTGACAATTCAAAAAATGAATGGTATCAAATGGAC
GACTCAGCTATTACTA(5R)AAGTTAGTTCCAAATCCATAAACCGAATTTCTAAAGATCCATCAAATGATCACACTCCTTACGTTTTATTTTAT
CGTTGCAAACAAGCTCCCGATTCCCCAAGCTTATACTTTTAATCATATTTCAAAATTGCAACAATTTTGCTAACGCTTTATTATTTTATATACG
TGCACCTTTGAACGAAAAC(6R)CCTTTTTAAGTTATATTTTTTGTTTAGTTTTTCCGATTATGTTTGTATATATATATATGTATATATAATGT
GTGCGATCTTTTTTGTCGCCTAATTAATTAATGAGTATTTGCTCTATGAAATCTAGTTTTTTTATAGTTTTCATTTCTTTGTTATTGTATATTA
CATATA 
 
Note: The gene is composed by: 
3 exons, 
197855 – 197933bp 79 b. p.  
197998 – 200899bp 2902 b. p.  
201129 – 201468bp 340 b. p.  
 
2 short introns 
* 63 b. p.  
* 229 b. p.  
 
Total genomic  = 3321 + 63 + 229 = 3613b. p. 
 
Protein =1106 a. a.  
 
B - Pcubiquitin carboxyl-terminal hydrolase predicted translation 
 
MICCSDANELKLLVFLGICIKIVICRISNLLNAKACLEQFYYFINHKILGLKIFRHSHIVLVYFIPFFKKYYFLWKFIEHEIDPEIIKLINAII
NNLENLQNNKNINNIGSNPMLHPYTRSNTSLPEVDHFSFPSKDKNLNHTFNNFSTQYNPHDYKTSFSHSISIENNNSKQNFFKHKQNDLSLDSD
LPTPDLFNPKNKKKKKKNSEKFEDSHNKNQQHPHDYSEFDSHNNFHKNIINNINNINYFRPSSLFNTNENCDHGITYDDMFRDNDNSSDDNYFD
KGKNKICNVKEYITNLHFNNLPDYPTSLKNSDENKKSEDKKKKKKKIKNENQNSKEEQDNGEEENHSNKTQHKENNNISKVNEQNENILLYNIQ
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DNENAENKISKNSNTTRKYMIDENLNEYKIENKKDVSNNYNNKEGSPTFEEDKYRHNNRSSTPQNNGIKKFPTVSYEDADNSNNMVDKKSQKNY
INLELDREKKENFGSSKKLTNIESAKGMNNDDNYNSNNEILNNRRTIQTNGHTVNYNRNNNNMRPDEYENFVKDKKNDLDIIQRKGISLVNATT
NNNYEEINIVNNPIEKNKHVSSDKLIQKRPKYLMLPIDTTELKKMQKGKLRHPPVGLINLGNTCYLNSLLQALYSTVSFVVNLYIFNIDDNKEL
KHINNKNISNEMPIKNKLSFNLNNTNMNNNNNNANLLSKRFLYELKILFKLMTTTNKKYVSPDNILGILPQELNNRNQQDVTELFRYTFEQLGG
SEKKFLRLIFSGVVIQKVQCQKCFFISKKEEIIHDLSFHVPAKSSKKQSIQKFFDTYIQKEKIYGNNKYKCSKCNKRRNALKWNEIISPPCHLI
LILNRYNWSFSSNEKKKIKTHVKINKKIVVNNFDYRLYGGIIHSGVSASSGHYYFIGKKSEKGDNSKNEWYQMDDSAITKVSSKSINRISKDPS
NDHTPYVLFYRCKQAPDSPSLYF* 
  
Note: In grey the codons where mutations were found 
Effect of mutations:G2215T  gives V739F  GTT to TTT 
                                G2308T  gives V770F  GTT to TTT 
 
C – Sequence of the ubp-1 gene of the different P. chabaudi clones  
 
Note: non-coding sequence in small caps 
Length: unspliced 3079 bp; spliced 2942 bp 
 
C.1 - AS-15CQ (Intermediate chloroquine-resistant, progenitor of AS-
ATN) 
 
ttcccattctctttgcagcagaaaaccgagaggaaatcgaacaggccaaggaaaacacgatcggaataaaaaatatgcttaagttcataatcca
aaaaagcaaaaaggaaaaaaatATGATATGTTGTAGTGATGCTAATGAACTGAAACTGTTGGTATTTTTAGGCATATGTATAAAAATTGTCATA
TGTAGGATATCAAATTTATTAAATGCAAAAGCATGCTTAGAACAATTTTACTATTTCATAAATCATAAAATATTGGGTTTAAAAATATTTCGAC
ATTCTCATATCGTTTTAGTTTATTTTATTCCGTTTTTCAAAAAATATTATTTTTTATGGAAGTTTATTGAACATGAAATTGATCCAGAAATTAT
TAAACTCATAAATGCAATTATAAATAATTTAGAAAACTTACAAAATAATAAAAATATAAATAATATTGGAAGTAATCCTATGTTACATCCATAC
ACTCGTAGTAATACATCATTACCTGAAGTAGATCATTTCTCTTTCCCTTCAAAAGATAAGAATCTAAATCATACTTTTAATAATTTTTCTACCC
AATATAACCCACATGATTATAAAACAAGCTTCTCTCACAGCATATCAATAGAAAATAACAATTCAAAACAAAACTTTTTTAAACATAAACAGAA
TGATTTATCATTAGATTCTGATTTGCCAACACCAGATTTATTTAACCCAAAAAATAAAAAAAAAAAAAAAAAAAATTCTGAAAAATTTGAAGAT
TCACATAATAAAAATCAGCAACATCCTCATGATTATTCCGAATTTGATTCACATAATAATTTTCACAAAAATATAATTAATAATATTAATAATA
TTAATTATTTTAGACCTAGCTCTTTATTTAATACAAATGAAAATTGTGATCACGGTATTACTTATGATGACATGTTTAGAGATAATGACAATAG
CAGTGATGATAATTATTTTGATAAAGGTAAAAATAAAATTTGTAATGTTAAAGAATATATTACAAACTTACATTTTAATAATTTACCGGACTAT
CCTACTTCTTTGAAAAATAGTGATGAAAATAAAAAATCGGAAGATAAAAAAAAAAAAAAAAAAAAAATAAAAAATGAAAATCAAAATAGTAAAG
AAGAACAAGATAATGGGGAAGAAGAAAATCATAGTAATAAAACTCAACATAAAGAAAATAATAATATTTCAAAAGTCAATGAGCAAAATGAAAA
TATTTTACTTTATAATATACAAGATAATGAAAATGCAGAAAACAAAATATCCAAAAATTCTAACACTACTCGAAAATATATGATTGATGAAAAC
CTTAATGAATATAAAATTGAAAACAAAAAAGATGTATCAAACAATTATAATAATAAAGAAGGATCACCAACTTTTGAAGAAGATAAGTATAGAC
ATAATAATCGATCAAGCACTCCTCAAAACAATGGAATTAAAAAATTTCCTACTGTTTCCTATGAAGATGCTGATAATTCAAATAATATGGTGGA
TAAAAAATCACAAAAGAATTATATAAATTTAGAATTAGATAGAGAGAAAAAAGAAAATTTTGGATCCTCAAAAAAGTTAACTAACATTGAAAGT
GCTAAAGGAATGAATAATGATGACAATTATAATAGCAATAATGAAATATTAAATAATCGTAGAACAATTCAAACCAATGGACATACTGTTAACT
ACAACAGAAATAATAACAATATGAGACCAGATGAATATGAAAACTTTGTAAAAGATAAAAAAAACGATTTAGATATTATACAAAGAAAAGGAAT
ATCTCTTGTTAATGCTACAACAAATAATAATTATGAAGAAATAAATATAGTTAATAATCCTATAGAAAAAAATAAACATGTTAGTTCAGATAAG
TTAATACAAAAACGACCCAAATATTTAATGTTACCAATTGATACGACTGAATTAAAAAAAATGCAAAAAGGAAAATTACGACACCCACCTGTTG
GTTTGATAAATTTAGGAAATACTTGCTACTTAAATAGTTTATTACAAGCATTATATAGTACTGTTTCATTTGTTGTTAATTTATACATTTTTAA
TATTGATGATAATAAAGAATTAAAACACATAAATAATAAAAATATCTCTAACGAAATGCCCATCAAAAATAAATTATCATTTAACCTGAACAAT
ACAAACATGAATAATAATAATAATAATGCAAACTTACTTTCAAAACGATTTTTATATGAGTTGAAAATATTATTTAAATTAATGACTACAACAA
ATAAAAAATATGTTTCACCAGATAATATTTTAGGTATACTACCTCAAGAACTTAACAATAGAAATCAACAAGATGTTACAGAATTATTTAGATA
TACATTTGAACAATTAGGAGGATCAGAAAAAAAATTTCTAAGATTAATATTTTCAGGAGTTGTTATACAAAAAGTTCAATGCCAAAAATGTTTT
TTTATTTCAAAGAAAGAAGAAATTATCCACGATTTATCATTTCATGTTCCTGCAAAGTCAAGTAAAAAACAGTCTATCCAAAAATTCTTTGATA
CATATATTCAAAAAGAAAAAATTTATGGAAACAATAAATACAAATGCTCGAAATGCAACAAAAGGCGAAATGCCCTCAAGTGGAACGAAATCAT
ATCCCCCCCCTGCCACCTCATACTAATTCTGAACAGgtaaaccaaaaaatgcaaaaaaatccaaaaaaatccaaaaaaatccaaaaaaatccaa
aaaaaagcaaaaaaaaatatttttcacttcgtcaatttttcatttttcaattttccatttcgtcaatttttcacttcgtcaatttttcacttcg
tcatttttccattttccactccttcccactttcagGTACAACTGGTCGTTTAGCTCCAACGAAAAGAAGAAAATAAAAACGCACGTCAAGATCA
ACAAAAAGATAGTTGTAAACAATTTTGATTACCGATTGTATGGAGGAATAATTCACAGTGGCGTGTCAGCATCATCAGGTCATTATTATTTTAT
CGGAAAGAAATCCGAAAAAGGTGACAATTCAAAAAATGAATGGTATCAAATGGACGACTCAGCTATTACTAAAGTTAGTTCCAAATCCATAAAC
CGAATTTCTAAAGATCCATCAAATGATCACACTCCTTACGTTTTATTTTATCGTTGCAAACAAGCTCCCGATTCCCCAAGCTTATACTTTTAAt
catatttcaaaattgcaacaattttgctaacgctttattattttatata 
 
C.2 - AS-30CQ (High chloroquine-resistant; derived from AS15CQ, 
progenitor from AS-ART) 
 
ttcccattctctttgcagcagaaaaccgagaggaaatcgaacaggccaaggaaaacacgatcggaataaaaaatatgcttaagttcataatcca
aaaaagcaaaaaggaaaaaaatATGATATGTTGTAGTGATGCTAATGAACTGAAACTGTTGGTATTTTTAGGCATATGTATAAAAATTGTCATA
TGTAGGATATCAAATTTATTAAATGCAAAAGCATGCTTAGAACAATTTTACTATTTCATAAATCATAAAATATTGGGTTTAAAAATATTTCGAC
ATTCTCATATCGTTTTAGTTTATTTTATTCCGTTTTTCAAAAAATATTATTTTTTATGGAAGTTTATTGAACATGAAATTGATCCAGAAATTAT
TAAACTCATAAATGCAATTATAAATAATTTAGAAAACTTACAAAATAATAAAAATATAAATAATATTGGAAGTAATCCTATGTTACATCCATAC
ACTCGTAGTAATACATCATTACCTGAAGTAGATCATTTCTCTTTCCCTTCAAAAGATAAGAATCTAAATCATACTTTTAATAATTTTTCTACCC
AATATAACCCACATGATTATAAAACAAGCTTCTCTCACAGCATATCAATAGAAAATAACAATTCAAAACAAAACTTTTTTAAACATAAACAGAA
TGATTTATCATTAGATTCTGATTTGCCAACACCAGATTTATTTAACCCAAAAAATAAAAAAAAAAAAAAAAAAAATTCTGAAAAATTTGAAGAT
TCACATAATAAAAATCAGCAACATCCTCATGATTATTCCGAATTTGATTCACATAATAATTTTCACAAAAATATAATTAATAATATTAATAATA
TTAATTATTTTAGACCTAGCTCTTTATTTAATACAAATGAAAATTGTGATCACGGTATTACTTATGATGACATGTTTAGAGATAATGACAATAG
CAGTGATGATAATTATTTTGATAAAGGTAAAAATAAAATTTGTAATGTTAAAGAATATATTACAAACTTACATTTTAATAATTTACCGGACTAT
CCTACTTCTTTGAAAAATAGTGATGAAAATAAAAAATCGGAAGATAAAAAAAAAAAAAAAAAAAAAATAAAAAATGAAAATCAAAATAGTAAAG
AAGAACAAGATAATGGGGAAGAAGAAAATCATAGTAATAAAACTCAACATAAAGAAAATAATAATATTTCAAAAGTCAATGAGCAAAATGAAAA
TATTTTACTTTATAATATACAAGATAATGAAAATGCAGAAAACAAAATATCCAAAAATTCTAACACTACTCGAAAATATATGATTGATGAAAAC
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CTTAATGAATATAAAATTGAAAACAAAAAAGATGTATCAAACAATTATAATAATAAAGAAGGATCACCAACTTTTGAAGAAGATAAGTATAGAC
ATAATAATCGATCAAGCACTCCTCAAAACAATGGAATTAAAAAATTTCCTACTGTTTCCTATGAAGATGCTGATAATTCAAATAATATGGTGGA
TAAAAAATCACAAAAGAATTATATAAATTTAGAATTAGATAGAGAGAAAAAAGAAAATTTTGGATCCTCAAAAAAGTTAACTAACATTGAAAGT
GCTAAAGGAATGAATAATGATGACAATTATAATAGCAATAATGAAATATTAAATAATCGTAGAACAATTCAAACCAATGGACATACTGTTAACT
ACAACAGAAATAATAACAATATGAGACCAGATGAATATGAAAACTTTGTAAAAGATAAAAAAAACGATTTAGATATTATACAAAGAAAAGGAAT
ATCTCTTGTTAATGCTACAACAAATAATAATTATGAAGAAATAAATATAGTTAATAATCCTATAGAAAAAAATAAACATGTTAGTTCAGATAAG
TTAATACAAAAACGACCCAAATATTTAATGTTACCAATTGATACGACTGAATTAAAAAAAATGCAAAAAGGAAAATTACGACACCCACCTGTTG
GTTTGATAAATTTAGGAAATACTTGCTACTTAAATAGTTTATTACAAGCATTATATAGTACTGTTTCATTTGTTGTTAATTTATACATTTTTAA
TATTGATGATAATAAAGAATTAAAACACATAAATAATAAAAATATCTCTAACGAAATGCCCATCAAAAATAAATTATCATTTAACCTGAACAAT
ACAAACATGAATAATAATAATAATAATGCAAACTTACTTTCAAAACGATTTTTATATGAGTTGAAAATATTATTTAAATTAATGACTACAACAA
ATAAAAAATATGTTTCACCAGATAATATTTTAGGTATACTACCTCAAGAACTTAACAATAGAAATCAACAAGATGTTACAGAATTATTTAGATA
TACATTTGAACAATTAGGAGGATCAGAAAAAAAATTTCTAAGATTAATATTTTCAGGAGTTGTTATACAAAAATTTCAATGCCAAAAATGTTTT
TTTATTTCAAAGAAAGAAGAAATTATCCACGATTTATCATTTCATGTTCCTGCAAAGTCAAGTAAAAAACAGTCTATCCAAAAATTCTTTGATA
CATATATTCAAAAAGAAAAAATTTATGGAAACAATAAATACAAATGCTCGAAATGCAACAAAAGGCGAAATGCCCTCAAGTGGAACGAAATCAT
ATCCCCCCCCTGCCACCTCATACTAATTCTGAACAGgtaaaccaaaaaatgcaaaaaaatccaaaaaaatccaaaaaaatccaaaaaaatccaa
aaaaaagcaaaaaaaaatatttttcacttcgtcaatttttcatttttcaattttccatttcgtcaatttttcacttcgtcaatttttcacttcg
tcatttttccattttccactccttcccactttcagGTACAACTGGTCGTTTAGCTCCAACGAAAAGAAGAAAATAAAAACGCACGTCAAGATCA
ACAAAAAGATAGTTGTAAACAATTTTGATTACCGATTGTATGGAGGAATAATTCACAGTGGCGTGTCAGCATCATCAGGTCATTATTATTTTAT
CGGAAAGAAATCCGAAAAAGGTGACAATTCAAAAAATGAATGGTATCAAATGGACGACTCAGCTATTACTAAAGTTAGTTCCAAATCCATAAAC
CGAATTTCTAAAGATCCATCAAATGATCACACTCCTTACGTTTTATTTTATCGTTGCAAACAAGCTCCCGATTCCCCAAGCTTATACTTTTAAt
catatttcaaaattgcaacaattttgctaacgctttattattttatata 
 
Note: A mutation G2308T detected between 15CQ and 30CQ 
 
C.3 - AS-ATN (Artesunate-resistant; derived from AS15CQ) 
 
tttcccaaacagaaattataataaactttcatccaaagcttcttcaacatatgctgaatcacaaaacaaaggtaattacaatgatgaatctgat
gatttcaatctttttgatgttgaaaatattatcaaagagttcaattttaatgatattgttaatgctgaggtgagttcaaaaaacctaatgcact
cccctcgcgatcacaatcacgattcccacggaacccacccctccgaatccattgaatcaggtatgttcggcgcccgatgccacgcccaccattt
gcttgtcatgcttgccatgcatcggtttaggcccacttgtttagtttcacttgcattttctttgtttcacttgcattttctttgttgcactcgt
ttcgttcttcgcccactctcacattgacattcccattctctttgcagcagaaaaccgagaggaaatcgaacaggccaaggaaaacacgatcgga
ataaaaaatatgcttaagttcataatccaaaaaagcaaaaaggaaaaaaatATGATATGTTGTAGTGATGCTAATGAACTGAAACTGTTGGTAT
TTTTAGGCATATGTATAAAAATTGTCATATGTAGGATATCAAATTTATTAAATGCAAAAGCATGCTTAGAACAATTTTACTATTTCATAAATCA
TAAAATATTGGGTTTAAAAATATTTCGACATTCTCATATCGTTTTAGTTTATTTTATTCCGTTTTTCAAAAAATATTATTTTTTATGGAAGTTT
ATTGAACATGAAATTGATCCAGAAATTATTAAACTCATAAATGCAATTATAAATAATTTAGAAAACTTACAAAATAATAAAAATATAAATAATA
TTGGAAGTAATCCTATGTTACATCCATACACTCGTAGTAATACATCATTACCTGAAGTAGATCATTTCTCTTTCCCTTCAAAAGATAAGAATCT
AAATCATACTTTTAATAATTTTTCTACCCAATATAACCCACATGATTATAAAACAAGCTTCTCTCACAGCATATCAATAGAAAATAACAATTCA
AAACAAAACTTTTTTAAACATAAACAGAATGATTTATCATTAGATTCTGATTTGCCAACACCAGATTTATTTAACCCAAAAAATAAAAAAAAAA
AAAAAAAAAATTCTGAAAAATTTGAAGATTCACATAATAAAAATCAGCAACATCCTCATGATTATTCCGAATTTGATTCACATAATAATTTTCA
CAAAAATATAATTAATAATATTAATAATATTAATTATTTTAGACCTAGCTCTTTATTTAATACAAATGAAAATTGTGATCACGGTATTACTTAT
GATGACATGTTTAGAGATAATGACAATAGCAGTGATGATAATTATTTTGATAAAGGTAAAAATAAAATTTGTAATGTTAAAGAATATATTACAA
ACTTACATTTTAATAATTTACCGGACTATCCTACTTCTTTGAAAAATAGTGATGAAAATAAAAAATCGGAAGATAAAAAAAAAAAAAAAAAAAA
AATAAAAAATGAAAATCAAAATAGTAAAGAAGAACAAGATAATGGGGAAGAAGAAAATCATAGTAATAAAACTCAACATAAAGAAAATAATAAT
ATTTCAAAAGTCAATGAGCAAAATGAAAATATTTTACTTTATAATATACAAGATAATGAAAATGCAGAAAACAAAATATCCAAAAATTCTAACA
CTACTCGAAAATATATGATTGATGAAAACCTTAATGAATATAAAATTGAAAACAAAAAAGATGTATCAAACAATTATAATAATAAAGAAGGATC
ACCAACTTTTGAAGAAGATAAGTATAGACATAATAATCGATCAAGCACTCCTCAAAACAATGGAATTAAAAAATTTCCTACTGTTTCCTATGAA
GATGCTGATAATTCAAATAATATGGTGGATAAAAAATCACAAAAGAATTATATAAATTTAGAATTAGATAGAGAGAAAAAAGAAAATTTTGGAT
CCTCAAAAAAGTTAACTAACATTGAAAGTGCTAAAGGAATGAATAATGATGACAATTATAATAGCAATAATGAAATATTAAATAATCGTAGAAC
AATTCAAACCAATGGACATACTGTTAACTACAACAGAAATAATAACAATATGAGACCAGATGAATATGAAAACTTTGTAAAAGATAAAAAAAAC
GATTTAGATATTATACAAAGAAAAGGAATATCTCTTGTTAATGCTACAACAAATAATAATTATGAAGAAATAAATATAGTTAATAATCCTATAG
AAAAAAATAAACATGTTAGTTCAGATAAGTTAATACAAAAACGACCCAAATATTTAATGTTACCAATTGATACGACTGAATTAAAAAAAATGCA
AAAAGGAAAATTACGACACCCACCTGTTGGTTTGATAAATTTAGGAAATACTTGCTACTTAAATAGTTTATTACAAGCATTATATAGTACTGTT
TCATTTGTTGTTAATTTATACATTTTTAATATTGATGATAATAAAGAATTAAAACACATAAATAATAAAAATATCTCTAACGAAATGCCCATCA
AAAATAAATTATCATTTAACCTGAACAATACAAACATGAATAATAATAATAATAATGCAAACTTACTTTCAAAACGATTTTTATATGAGTTGAA
AATATTATTTAAATTAATGACTACAACAAATAAAAAATATGTTTCACCAGATAATATTTTAGGTATACTACCTCAAGAACTTAACAATAGAAAT
CAACAAGATTTTACAGAATTATTTAGATATACATTTGAACAATTAGGAGGATCAGAAAAAAAATTTCTAAGATTAATATTTTCAGGAGTTGTTA
TACAAAAAGTTCAATGCCAAAAATGTTTTTTTATTTCAAAGAAAGAAGAAATTATCCACGATTTATCATTTCATGTTCCTGCAAAGTCAAGTAA
AAAACAGTCTATCCAAAAATTCTTTGATACATATATTCAAAAAGAAAAAATTTATGGAAACAATAAATACAAATGCTCGAAATGCAACAAAAGG
CGAAATGCCCTCAAGTGGAACGAAATCATATCCCCCCCCTGCCACCTCATACTAATTCTGAACAGgtaaaccaaaaaatgcaaaaaaatccaaa
aaaatccaaaaaaatccaaaaaaatccaaaaaaaagcaaaaaaaaatatttttcacttcgtcaatttttcatttttcaattttccatttcgtca
atttttcacttcgtcaatttttcacttcgtcatttttccattttccactccttcccactttcagGTACAACTGGTCGTTTAGCTCCAACGAAAA
GAAGAAAATAAAAACGCACGTCAAGATCAACAAAAAGATAGTTGTAAACAATTTTGATTACCGATTGTATGGAGGAATAATTCACAGTGGCGTG
TCAGCATCATCAGGTCATTATTATTTTATCGGAAAGAAATCCGAAAAAGGTGACAATTCAAAAAATGAATGGTATCAAATGGACGACTCAGCTA
TTACTAAAGTTAGTTCCAAATCCATAAACCGAATTTCTAAAGATCCATCAAATGATCACACTCCTTACGTTTTATTTTATCGTTGCAAACAAGC
TCCCGATTCCCCAAGCTTATACTTTTAAtcatatttcaaaattgcaacaattttgctaacgctttattattttatatacgtgcacctttgaacg
aaaaccctttttaagttatattttttgtttagtttttccgattatgtttgtatatatatatatgtatatataatgtgtgcgatcttttttgtcg
cctaattaattaatgagtatttgctctatgaaatctagtttttttatagttttcatttctttgttattgtatattacatatatttgataactta
tttttatttaattcatttaaagtttgtaataatttcaagcaaaattatgggcacaataaatcctatacttttctatgcataggtaaacctaaac
gggtttcacatcgacaattttttttttcttattttccaactctacaaagtta 
 
Note: There is one difference between this sequence and 15CQ - G2736T 
 
 
C.4 - AS-ART (Artemisinin-resistant; derived from AS30CQ) 
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tttcccaaacagaaattataataaactttcatccaaagcttcttcaacatatgctgaatcacaaaacaaaggtaattacaatgatgaatctgat
gatttcaatctttttgatgttgaaaatattatcaaagagttcaattttaatgatattgttaatgctgaggtgagttcaaaaaacctaatgcact
cccctcgcgatcacaatcacgattcccacggaacccacccctccgaatccattgaatcaggtatgttcggcgcccgatgccacgcccaccattt
gcttgtcatgcttgccatgcatcggtttaggcccacttgtttagtttcacttgcattttctttgtttcacttgcattttctttgttgcactcgt
ttcgttcttcgcccactctcacattgacattcccattctctttgcagcagaaaaccgagaggaaatcgaacaggccaaggaaaacacgatcgga
ataaaaaatatgcttaagttcataatccaaaaaagcaaaaaggaaaaaaatATGATATGTTGTAGTGATGCTAATGAACTGAAACTGTTGGTAT
TTTTAGGCATATGTATAAAAATTGTCATATGTAGGATATCAAATTTATTAAATGCAAAAGCATGCTTAGAACAATTTTACTATTTCATAAATCA
TAAAATATTGGGTTTAAAAATATTTCGACATTCTCATATCGTTTTAGTTTATTTTATTCCGTTTTTCAAAAAATATTATTTTTTATGGAAGTTT
ATTGAACATGAAATTGATCCAGAAATTATTAAACTCATAAATGCAATTATAAATAATTTAGAAAACTTACAAAATAATAAAAATATAAATAATA
TTGGAAGTAATCCTATGTTACATCCATACACTCGTAGTAATACATCATTACCTGAAGTAGATCATTTCTCTTTCCCTTCAAAAGATAAGAATCT
AAATCATACTTTTAATAATTTTTCTACCCAATATAACCCACATGATTATAAAACAAGCTTCTCTCACAGCATATCAATAGAAAATAACAATTCA
AAACAAAACTTTTTTAAACATAAACAGAATGATTTATCATTAGATTCTGATTTGCCAACACCAGATTTATTTAACCCAAAAAATAAAAAAAAAA
AAAAAAAAAATTCTGAAAAATTTGAAGATTCACATAATAAAAATCAGCAACATCCTCATGATTATTCCGAATTTGATTCACATAATAATTTTCA
CAAAAATATAATTAATAATATTAATAATATTAATTATTTTAGACCTAGCTCTTTATTTAATACAAATGAAAATTGTGATCACGGTATTACTTAT
GATGACATGTTTAGAGATAATGACAATAGCAGTGATGATAATTATTTTGATAAAGGTAAAAATAAAATTTGTAATGTTAAAGAATATATTACAA
ACTTACATTTTAATAATTTACCGGACTATCCTACTTCTTTGAAAAATAGTGATGAAAATAAAAAATCGGAAGATAAAAAAAAAAAAAAAAAAAA
AATAAAAAATGAAAATCAAAATAGTAAAGAAGAACAAGATAATGGGGAAGAAGAAAATCATAGTAATAAAACTCAACATAAAGAAAATAATAAT
ATTTCAAAAGTCAATGAGCAAAATGAAAATATTTTACTTTATAATATACAAGATAATGAAAATGCAGAAAACAAAATATCCAAAAATTCTAACA
CTACTCGAAAATATATGATTGATGAAAACCTTAATGAATATAAAATTGAAAACAAAAAAGATGTATCAAACAATTATAATAATAAAGAAGGATC
ACCAACTTTTGAAGAAGATAAGTATAGACATAATAATCGATCAAGCACTCCTCAAAACAATGGAATTAAAAAATTTCCTACTGTTTCCTATGAA
GATGCTGATAATTCAAATAATATGGTGGATAAAAAATCACAAAAGAATTATATAAATTTAGAATTAGATAGAGAGAAAAAAGAAAATTTTGGAT
CCTCAAAAAAGTTAACTAACATTGAAAGTGCTAAAGGAATGAATAATGATGACAATTATAATAGCAATAATGAAATATTAAATAATCGTAGAAC
AATTCAAACCAATGGACATACTGTTAACTACAACAGAAATAATAACAATATGAGACCAGATGAATATGAAAACTTTGTAAAAGATAAAAAAAAC
GATTTAGATATTATACAAAGAAAAGGAATATCTCTTGTTAATGCTACAACAAATAATAATTATGAAGAAATAAATATAGTTAATAATCCTATAG
AAAAAAATAAACATGTTAGTTCAGATAAGTTAATACAAAAACGACCCAAATATTTAATGTTACCAATTGATACGACTGAATTAAAAAAAATGCA
AAAAGGAAAATTACGACACCCACCTGTTGGTTTGATAAATTTAGGAAATACTTGCTACTTAAATAGTTTATTACAAGCATTATATAGTACTGTT
TCATTTGTTGTTAATTTATACATTTTTAATATTGATGATAATAAAGAATTAAAACACATAAATAATAAAAATATCTCTAACGAAATGCCCATCA
AAAATAAATTATCATTTAACCTGAACAATACAAACATGAATAATAATAATAATAATGCAAACTTACTTTCAAAACGATTTTTATATGAGTTGAA
AATATTATTTAAATTAATGACTACAACAAATAAAAAATATGTTTCACCAGATAATATTTTAGGTATACTACCTCAAGAACTTAACAATAGAAAT
CAACAAGATGTTACAGAATTATTTAGATATACATTTGAACAATTAGGAGGATCAGAAAAAAAATTTCTAAGATTAATATTTTCAGGAGTTGTTA
TACAAAAATTTCAATGCCAAAAATGTTTTTTTATTTCAAAGAAAGAAGAAATTATCCACGATTTATCATTTCATGTTCCTGCAAAGTCAAGTAA
AAAACAGTCTATCCAAAAATTCTTTGATACATATATTCAAAAAGAAAAAATTTATGGAAACAATAAATACAAATGCTCGAAATGCAACAAAAGG
CGAAATGCCCTCAAGTGGAACGAAATCATATCCCCCCCCTGCCACCTCATACTAATTCTGAACAGgtaaaccaaaaaatgcaaaaaaatccaaa
aaaatccaaaaaaatccaaaaaaatccaaaaaaaagcaaaaaaaaatatttttcacttcgtcaatttttcatttttcaattttccatttcgtca
atttttcacttcgtcaatttttcacttcgtcatttttccattttccactccttcccactttcagGTACAACTGGTCGTTTAGCTCCAACGAAAA
GAAGAAAATAAAAACGCACGTCAAGATCAACAAAAAGATAGTTGTAAACAATTTTGATTACCGATTGTATGGAGGAATAATTCACAGTGGCGTG
TCAGCATCATCAGGTCATTATTATTTTATCGGAAAGAAATCCGAAAAAGGTGACAATTCAAAAAATGAATGGTATCAAATGGACGACTCAGCTA
TTACTAAAGTTAGTTCCAAATCCATAAACCGAATTTCTAAAGATCCATCAAATGATCACACTCCTTACGTTTTATTTTATCGTTGCAAACAAGC
TCCCGATTCCCCAAGCTTATACTTTTAAtcatatttcaaaattgcaacaattttgctaacgctttattattttatatacgtgcacctttgaacg
aaaaccctttttaagttatattttttgtttagtttttccgattatgtttgtatatatatatatgtatatataatgtgtgcgatcttttttgtcg
cctaattaattaatgagtatttgctctatgaaatctagtttttttatagttttcatttctttgttattgtatattacatatatttgataactta
tttttatttaattcatttaaagtttgtaataatttcaagcaaaattatgggcacaataaatcctatacttttctatgcataggtaaacctaaac
gggtttcacatcgacaattttttttttcttattttccaactctacaaagtta 
 
Note: This has a mutation G2308T that occurred during the chloroquine selection going from AS-SENS to AS-
15CQ. AS30CQ contains the same mutation. Therefore confirms that ART is a direct descendant of AS30CQ (as 
expected because AS-ART was selected by ART pressure from AS-30CQ), AS-ATN has a different mutation.  
 
D – Alignment of the ubp-1 gene sequence for AS-15CQ, AS-30CQ, AS-ART and AS-ATN 
 
Note: Mutations indicated in the sequence in highlighted grey, bold and underlined.  
 
           1                                                                                                                             130 
    AS15CQ ATGATATGTTGTAGTGATGCTAATGAACTGAAACTGTTGGTATTTTTAGGCATATGTATAAAAATTGTCATATGTAGGATATCAAATTTATTAAATGCAAAAGCATGCTTAGAACAATTTTACTATTTCA 
    AS30CQ ATGATATGTTGTAGTGATGCTAATGAACTGAAACTGTTGGTATTTTTAGGCATATGTATAAAAATTGTCATATGTAGGATATCAAATTTATTAAATGCAAAAGCATGCTTAGAACAATTTTACTATTTCA 
    AS-ART ATGATATGTTGTAGTGATGCTAATGAACTGAAACTGTTGGTATTTTTAGGCATATGTATAAAAATTGTCATATGTAGGATATCAAATTTATTAAATGCAAAAGCATGCTTAGAACAATTTTACTATTTCA 
    AS-ATN ATGATATGTTGTAGTGATGCTAATGAACTGAAACTGTTGGTATTTTTAGGCATATGTATAAAAATTGTCATATGTAGGATATCAAATTTATTAAATGCAAAAGCATGCTTAGAACAATTTTACTATTTCA 
 
           131                                                                                                                            260 
    AS15CQ TAAATCATAAAATATTGGGTTTAAAAATATTTCGACATTCTCATATCGTTTTAGTTTATTTTATTCCGTTTTTCAAAAAATATTATTTTTTATGGAAGTTTATTGAACATGAAATTGATCCAGAAATTAT 
    AS30CQ TAAATCATAAAATATTGGGTTTAAAAATATTTCGACATTCTCATATCGTTTTAGTTTATTTTATTCCGTTTTTCAAAAAATATTATTTTTTATGGAAGTTTATTGAACATGAAATTGATCCAGAAATTAT 
    AS-ART TAAATCATAAAATATTGGGTTTAAAAATATTTCGACATTCTCATATCGTTTTAGTTTATTTTATTCCGTTTTTCAAAAAATATTATTTTTTATGGAAGTTTATTGAACATGAAATTGATCCAGAAATTAT 
    AS-ATN TAAATCATAAAATATTGGGTTTAAAAATATTTCGACATTCTCATATCGTTTTAGTTTATTTTATTCCGTTTTTCAAAAAATATTATTTTTTATGGAAGTTTATTGAACATGAAATTGATCCAGAAATTAT 
 
           261                                                                                                                           390 
    AS15CQ TAAACTCATAAATGCAATTATAAATAATTTAGAAAACTTACAAAATAATAAAAATATAAATAATATTGGAAGTAATCCTATGTTACATCCATACACTCGTAGTAATACATCATTACCTGAAGTAGATCAT 
    AS30CQ TAAACTCATAAATGCAATTATAAATAATTTAGAAAACTTACAAAATAATAAAAATATAAATAATATTGGAAGTAATCCTATGTTACATCCATACACTCGTAGTAATACATCATTACCTGAAGTAGATCAT 
    AS-ART TAAACTCATAAATGCAATTATAAATAATTTAGAAAACTTACAAAATAATAAAAATATAAATAATATTGGAAGTAATCCTATGTTACATCCATACACTCGTAGTAATACATCATTACCTGAAGTAGATCAT 
    AS-ATN TAAACTCATAAATGCAATTATAAATAATTTAGAAAACTTACAAAATAATAAAAATATAAATAATATTGGAAGTAATCCTATGTTACATCCATACACTCGTAGTAATACATCATTACCTGAAGTAGATCAT 
 
           391                                                                                                                            520 
    AS15CQ TTCTCTTTCCCTTCAAAAGATAAGAATCTAAATCATACTTTTAATAATTTTTCTACCCAATATAACCCACATGATTATAAAACAAGCTTCTCTCACAGCATATCAATAGAAAATAACAATTCAAAACAAA 
    AS30CQ TTCTCTTTCCCTTCAAAAGATAAGAATCTAAATCATACTTTTAATAATTTTTCTACCCAATATAACCCACATGATTATAAAACAAGCTTCTCTCACAGCATATCAATAGAAAATAACAATTCAAAACAAA 
    AS-ART TTCTCTTTCCCTTCAAAAGATAAGAATCTAAATCATACTTTTAATAATTTTTCTACCCAATATAACCCACATGATTATAAAACAAGCTTCTCTCACAGCATATCAATAGAAAATAACAATTCAAAACAAA 
    AS-ATN TTCTCTTTCCCTTCAAAAGATAAGAATCTAAATCATACTTTTAATAATTTTTCTACCCAATATAACCCACATGATTATAAAACAAGCTTCTCTCACAGCATATCAATAGAAAATAACAATTCAAAACAAA 
 
           521                                                                                                                            650 
    AS15CQ ACTTTTTTAAACATAAACAGAATGATTTATCATTAGATTCTGATTTGCCAACACCAGATTTATTTAACCCAAAAAATAAAAAAAAAAAAAAAAAAAATTCTGAAAAATTTGAAGATTCACATAATAAAAA 
    AS30CQ ACTTTTTTAAACATAAACAGAATGATTTATCATTAGATTCTGATTTGCCAACACCAGATTTATTTAACCCAAAAAATAAAAAAAAAAAAAAAAAAAATTCTGAAAAATTTGAAGATTCACATAATAAAAA 
    AS-ART ACTTTTTTAAACATAAACAGAATGATTTATCATTAGATTCTGATTTGCCAACACCAGATTTATTTAACCCAAAAAATAAAAAAAAAAAAAAAAAAAATTCTGAAAAATTTGAAGATTCACATAATAAAAA 
    AS-ATN ACTTTTTTAAACATAAACAGAATGATTTATCATTAGATTCTGATTTGCCAACACCAGATTTATTTAACCCAAAAAATAAAAAAAAAAAAAAAAAAAATTCTGAAAAATTTGAAGATTCACATAATAAAAA 
 
           651                                                                                                                            780 
    AS15CQ TCAGCAACATCCTCATGATTATTCCGAATTTGATTCACATAATAATTTTCACAAAAATATAATTAATAATATTAATAATATTAATTATTTTAGACCTAGCTCTTTATTTAATACAAATGAAAATTGTGAT 
    AS30CQ TCAGCAACATCCTCATGATTATTCCGAATTTGATTCACATAATAATTTTCACAAAAATATAATTAATAATATTAATAATATTAATTATTTTAGACCTAGCTCTTTATTTAATACAAATGAAAATTGTGAT 
    AS-ART TCAGCAACATCCTCATGATTATTCCGAATTTGATTCACATAATAATTTTCACAAAAATATAATTAATAATATTAATAATATTAATTATTTTAGACCTAGCTCTTTATTTAATACAAATGAAAATTGTGAT 
    AS-ATN TCAGCAACATCCTCATGATTATTCCGAATTTGATTCACATAATAATTTTCACAAAAATATAATTAATAATATTAATAATATTAATTATTTTAGACCTAGCTCTTTATTTAATACAAATGAAAATTGTGAT 
 
           781                                                                                                                            910 
    AS15CQ CACGGTATTACTTATGATGACATGTTTAGAGATAATGACAATAGCAGTGATGATAATTATTTTGATAAAGGTAAAAATAAAATTTGTAATGTTAAAGAATATATTACAAACTTACATTTTAATAATTTAC 
    AS30CQ CACGGTATTACTTATGATGACATGTTTAGAGATAATGACAATAGCAGTGATGATAATTATTTTGATAAAGGTAAAAATAAAATTTGTAATGTTAAAGAATATATTACAAACTTACATTTTAATAATTTAC 
    AS-ART CACGGTATTACTTATGATGACATGTTTAGAGATAATGACAATAGCAGTGATGATAATTATTTTGATAAAGGTAAAAATAAAATTTGTAATGTTAAAGAATATATTACAAACTTACATTTTAATAATTTAC 
    AS-ATN CACGGTATTACTTATGATGACATGTTTAGAGATAATGACAATAGCAGTGATGATAATTATTTTGATAAAGGTAAAAATAAAATTTGTAATGTTAAAGAATATATTACAAACTTACATTTTAATAATTTAC 
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           911                                                                                                                           1040 
    AS15CQ CGGACTATCCTACTTCTTTGAAAAATAGTGATGAAAATAAAAAATCGGAAGATAAAAAAAAAAAAAAAAAAAAAATAAAAAATGAAAATCAAAATAGTAAAGAAGAACAAGATAATGGGGAAGAAGAAAA 
    AS30CQ CGGACTATCCTACTTCTTTGAAAAATAGTGATGAAAATAAAAAATCGGAAGATAAAAAAAAAAAAAAAAAAAAAATAAAAAATGAAAATCAAAATAGTAAAGAAGAACAAGATAATGGGGAAGAAGAAAA 
    AS-ART CGGACTATCCTACTTCTTTGAAAAATAGTGATGAAAATAAAAAATCGGAAGATAAAAAAAAAAAAAAAAAAAAAATAAAAAATGAAAATCAAAATAGTAAAGAAGAACAAGATAATGGGGAAGAAGAAAA 
    AS-ATN CGGACTATCCTACTTCTTTGAAAAATAGTGATGAAAATAAAAAATCGGAAGATAAAAAAAAAAAAAAAAAAAAAATAAAAAATGAAAATCAAAATAGTAAAGAAGAACAAGATAATGGGGAAGAAGAAAA 
 
           1041                                                                                                                          1170 
    AS15CQ TCATAGTAATAAAACTCAACATAAAGAAAATAATAATATTTCAAAAGTCAATGAGCAAAATGAAAATATTTTACTTTATAATATACAAGATAATGAAAATGCAGAAAACAAAATATCCAAAAATTCTAAC 
    AS30CQ TCATAGTAATAAAACTCAACATAAAGAAAATAATAATATTTCAAAAGTCAATGAGCAAAATGAAAATATTTTACTTTATAATATACAAGATAATGAAAATGCAGAAAACAAAATATCCAAAAATTCTAAC 
    AS-ART TCATAGTAATAAAACTCAACATAAAGAAAATAATAATATTTCAAAAGTCAATGAGCAAAATGAAAATATTTTACTTTATAATATACAAGATAATGAAAATGCAGAAAACAAAATATCCAAAAATTCTAAC 
    AS-ATN TCATAGTAATAAAACTCAACATAAAGAAAATAATAATATTTCAAAAGTCAATGAGCAAAATGAAAATATTTTACTTTATAATATACAAGATAATGAAAATGCAGAAAACAAAATATCCAAAAATTCTAAC 
 
           1171                                                                                                                          1300 
    AS15CQ ACTACTCGAAAATATATGATTGATGAAAACCTTAATGAATATAAAATTGAAAACAAAAAAGATGTATCAAACAATTATAATAATAAAGAAGGATCACCAACTTTTGAAGAAGATAAGTATAGACATAATA 
    AS30CQ ACTACTCGAAAATATATGATTGATGAAAACCTTAATGAATATAAAATTGAAAACAAAAAAGATGTATCAAACAATTATAATAATAAAGAAGGATCACCAACTTTTGAAGAAGATAAGTATAGACATAATA 
    AS-ART ACTACTCGAAAATATATGATTGATGAAAACCTTAATGAATATAAAATTGAAAACAAAAAAGATGTATCAAACAATTATAATAATAAAGAAGGATCACCAACTTTTGAAGAAGATAAGTATAGACATAATA 
    AS-ATN ACTACTCGAAAATATATGATTGATGAAAACCTTAATGAATATAAAATTGAAAACAAAAAAGATGTATCAAACAATTATAATAATAAAGAAGGATCACCAACTTTTGAAGAAGATAAGTATAGACATAATA 
 
           1301                                                                                                                          1430 
    AS15CQ ATCGATCAAGCACTCCTCAAAACAATGGAATTAAAAAATTTCCTACTGTTTCCTATGAAGATGCTGATAATTCAAATAATATGGTGGATAAAAAATCACAAAAGAATTATATAAATTTAGAATTAGATAG 
    AS30CQ ATCGATCAAGCACTCCTCAAAACAATGGAATTAAAAAATTTCCTACTGTTTCCTATGAAGATGCTGATAATTCAAATAATATGGTGGATAAAAAATCACAAAAGAATTATATAAATTTAGAATTAGATAG 
    AS-ART ATCGATCAAGCACTCCTCAAAACAATGGAATTAAAAAATTTCCTACTGTTTCCTATGAAGATGCTGATAATTCAAATAATATGGTGGATAAAAAATCACAAAAGAATTATATAAATTTAGAATTAGATAG 
    AS-ATN ATCGATCAAGCACTCCTCAAAACAATGGAATTAAAAAATTTCCTACTGTTTCCTATGAAGATGCTGATAATTCAAATAATATGGTGGATAAAAAATCACAAAAGAATTATATAAATTTAGAATTAGATAG 
 
           1431                                                                                                                          1560 
    AS15CQ AGAGAAAAAAGAAAATTTTGGATCCTCAAAAAAGTTAACTAACATTGAAAGTGCTAAAGGAATGAATAATGATGACAATTATAATAGCAATAATGAAATATTAAATAATCGTAGAACAATTCAAACCAAT 
    AS30CQ AGAGAAAAAAGAAAATTTTGGATCCTCAAAAAAGTTAACTAACATTGAAAGTGCTAAAGGAATGAATAATGATGACAATTATAATAGCAATAATGAAATATTAAATAATCGTAGAACAATTCAAACCAAT 
    AS-ART AGAGAAAAAAGAAAATTTTGGATCCTCAAAAAAGTTAACTAACATTGAAAGTGCTAAAGGAATGAATAATGATGACAATTATAATAGCAATAATGAAATATTAAATAATCGTAGAACAATTCAAACCAAT 
    AS-ATN AGAGAAAAAAGAAAATTTTGGATCCTCAAAAAAGTTAACTAACATTGAAAGTGCTAAAGGAATGAATAATGATGACAATTATAATAGCAATAATGAAATATTAAATAATCGTAGAACAATTCAAACCAAT 
 
           1561                                                                                                                          1690 
    AS15CQ GGACATACTGTTAACTACAACAGAAATAATAACAATATGAGACCAGATGAATATGAAAACTTTGTAAAAGATAAAAAAAACGATTTAGATATTATACAAAGAAAAGGAATATCTCTTGTTAATGCTACAA 
    AS30CQ GGACATACTGTTAACTACAACAGAAATAATAACAATATGAGACCAGATGAATATGAAAACTTTGTAAAAGATAAAAAAAACGATTTAGATATTATACAAAGAAAAGGAATATCTCTTGTTAATGCTACAA 
    AS-ART GGACATACTGTTAACTACAACAGAAATAATAACAATATGAGACCAGATGAATATGAAAACTTTGTAAAAGATAAAAAAAACGATTTAGATATTATACAAAGAAAAGGAATATCTCTTGTTAATGCTACAA 
    AS-ATN GGACATACTGTTAACTACAACAGAAATAATAACAATATGAGACCAGATGAATATGAAAACTTTGTAAAAGATAAAAAAAACGATTTAGATATTATACAAAGAAAAGGAATATCTCTTGTTAATGCTACAA 
 
           1691                                                                                                                          1820 
    AS15CQ CAAATAATAATTATGAAGAAATAAATATAGTTAATAATCCTATAGAAAAAAATAAACATGTTAGTTCAGATAAGTTAATACAAAAACGACCCAAATATTTAATGTTACCAATTGATACGACTGAATTAAA 
    AS30CQ CAAATAATAATTATGAAGAAATAAATATAGTTAATAATCCTATAGAAAAAAATAAACATGTTAGTTCAGATAAGTTAATACAAAAACGACCCAAATATTTAATGTTACCAATTGATACGACTGAATTAAA 
    AS-ART CAAATAATAATTATGAAGAAATAAATATAGTTAATAATCCTATAGAAAAAAATAAACATGTTAGTTCAGATAAGTTAATACAAAAACGACCCAAATATTTAATGTTACCAATTGATACGACTGAATTAAA 
    AS-ATN CAAATAATAATTATGAAGAAATAAATATAGTTAATAATCCTATAGAAAAAAATAAACATGTTAGTTCAGATAAGTTAATACAAAAACGACCCAAATATTTAATGTTACCAATTGATACGACTGAATTAAA 
 
           1821                                                                                                                          1950 
    AS15CQ AAAAATGCAAAAAGGAAAATTACGACACCCACCTGTTGGTTTGATAAATTTAGGAAATACTTGCTACTTAAATAGTTTATTACAAGCATTATATAGTACTGTTTCATTTGTTGTTAATTTATACATTTTT 
    AS30CQ AAAAATGCAAAAAGGAAAATTACGACACCCACCTGTTGGTTTGATAAATTTAGGAAATACTTGCTACTTAAATAGTTTATTACAAGCATTATATAGTACTGTTTCATTTGTTGTTAATTTATACATTTTT 
    AS-ART AAAAATGCAAAAAGGAAAATTACGACACCCACCTGTTGGTTTGATAAATTTAGGAAATACTTGCTACTTAAATAGTTTATTACAAGCATTATATAGTACTGTTTCATTTGTTGTTAATTTATACATTTTT 
    AS-ATN AAAAATGCAAAAAGGAAAATTACGACACCCACCTGTTGGTTTGATAAATTTAGGAAATACTTGCTACTTAAATAGTTTATTACAAGCATTATATAGTACTGTTTCATTTGTTGTTAATTTATACATTTTT 
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           1951                                                                                                                          2080 
    AS15CQ AATATTGATGATAATAAAGAATTAAAACACATAAATAATAAAAATATCTCTAACGAAATGCCCATCAAAAATAAATTATCATTTAACCTGAACAATACAAACATGAATAATAATAATAATAATGCAAACT 
    AS30CQ AATATTGATGATAATAAAGAATTAAAACACATAAATAATAAAAATATCTCTAACGAAATGCCCATCAAAAATAAATTATCATTTAACCTGAACAATACAAACATGAATAATAATAATAATAATGCAAACT 
    AS-ART AATATTGATGATAATAAAGAATTAAAACACATAAATAATAAAAATATCTCTAACGAAATGCCCATCAAAAATAAATTATCATTTAACCTGAACAATACAAACATGAATAATAATAATAATAATGCAAACT 
    AS-ATN AATATTGATGATAATAAAGAATTAAAACACATAAATAATAAAAATATCTCTAACGAAATGCCCATCAAAAATAAATTATCATTTAACCTGAACAATACAAACATGAATAATAATAATAATAATGCAAACT 
 
           2081                                                                                                                          2210 
    AS15CQ TACTTTCAAAACGATTTTTATATGAGTTGAAAATATTATTTAAATTAATGACTACAACAAATAAAAAATATGTTTCACCAGATAATATTTTAGGTATACTACCTCAAGAACTTAACAATAGAAATCAACA 
    AS30CQ TACTTTCAAAACGATTTTTATATGAGTTGAAAATATTATTTAAATTAATGACTACAACAAATAAAAAATATGTTTCACCAGATAATATTTTAGGTATACTACCTCAAGAACTTAACAATAGAAATCAACA 
    AS-ART TACTTTCAAAACGATTTTTATATGAGTTGAAAATATTATTTAAATTAATGACTACAACAAATAAAAAATATGTTTCACCAGATAATATTTTAGGTATACTACCTCAAGAACTTAACAATAGAAATCAACA 
    AS-ATN TACTTTCAAAACGATTTTTATATGAGTTGAAAATATTATTTAAATTAATGACTACAACAAATAAAAAATATGTTTCACCAGATAATATTTTAGGTATACTACCTCAAGAACTTAACAATAGAAATCAACA 
 
           2211                                                                                                                          2340 
    AS15CQ AGATGTTACAGAATTATTTAGATATACATTTGAACAATTAGGAGGATCAGAAAAAAAATTTCTAAGATTAATATTTTCAGGAGTTGTTATACAAAAAGTTCAATGCCAAAAATGTTTTTTTATTTCAAAG 
    AS30CQ AGATGTTACAGAATTATTTAGATATACATTTGAACAATTAGGAGGATCAGAAAAAAAATTTCTAAGATTAATATTTTCAGGAGTTGTTATACAAAAATTTCAATGCCAAAAATGTTTTTTTATTTCAAAG 
    AS-ART AGATGTTACAGAATTATTTAGATATACATTTGAACAATTAGGAGGATCAGAAAAAAAATTTCTAAGATTAATATTTTCAGGAGTTGTTATACAAAAATTTCAATGCCAAAAATGTTTTTTTATTTCAAAG 
    AS-ATN AGATTTTACAGAATTATTTAGATATACATTTGAACAATTAGGAGGATCAGAAAAAAAATTTCTAAGATTAATATTTTCAGGAGTTGTTATACAAAAAGTTCAATGCCAAAAATGTTTTTTTATTTCAAAG 
 
           2341                                                                                                                          2470 
    AS15CQ AAAGAAGAAATTATCCACGATTTATCATTTCATGTTCCTGCAAAGTCAAGTAAAAAACAGTCTATCCAAAAATTCTTTGATACATATATTCAAAAAGAAAAAATTTATGGAAACAATAAATACAAATGCT 
    AS30CQ AAAGAAGAAATTATCCACGATTTATCATTTCATGTTCCTGCAAAGTCAAGTAAAAAACAGTCTATCCAAAAATTCTTTGATACATATATTCAAAAAGAAAAAATTTATGGAAACAATAAATACAAATGCT 
    AS-ART AAAGAAGAAATTATCCACGATTTATCATTTCATGTTCCTGCAAAGTCAAGTAAAAAACAGTCTATCCAAAAATTCTTTGATACATATATTCAAAAAGAAAAAATTTATGGAAACAATAAATACAAATGCT 
    AS-ATN AAAGAAGAAATTATCCACGATTTATCATTTCATGTTCCTGCAAAGTCAAGTAAAAAACAGTCTATCCAAAAATTCTTTGATACATATATTCAAAAAGAAAAAATTTATGGAAACAATAAATACAAATGCT 
 
           2471                                                                                                                          2600 
    AS15CQ CGAAATGCAACAAAAGGCGAAATGCCCTCAAGTGGAACGAAATCATATCCCCCCCCTGCCACCTCATACTAATTCTGAACAGGTAAACCAAAAAATGCAAAAAAATCCAAAAAAATCCAAAAAAATCCAA 
    AS30CQ CGAAATGCAACAAAAGGCGAAATGCCCTCAAGTGGAACGAAATCATATCCCCCCCCTGCCACCTCATACTAATTCTGAACAGGTAAACCAAAAAATGCAAAAAAATCCAAAAAAATCCAAAAAAATCCAA 
    AS-ART CGAAATGCAACAAAAGGCGAAATGCCCTCAAGTGGAACGAAATCATATCCCCCCCCTGCCACCTCATACTAATTCTGAACAGGTAAACCAAAAAATGCAAAAAAATCCAAAAAAATCCAAAAAAATCCAA 
    AS-ATN CGAAATGCAACAAAAGGCGAAATGCCCTCAAGTGGAACGAAATCATATCCCCCCCCTGCCACCTCATACTAATTCTGAACAGGTAAACCAAAAAATGCAAAAAAATCCAAAAAAATCCAAAAAAATCCAA 
 
           2601                                                                                                                          2730 
    AS15CQ AAAAATCCAAAAAAAAGCAAAAAAAAATATTTTTCACTTCGTCAATTTTTCATTTTTCAATTTTCCATTTCGTCAATTTTTCACTTCGTCAATTTTTCACTTCGTCATTTTTCCATTTTCCACTCCTTCC 
    AS30CQ AAAAATCCAAAAAAAAGCAAAAAAAAATATTTTTCACTTCGTCAATTTTTCATTTTTCAATTTTCCATTTCGTCAATTTTTCACTTCGTCAATTTTTCACTTCGTCATTTTTCCATTTTCCACTCCTTCC 
    AS-ART AAAAATCCAAAAAAAAGCAAAAAAAAATATTTTTCACTTCGTCAATTTTTCATTTTTCAATTTTCCATTTCGTCAATTTTTCACTTCGTCAATTTTTCACTTCGTCATTTTTCCATTTTCCACTCCTTCC 
    AS-ATN AAAAATCCAAAAAAAAGCAAAAAAAAATATTTTTCACTTCGTCAATTTTTCATTTTTCAATTTTCCATTTCGTCAATTTTTCACTTCGTCAATTTTTCACTTCGTCATTTTTCCATTTTCCACTCCTTCC 
 
           2731                                                                                                                          2860 
    AS15CQ CACTTTCAGGTACAACTGGTCGTTTAGCTCCAACGAAAAGAAGAAAATAAAAACGCACGTCAAGATCAACAAAAAGATAGTTGTAAACAATTTTGATTACCGATTGTATGGAGGAATAATTCACAGTGGC 
    AS30CQ CACTTTCAGGTACAACTGGTCGTTTAGCTCCAACGAAAAGAAGAAAATAAAAACGCACGTCAAGATCAACAAAAAGATAGTTGTAAACAATTTTGATTACCGATTGTATGGAGGAATAATTCACAGTGGC 
    AS-ART CACTTTCAGGTACAACTGGTCGTTTAGCTCCAACGAAAAGAAGAAAATAAAAACGCACGTCAAGATCAACAAAAAGATAGTTGTAAACAATTTTGATTACCGATTGTATGGAGGAATAATTCACAGTGGC 
    AS-ATN CACTTTCAGGTACAACTGGTCGTTTAGCTCCAACGAAAAGAAGAAAATAAAAACGCACGTCAAGATCAACAAAAAGATAGTTGTAAACAATTTTGATTACCGATTGTATGGAGGAATAATTCACAGTGGC 
 
           2861                                                                                                                          2990 
    AS15CQ GTGTCAGCATCATCAGGTCATTATTATTTTATCGGAAAGAAATCCGAAAAAGGTGACAATTCAAAAAATGAATGGTATCAAATGGACGACTCAGCTATTACTAAAGTTAGTTCCAAATCCATAAACCGAA 
    AS30CQ GTGTCAGCATCATCAGGTCATTATTATTTTATCGGAAAGAAATCCGAAAAAGGTGACAATTCAAAAAATGAATGGTATCAAATGGACGACTCAGCTATTACTAAAGTTAGTTCCAAATCCATAAACCGAA 
    AS-ART GTGTCAGCATCATCAGGTCATTATTATTTTATCGGAAAGAAATCCGAAAAAGGTGACAATTCAAAAAATGAATGGTATCAAATGGACGACTCAGCTATTACTAAAGTTAGTTCCAAATCCATAAACCGAA 
    AS-ATN GTGTCAGCATCATCAGGTCATTATTATTTTATCGGAAAGAAATCCGAAAAAGGTGACAATTCAAAAAATGAATGGTATCAAATGGACGACTCAGCTATTACTAAAGTTAGTTCCAAATCCATAAACCGAA 
 201
 
 
 
 
 
            2991                                                                                 3079 
    AS15CQ  TTTCTAAAGATCCATCAAATGATCACACTCCTTACGTTTTATTTTATCGTTGCAAACAAGCTCCCGATTCCCCAAGCTTATACTTTTAA 
    AS30CQ  TTTCTAAAGATCCATCAAATGATCACACTCCTTACGTTTTATTTTATCGTTGCAAACAAGCTCCCGATTCCCCAAGCTTATACTTTTAA 
    AS-ART  TTTCTAAAGATCCATCAAATGATCACACTCCTTACGTTTTATTTTATCGTTGCAAACAAGCTCCCGATTCCCCAAGCTTATACTTTTAA 
    AS-ATN  TTTCTAAAGATCCATCAAATGATCACACTCCTTACGTTTTATTTTATCGTTGCAAACAAGCTCCCGATTCCCCAAGCTTATACTTTTAA 
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APPENDIX 5 
 
THE RELATIVE INTENSITY AND COMPARATIVE INTENSITES OF 
ALL AFLP MARKERS ANALYSED IN THE LGS EXPERIMENTS 
DESCRIBED IN CHAPTER V 
 
A - AS-ART x AJ – AJ specific AFLP markers 
 
Marker Name 
CM distance along chromosome 
Relative Intensity 
Comparative Intensity ART 
treated/Untreated AJ Marker 
Non 
passaged Untreated  
ART 
treated 
Chromosome 1 
AJTG01GT 12 1,31 1,26 1,09 0,8651 
AJAC03TA 16,2 1,19 1,23 0,59 0,4797 
AJAG02TC 16,2 0,5 0,3 0,2 0,6667 
AJTA03AT 16,2 0,5 0,42 0,34 0,8095 
AJAG01GT 25,4 1,8 2,3 1,2 0,5217 
AJTG01AA 43,4 0,64 0,9 0,57 0,6333 
Chromosome 5 
AJAA04AC 70 0,5 0,7 0,6 0,8571 
AJAT07AT 70 0,4 0,41 0,23 0,5610 
AJAT01AT 73,9 1,16 2,51 1,28 0,5100 
AJTA01AC 77,5 1,97 1,02 0,56 0,5490 
AJAG01TT 82,7 0,4 0,3 0,3 1,0000 
AJAA03TA 82,9 0,6 0,6 0,3 0,5000 
Chromosome 6 
AJAG02AG 11,3 0,1 0,3 0,3 1,0000 
AJAG02CT 11,3 0,6 0,4 0,2 0,5000 
AJAC01GT 11,3 1,06 0,55 0,8 1,4545 
AJAT02TA 11,3 0,93 0,88 0,8 0,9091 
AJTC02CT 11,3 1,08 0,81 0,64 0,7901 
AJTC01TC 11,3 0,45 0,45 0,45 1,0000 
AJTG02AA 11,3 0,84 0,82 0,75 0,9146 
AJTT05AT 11,3 7,03 10,78 1,35 0,1252 
AJAG01CT 16,1 0,5 0,7 0,5 0,7143 
AJAT03TG 29,3 0,82 0,8 0,6 0,7500 
AJTA02GA 37,1 2,07 2,3 2,22 0,9652 
AJTT01CA 44,3 1,44 0,45 0,38 0,8444 
AJTA02AC 62,7 0,34 0,31 0,22 0,7097 
Chromosome 7 
AJAA02TG 24,1 2 2 1 0,5000 
AJAG01AG 37,2 0,5 0,5 0,5 1,0000 
AJAA01GA 37,3 2,9 1,7 1,2 0,7059 
AJAT01GT 37,3 0,61 0,54 0,31 0,5741 
AJTT06AT 48,5 0,49 2,55 2,66 1,0431 
AJTA01CA 62,3 0,73 0,58 0,26 0,4483 
AJGA03AC 77,5 0,87 1,29 0,58 0,4496 
AJAT02TC 77,5 1,05 0,73 0,45 0,6164 
AJTG02AT 77,5 2,54 1,51 0,71 0,4702 
AJTG01TC 77,5 1,28 1,07 0,69 0,6449 
AJAT02AC 77,7 1,82 1,41 0,81 0,5745 
AJTT03TG 81,4 0,1 0,54 0,88 1,6296 
AJAA05CA 96,3 0,68 0,47 0,29 0,6170 
AJAG02CA 100,3 0,8 0,7 0,6 0,8571 
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AJTG01AG 104,4 0,05 0,15 0,12 0,8000 
AJTG01GA 104,4 0,68 0,96 0,7 0,7292 
AJAC02TT 123,8 3,39 2,44 1,23 0,5041 
AJTC01AG 135,1 0,06 0,03 0,03 1,0000 
AJAA03AT 135,3 0,3 0,4 0,3 0,7500 
Chromosome 8 
AJAG03AG 0 0,2 0,2 0,06 0,3000 
AJTT02AT 17,3 0,8 0,4 0,06 0,1500 
AJAT01TA 21,3 2,99 3,22 1,04 0,3230 
AJTT07AT 25,9 0,86 0,82 1,04 1,2683 
AJAC02AG 43 1,2 1 0,7 0,7000 
AJAC02AT 46,2 0,37 0,42 0,21 0,5000 
AJTG03AA 55 0,69 1,2 0,56 0,4667 
AJTC01TG 58,5 2,13 2,15 1,33 0,6186 
AJAC03AT 73,2 1,96 1,57 0,5 0,3185 
Chromosome 9 
AJAT05TG 40,2 2,26 1,45 1,35 0,9310 
AJAT01TC 40,2 1,86 1,31 0,84 0,6412 
AJTA01GT 40,2 5,96 6,75 4,09 0,6059 
AJAC01AA 51,7 0,83 0,9 0,5 0,5556 
AJAC01CT 51,7 1,45 0,64 0,53 0,8281 
AJAG01TC 63,5 0,2 0,4 0,3 0,7500 
AJAT04TA 67,2 0,57 0,64 0,47 0,7344 
Chromosome 10 
AJGA01TT 7,2 0,65 0,45 0,12 0,2667 
AJAG03AC 10,9 0,8 0,8 0,2 0,2500 
AJAC02AC 10,9 3,7 2,6 0,8 0,3077 
AJAC02AA 18,4 0,75 0,6 0,1 0,1667 
AJGA03AG 18,4 0,67 0,82 0,18 0,2195 
AJGA01CA 18,4 0,75 0,74 0,15 0,2027 
AJGA02CA 18,4 1,46 1,18 0,33 0,2797 
Chromosome 11 
AJAT03CT 5,3 0,64 0,83 0,41 0,4940 
AJAC01CA 9,6 1,26 1,52 0,93 0,6118 
AJTT03AT 9,7 0,7 0,39 0,06 0,1538 
AJTT03CA 9,7 14,2 0,8 0,58 0,7250 
AJTT02GA 9,7 0,26 0,4 0,38 0,9500 
AJTT03AA 13,6 0,99 0,9 0,66 0,7333 
AJAT03AA 17,6 1,67 1,75 1 0,5714 
AJAT01AA 21,6 0,71 0,99 0,46 0,4646 
AJGA02TT 31,2 0,53 0,23 0,12 0,5217 
AJTA01TT 39,3 0,74 0,71 0,55 0,7746 
AJTG05AT 39,3 0,5 0,61 0,38 0,6230 
AJAT06CT 44,6 3,08 2,15 1,72 0,8000 
AJAG01TA 48,7 0,5 0,5 0,4 0,8000 
AJAC01TA 53 1,71 1,11 0,82 0,7387 
Chromosome 12 
AJTT04AT 13,3 1,05 0,44 0,06 0,1364 
AJAC01GA 20,8 0,42 0,38 0,24 0,6316 
AJTT01CT 24,6 0,04 0,19 0,69 3,6316 
AJAA02TC 35,9 2 0,8 0,5 0,6250 
AJTC01CT 50,9 1,29 0,8 0,46 0,5750 
AJAT04CT 79,9 0,53 0,8 0,59 0,7375 
AJAG01TG 106,8 0,3 0,5 0,4 0,8000 
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AJTC01TA 111,4 0,56 0,46 0,29 0,6304 
AJTT02AA 123,5 0,79 0,47 0,34 0,7234 
AJAA03TC 123,6 0,5 0,4 0,3 0,7500 
Chromosome 13 
AJTT01AG 15,2 1,02 0,77 0,69 0,8961 
AJAA03TG 28,5 1 1,5 1 0,6667 
AJAC04.0AT 28,5 0,51 0,65 0,46 0,7077 
AJTA01GA 28,5 1,51 2,38 1,35 0,5672 
AJTT04AA 32,4 0,31 0,29 0,42 1,4483 
AJTT02AC 36,7 0,71 0,97 1,03 1,0619 
AJAA01AT 44,5 0,8 0,8 0,8 1,0000 
AJAT02TG 64 1,01 0,53 0,51 0,9623 
AJTA01AG 72,9 15,39 18,47 6,69 0,3622 
AJGA02AA 76,9 1,02 0,98 0,71 0,7245 
AJAA03AC 136,1 0,7 0,8 0,5 0,6250 
AJAA01TG 151,2 0,3 0,1 0,1 1,0000 
AJAG04AG 177,9 0,9 0,3 0,2 0,6667 
AJTG02AG 183,4 0,57 0,76 0,83 1,0921 
AJTT02TG 183,4 1,4 1,47 1,16 0,7891 
AJTT02TT 183,4 0,95 1,38 1,35 0,9783 
AJTT02CA 183,4 1,28 0,32 0,2 0,6250 
AJGA02AG 183,5 1,88 1,96 1,47 0,7500 
AJGA02CT 183,5 0,3 0,29 0,23 0,7931 
AJTA01TC 187,9 0,3 0,32 0,17 0,5313 
AJAA03CA 200 1,09 1,23 0,73 0,5935 
AJAC03TT 200 5,47 4,07 2,94 0,7224 
AJAT02AT 200 1,49 1,09 0,97 0,8899 
AJAA01AG 208,2 0,5 0,3 0,3 1,0000 
AJTG01TG 217,8 0,04 0,02 0,03 1,5000 
Group 31 
AJTT02CT 0 58,5 1,33 1,11 0,8346 
Group 12 
AJAG02AC 28,3 0,6 0,4 0,3 0,7500 
AJAG02TA 0 0,2 0,3 0,2 0,6667 
AJGA01AG 4 0,35 0,35 0,5 1,4286 
AJAC04TA 4 0,89 1,11 0,67 0,6036 
AJTG03AT 12,8 0,73 0,54 0,37 0,6852 
AJAC04AA 20,3 0,5 0,6 0,6 1,0000 
AJGA01AC 20,3 1,78 1,44 1,06 0,7361 
AJAT04AT 20,3 2,1 1,35 1,15 0,8519 
AJTT03CT 28,3 57,19 0,49 0,42 0,8571 
AJGA02AC 28,3 1,64 1,91 0,84 0,4398 
Group 14 
AJTG02CT 4 1,5 1 1,14 1,1400 
AJTT01TT 8,2 0,31 0,49 0,45 0,9184 
Group 15 
AJAT03AC 0 1,03 0,88 0,5 0,5682 
AJTC01GT 4,4 0,9 0,87 0,64 0,7356 
AJTG04AT 24,5 0,94 1,19 0,56 0,4706 
AJTT01AA 48,4 O,73 0,41 0,28 0,6829 
Group 2 
AJAA02TA 0 0,6 0,5 0,3 0,6000 
AJAG02TT 19,8 0,8 0,9 0,5 0,5556 
AJAC05AT 24,4 2,44 1,49 0,75 0,5034 
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AJAA01TA 28,1 0,4 0,5 0,2 0,4000 
AJGA02TA 33,1 0,67 0,69 0,37 0,5362 
AJAG02AT 36,8 0,7 0,6 0,2 0,3333 
AJTT01TC 44,6 2,25 2,43 1,5 0,6173 
AJGA01GA 71,9 1,37 1,22 0,46 0,3770 
AJTT01GT 71,9 4,82 0,67 1,03 1,5373 
AJTA03AC 79,6 0,55 0,47 0,17 0,3617 
AJAC01TT 88,4 3,9 2,9 1,27 0,4379 
AJGA01AT 88,4 0,42 0,59 0,53 0,8983 
AJAT05AT 120,6 1,13 0,83 0,52 0,6265 
Group 20 
AJAT03TA 4,6 5,01 4,35 3,43 0,7885 
AJAA01GT 8,7 0,5 0,5 0,5 1,0000 
AJAT02AA 8,7 0,36 0,41 0,28 0,6829 
AJAT01AC 8,7 1,26 1,4 0,96 0,6857 
AJTC02TA 8,7 2,36 2,12 1,47 0,6934 
AJAA05AC 16,8 1,5 1,3 1 0,7692 
AJAT02GT 16,8 1,13 0,83 0,61 0,7349 
AJAT04TG 25,5 1 0,65 0,57 0,8769 
AJTT05AA 43,7 0,15 0,11 0,13 1,1818 
AJAT01TG 43,7 0,95 0,5 0,42 0,8400 
AJAT04AA 47,5 0,31 0,45 0,34 0,7556 
AJAT02CT 71,9 1,12 0,99 0,41 0,4141 
AJAT01CT 84,2 1,98 0,9 0,8 0,8889 
AJTG01CT 84,2 0,98 1,08 1 0,9259 
AJTT06AA 84,2 0,16 0,15 0,13 0,8667 
AJAG03AT 92,7 1,5 1 0,6 0,6000 
AJGA02AT 92,7 0,85 0,81 0,74 0,9136 
Group 21 
AJAA01AC 0 1,2 1,3 1,2 0,9231 
Group 29 
AJAT01CA 0 0,33 0,44 0,29 0,6591 
Group 3 
AJTT07AA 40,7 1,63 0,91 0,87 0,9560 
AJAC01AG 44,2 1,44 1,42 1,4 0,9859 
AJTT01AC 49,5 0,49 0,53 0,45 0,8491 
AJTA02AT 51,4 0,29 0,3 0,21 0,7000 
AJAC01AT 63,8 0,88 0,97 0,87 0,8969 
AJAA02TT 75,5 1,9 1,1 0,6 0,5455 
AJTA01AT 86,4 0,58 0,48 0,42 0,8750 
Group 33 
AJTT01AT 8,1 0,52 1,21 0,18 0,1488 
AJGA01AA 22,5 1,28 0,83 0,44 0,5301 
Group 38 
AJTA02AG 7,5 1,24 0,91 0,26 0,2857 
AJAC01TG 11 0,65 0,53 0,24 0,4528 
AJGA01TA 15,8 0,64 0,66 0,21 0,3182 
Group 6 
AJGA01TG 0 1,03 0,86 0,59 0,6860 
AJGA01CT 0 0,64 0,6 0,32 0,5333 
AJTT01TG 0 2,08 1,69 1,51 0,8935 
AJAA02AT 8,5 1 1 0,8 0,8000 
AJAG01AT 19,4 0,4 0,6 0,7 1,1667 
No data  
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AJAG02TG ................................................ 0,7 0,7 0,4 0,5714 
AJAA01TC ................................................ 1 0,9 0,9 1,0000 
AJAC04.5AT ................................................ 0,45 0,25 0,09 0,3600 
AJGA04AT ................................................ 0,56 0,8 0,49 0,6125 
AJGA05AT ................................................ 0,37 0,39 0,25 0,6410 
AJAC02TA .............................................. 0,92 0,75 0,46 0,6133 
AJGA03AA ............................................. 0,86 0,78 0,61 0,7821 
AJTA01TG ............................................. 3,91 3,46 2,86 0,8266 
AJTA03GA .............................................. 0,72 1,39 1,37 0,9856 
AJTC02AG .............................................. 0,43 0,53 0,24 0,4528 
AJTC02TG .............................................. 0,12 0,3 0,42 1,4000 
AJTG04AG ............................................. 0,88 0,97 0,76 0,7835 
AJTG05AG ............................................. 1,16 1,75 2,95 1,6857 
AJTG02TG .............................................. 0,04 0,03 0,04 1,3333 
AJTG03TG .............................................. 2,41 0,98 0,65 0,6633 
AJAG03CA .............................................. 0,3 0,4 0,3 0,7500 
AJAG05CT .............................................. 0,6 0,5 0,3 0,6000 
AJAG01AC .............................................. 0,09 0,09 0,15 1,6667 
AJAT01GA .............................................. 1,69 1,68 0,85 0,5060 
Unlinked 
AJAG01AA ............................................. 0,5 0,8 1 1,2500 
AJAA02AC .............................................. 1 1 1 1,0000 
AJAC03AG .............................................. 3,74 3,11 2,23 0,7170 
AJAA01CA .............................................. 1,39 1,08 0,7 0,6481 
AJAC02CT .............................................. 3,33 2,07 1,57 0,7585 
AJGA03AT .............................................. 1,41 0,91 0,41 0,4505 
AJAT06AT .............................................. 0,66 0,5 0,31 0,6200 
AJAT02CA .............................................. 0,8 0,53 0,3 0,5660 
AJTA01CT .............................................. 0,73 0,61 0,64 1,0492 
AJTC01AT .............................................. 0,86 0,3 0,5 1,6667 
AJTT03GA .............................................. 10,92 1,57 1,32 0,8408 
  
B - AS-ART x AJ – AS specific AFLP markers 
 
Marker Name 
CM distance along chromosome 
Relative Intensity 
Comparative Intensity ART 
treated/Untreated AS Markers 
Non 
passaged Untreated  
ART 
treated 
Chromosome 1 
ASAA01TC 16,2 0,56 0,09 0,28 3,1111 
ASAA02CA 16,2 1,39 0,25 0,9 3,6000 
ASTA01TT 16,2 1,08 0,42 0,65 1,5476 
ASTA02AT 16,2 0,29 0,07 0,22 3,1429 
ASTA02GT 16,2 1,47 0,24 0,57 2,3750 
ASTG01AA 43,4 0,7 0,13 0,3 2,3077 
Chromosome 5 
ASAA03TG 26,7 0,81 0,24 0,46 1,9167 
ASAA02GA 54,4 0,85 0,18 0,38 2,1111 
ASAC03AT 69,9 1,24 0,24 0,68 2,8333 
ASAA04AC 69,9 0,31 0,09 0,19 2,1111 
ASAC01AG 74,6 0,67 0,09 0,32 3,5556 
ASTA01AC 74,6 1,3 0,36 0,63 1,7500 
Chromosome 6 
ASAC02AT 11,3 0,75 0,08 0,2 2,5000 
ASAT01AA 11,3 0,31 0,13 0,24 1,8462 
ASTC01TC 11,3 0,17 0,09 0,18 2,0000 
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ASTG01AT 11,3 1,94 0,3 0,69 2,3000 
ASTT01CA 44,2 0 1,54 0,09 0,0584 
ASAG01TG 62,6 1,6 0,25 0,46 1,8400 
Chromosome 7 
ASAA02GT 31,6 1,08 0,29 0,42 1,4483 
ASAC01GT 31,6 0,68 0,13 0,18 1,3846 
ASAA01CA 48,4 1,21 0,28 1,03 3,6786 
ASAA05CA 62,2 1 0,35 0,97 2,7714 
ASTT03CA 62,2 1,09 0,72 0,8 1,1111 
ASAC05AA 69,7 0,85 0,58 0,6 1,0345 
ASAT02AT 69,7 0,55 0,11 0,37 3,3636 
ASTG01TC 77,5 0,17 0,11 0,31 2,8182 
ASAG02CA 100,3 1,7 0,2 0,6 3,0000 
ASTT01AG 123,6 0,07 0,13 0,14 1,0769 
ASAC01TA 127,6 1,23 0,19 0,61 3,2105 
Chromosome 8 
ASAC01TG 30,8 1,19 0,3 0,85 2,8333 
ASTA01AT 34,3 0,38 0,16 0,25 1,5625 
ASAG01CA 38,2 1,4 0,1 0,5 5,0000 
ASGA02AC 43 1,36 0,41 1,23 3,0000 
ASTG02AA 50,8 0,12 0,59 0,43 0,7288 
ASTC01CT 58,5 44,6 12,7 31,35 2,4646 
ASAC01AT 73,2 0,44 0,05 0,28 5,6000 
ASAT03AC 73,2 1,46 0,39 1,22 3,1282 
Chromosome 9 
ASTA01GT 40,2 4,04 2,18 3,43 1,5734 
ASAA04CA 40,2 1,02 0,24 0,68 2,8333 
ASAC03CT 51,7 0,91 0,18 0,64 3,5556 
ASTT05CA 51,7 0,85 0,8 0,6 0,7500 
ASAT04AA 59,2 0,41 0,16 0,33 2,0625 
ASTT02TT 71,1 389 0,55 0,04 0,0727 
Chromosome 10 
ASGA01TC 7,2 0,46 0,11 0,39 3,5455 
ASTG01CA 7,2 20,8 1,03 0,98 0,9515 
ASTT01TT 10,9 0,01 18,6 2,93 0,1573 
ASGA01CA 18,4 0,99 0,22 0,75 3,4091 
ASAT05AA 18,4 0,31 0,11 0,28 2,5455 
ASTA02AG 18,4 0,37 0,15 0,47 3,1333 
Chromosome 11 
ASAG03CA 5,3 2,4 0,1 0,9 9,0000 
ASAT03AA 5,3 0,95 0,27 0,78 2,8889 
ASTC02AC 5,3 0,25 0,12 0,28 2,3333 
ASTT02AA 5,3 0,09 0,07 0,07 1,0000 
ASTA03GA 21,5 1,17 0,17 0,59 3,4706 
ASTC01CA 21,5 1,21 0,28 0,8 2,8571 
ASTA01TA 39,2 0,29 0,12 0,21 1,7500 
ASTC01AC 39,2 0,07 0,04 0,06 1,5000 
ASTG01TA 39,2 0,59 0,15 0,34 2,2667 
ASAG01TA 48,7 0,6 0,3 0,4 1,3333 
ASAA01TG 52,9 1,32 0,82 0,47 0,5732 
ASAC02TA 52,9 1,65 0,14 0,35 2,5000 
Chromosome 12 
ASAC02CT 20,8 0,83 0,06 0,31 5,1667 
ASAA01AT 54,6 0,82 0,38 0,86 2,2632 
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ASAC03AA 54,6 0,99 0,25 0,66 2,6400 
ASGA02AG 66,4 1,17 0,39 1,09 2,7949 
ASTC01TA 111,4 0,61 0,07 0,33 4,7143 
Chromosome 13 
ASAA05AT 0 1,67 0,56 0,55 0,9821 
ASTG02TT 3,9 0,8 0,1 0,19 1,9000 
ASTA01AA 15,2 1,08 0,41 0,71 1,7317 
ASTT02AG 15,2 0,14 0,1 0,24 2,4000 
ASTT01GA 28,5 1,23 1,84 1,47 0,7989 
ASAA01TA 36,1 1,57 0,14 0,39 2,7857 
ASAA04TA 36,1 0,73 0,09 0,26 2,8889 
ASTA02CA 36,1 0,42 0,14 0,29 2,0714 
ASTA02CA 36,1 1,22 0,29 0,42 1,4483 
ASAA03AT 44,6 0,31 0,15 0,23 1,5333 
ASTA01AG 73 11,2 7,84 5,9 0,7526 
ASTT02TC 132,5 0,01 0,01 0,02 2,0000 
ASGA02TA 177,9 0,14 0,02 0,06 3,0000 
ASAT01AC 177,9 0,94 0,4 0,62 1,5500 
ASGA03CA 177,9 0,58 0,08 0,19 2,3750 
ASTA03TA 183,5 1,65 0,45 1,23 2,7333 
ASTG03AA 183,5 0,43 0,09 0,27 3,0000 
ASTT02CA 183,5 0 2,65 0,93 0,3509 
ASTA01CT 200,1 0,36 0,11 0,16 1,4545 
ASTA01CT 200,1 0,79 0,29 0,42 1,4483 
ASTT04AT 200,1 0,96 1,88 0,98 0,5213 
ASAT01AT 209,2 1,33 0,3 0,65 2,1667 
ASGA02AT 221,9 0,85 0,14 0,34 2,4286 
Group 12  
ASAC01GA 4 1,15 0,24 0,67 2,7917 
ASGA01AG 4 0,82 0,12 0,3 2,5000 
ASAT09AA 4 0,44 0,2 0,25 1,2500 
ASAT08AA 12,8 0,58 0,14 0,29 2,0714 
ASAA01GT 20,3 0,73 0,15 0,4 2,6667 
ASGA03AC 20,3 0,46 0,24 0,23 0,9583 
ASGA01AC 24,4 1,35 0,25 0,93 3,7200 
ASTA02TA 28,3 3,24 0,92 1,74 1,8913 
Group 14  
ASTA03AA 0 2,65 0,26 0,69 2,6538 
ASTA02AA 4 0,62 0,15 0,31 2,0667 
Group 16 
ASAT04AC 0 0,98 0,26 0,64 2,4615 
ASTG01TT 0 0,51 0,1 0,18 1,8000 
ASTT01CT 4,4 0 0,25 0,28 1,1200 
ASAG01CT 12,4 1,6 0,2 1 5,0000 
ASAA03TA 32,2 0,61 0,21 0,35 1,6667 
ASTT01AC 40,3 8,43 2,25 0,93 0,4133 
ASTT03AA 59,2 0,08 0,07 0,08 1,1429 
ASTT01AA 74,5 0,16 2,4 0,65 0,2708 
Group 2 
ASAA02AT 0 0,8 0,17 0,59 3,4706 
ASAG01TT 7,8 1,5 0,3 0,8 2,6667 
ASAC02AG 24,4 0,91 0,16 0,55 3,4375 
ASTC01GA 24,4 3,59 1,04 3,31 3,1827 
ASTT01AT 71,9 0,41 0,28 0,41 1,4643 
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ASTT04CA 71,9 46,8 0,71 1,11 1,5634 
Group 20 
ASGA02CA 4,6 0,59 0,06 0,15 2,5000 
ASAA04TC 8,7 0,77 0,11 0,21 1,9091 
ASAA01GA 8,7 1,34 0,27 0,66 2,4444 
ASTC02TC 8,7 0,04 0,03 0,03 1,0000 
ASAA06AC 16,8 0,17 0,68 0,52 0,7647 
ASAA03TC 43,7 1,06 0,25 0,35 1,4000 
ASAA02TG 55 0,99 0,52 0,65 1,2500 
ASAG01GA 64,2 2,3 0,48 1,4 2,9167 
ASAC01CT 84,2 0,42 0,14 0,36 2,5714 
ASTG02CT 84,2 1,09 1,19 1,07 0,8992 
Group 21 
ASAA01AC 0 0,09 0,05 0,08 1,6000 
Group 3 
ASGA01AT 40 0,81 0,06 0,28 4,6667 
ASAA02TA 44,2 1,11 0,57 0,34 0,5965 
ASAA03CT 44,2 2,55 0,54 0,95 1,7593 
ASAT11AA 44,2 0,94 0,25 0,3 1,2000 
ASAT02AA 63,8 0,21 0,12 0,07 0,5833 
ASTA01CA 75,5 1,24 0,13 0,66 5,0769 
ASTA01CA 75,5 0,8 0,13 0,27 2,0769 
Group 30 
ASTT01TC 11,9 1,97 1,16 1,22 1,0517 
Group 33 
ASTT02AT 0 0,09 0,04 0,02 0,5000 
ASAT02AC 8,1 1,73 0,4 0,62 1,5500 
Group 6 
ASGA01TA 0 1,92 0,49 1,05 2,1429 
ASGA01GA 0 1,7 1,22 0,46 0,3770 
ASTG01GA 0 0,13 1,4 1,18 0,8429 
ASAT06AA 23,4 0,33 0,13 0,25 1,9231 
No data 
ASTA04GA ............................................... 4,25 0,54 2,05 3,7963 
ASTA04CA ............................................... 0,27 0,2 0,18 0,9000 
ASTA02TG ............................................... 0,55 0,76 0,64 0,8421 
ASTA02GA ............................................... 0,71 0,16 0,4 2,5000 
ASTA03TG ............................................... 0,7 0,23 0,33 1,4348 
ASTA04TC ............................................... 2,68 1,39 4,56 3,2806 
ASTA02TC ............................................... 0,96 0,12 0,48 4,0000 
ASTA03TC ............................................... 1,78 0,12 0,58 4,8333 
ASGA01AA ............................................... 1,27 0,12 0,29 2,4167 
ASGA02AA ............................................... 1,26 0,14 0,66 4,7143 
ASGA03AA ............................................... 0,04 0,03 0,07 2,3333 
ASGA04AA ............................................... 1,56 0,94 0,63 0,6702 
ASGA05AA ............................................... 2,68 0,48 1,28 2,6667 
ASGA06AA ............................................... 1,35 0,31 0,68 2,1935 
ASGA07AA ............................................... 1,78 0,37 1,09 2,9459 
ASGA08AA ............................................... 0,78 0,16 0,31 1,9375 
ASTA01GA ............................................... 1,37 0,36 0,84 2,3333 
ASTA04TG ............................................... 1,7 1,33 1,29 0,9699 
ASTA02TT ............................................... 0,83 0,3 0,3 1,0000 
ASTA01TC ............................................... 1,77 0,05 0,04 0,8000 
ASTC02GT ............................................... 1,35 2,06 1,66 0,8058 
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ASTA03CA ............................................... 0,35 0,09 0,1 1,1111 
ASTA01TC ............................................... 1,27 0,13 0,43 3,3077 
ASTC03AA ............................................... 0,51 0,11 0,33 3,0000 
ASTC03TC ............................................... 1,41 0,28 1,19 4,2500 
ASTG04AA ............................................... 0,36 0,15 0,16 1,0667 
ASTG02TC ............................................... 0,58 0,06 0,49 8,1667 
ASTG02GA ............................................... 0,13 1,35 1,28 0,9481 
ASTG0AT ............................................... 0,84 0,08 0,18 2,2500 
ASTG0GT ............................................... 11,6 1,57 1,14 0,7261 
ASTT0TC ............................................... 0,14 0,44 0,44 1,0000 
ASTT00TC ............................................... 0,01 1,12 1,23 1,0982 
ASTT0TT ............................................... 58,1 0,82 0,9 1,0976 
ASTT00TT ............................................... 0,89 0,97 1 1,0309 
ASTT000TT ............................................... 0 1,02 1,15 1,1275 
ASTT0CT ............................................... 0,06 114 5,53 0,0483 
ASTT00CT ............................................... 1,61 1,46 1,14 0,7808 
ASTC02TT ............................................... 0,19 0,02 0,07 3,5000 
ASTG01CT ............................................... 0,03 1 0,84 0,8400 
ASAA05AC ............................................... 0,48 0,12 0,37 3,0833 
ASGA01TT ............................................... 0,38 0,24 0,28 1,1667 
ASTC01TT ............................................... 1,38 0,57 0,05 0,0877 
ASTT03AT ............................................... 1,29 1,04 1,24 1,1923 
Unlinked 
ASAA04AT ............................................... 1,86 0,47 0,72 1,5319 
ASAC06AA ............................................... 5,25 3,33 4,21 1,2643 
ASAA01CT ............................................... 1,28 0,23 0,6 2,6087 
ASAT07AA ............................................... 0,45 0,07 0,17 2,4286 
ASTC01AA ............................................... 0,95 0,31 0,88 2,8387 
ASTC02AA ............................................... 1,04 0,22 0,54 2,4545 
 
C - AS-ATN x AJ – AJ specific AFLP markers 
 
Marker Name 
CM distance along 
chromosome  
Relative Intensity 
Comparative Intensity ATN treated/Untreated AJ Marker Non passaged Untreated  
ATN 
treated 
Chromosome 1 
AJTG01GT 12 1,31 1 1,05 1,0500 
AJAC03TA 16,2 1,19 0,91 0,62 0,6813 
AJAG02TC 16,2 0,5 0,3 0,3 1,0000 
AJTA03AT 16,2 0,5 0,38 0,36 0,9474 
AJAG01GT 25,4 1,8 2,2 2 0,9091 
AJTG01AA 43,4 0,64 1,08 0,79 0,7315 
Chromosome 5 
AJAA04AC 70 0,5 0,8 0,5 0,6250 
AJAT07AT 70 0,4 0,39 0,33 0,8462 
AJAT01AT 73,9 1,16 2,59 1,57 0,6062 
AJTA01AC 77,5 1,97 0,8 0,7 0,8750 
AJAG01TT 82,7 0,4 0,2 0,2 1,0000 
AJAA03TA 82,9 0,6 0,5 0,4 0,8000 
Chromosome 6 
AJAG02AG 11,3 0,1 0,2 0,2 1,0000 
AJAG02CT 11,3 0,6 0,4 0,3 0,7500 
AJAC01GT 11,3 1,06 1,63 2,05 1,2577 
AJAT02TA 11,3 0,93 0,66 0,58 0,8788 
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AJTC02CT 11,3 1,08 0,59 0,56 0,9492 
AJTC01TC 11,3 0,45 0,34 0,35 1,0294 
AJTG02AA 11,3 0,84 0,65 0,63 0,9692 
AJTT05AT 11,3 7,03 1,09 1,28 1,1743 
AJAG01CT 16,1 0,5 0,3 0,4 1,3333 
AJAT03TG 29,3 0,82 0,49 0,44 0,8980 
AJTA02GA 37,1 2,07 1,75 1,09 0,6229 
AJTT01CA 44,3 1,44 1,84 2,6 1,4130 
AJTA02AC 62,7 0,34 0,14 0,1 0,7143 
Chromosome 7 
AJAA02TG 24,1 2 1 1 1,0000 
AJAG01AG 37,2 0,5 0,4 0,7 1,7500 
AJAA01GA 37,3 2,9 1,5 1,8 1,2000 
AJAT01GT 37,3 0,61 0,45 0,45 1,0000 
AJTT06AT 48,5 0,49 2,1 1,75 0,8333 
AJTA01CA 62,3 0,73 0,69 0,39 0,5652 
AJGA03AC 77,5 0,87 0,92 0,84 0,9130 
AJAT02TC 77,5 1,05 0,61 0,69 1,1311 
AJTG02AT 77,5 2,54 1,19 1,28 1,0756 
AJTG01TC 77,5 1,28 0,93 0,74 0,7957 
AJAT02AC 77,7 1,82 1,19 0,98 0,8235 
AJTT03TG 81,4 0,1 32 214 6,6875 
AJAA05CA 96,3 0,68 0,52 0,56 1,0769 
AJAG02CA 100,3 0,8 0,5 0,8 1,6000 
AJTG01AG 104,4 0,05 0,3 0,26 0,8667 
AJTG01GA 104,4 0,68 0,78 1 1,2821 
AJAC02TT 123,8 3,39 2,09 2,02 0,9665 
AJTC01AG 135,1 0,06 0,03 0,02 0,6667 
AJAA03AT 135,3 0,3 0,4 0,6 1,5000 
Chromosome 8 
AJAG03AG 0 0,2 0,14 0,1 0,7143 
AJTT02AT 17,3 0,8 0,5 0,3 0,6000 
AJAT01TA 21,3 2,99 2,37 1,62 0,6835 
AJTT07AT 25,9 0,86 0,83 0,73 0,8795 
AJAC02AG 43 1,2 1,5 0,8 0,5333 
AJAC02AT 46,2 0,37 0,45 0,25 0,5556 
AJTG03AA 55 0,69 1,25 0,73 0,5840 
AJTC01TG 58,5 2,13 2,33 1,06 0,4549 
AJAC03AT 73,2 1,96 1,54 0,91 0,5909 
Chromosome 9 
AJAT05TG 40,2 2,26 2,06 1,76 0,8544 
AJAT01TC 40,2 1,86 0,94 1,05 1,1170 
AJTA01GT 40,2 5,96 2,93 4,98 1,6997 
AJAC01AA 51,7 0,83 0,7 0,7 1,0000 
AJAC01CT 51,7 1,45 0,88 0,94 1,0682 
AJAG01TC 63,5 0,2 0,4 0,4 1,0000 
AJAT04TA 67,2 0,57 0,58 0,55 0,9483 
Chromosome 10 
AJGA01TT 7,2 0,65 0,48 0,32 0,6667 
AJAG03AC 10,9 0,8 0,9 0,5 0,5556 
AJAC02AC 10,9 3,7 2,8 1 0,3571 
AJAC02AA 18,4 0,75 0,6 0,4 0,6667 
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AJGA03AG 18,4 0,67 0,75 0,5 0,6667 
AJGA01CA 18,4 0,75 0,79 0,42 0,5316 
AJGA02CA 18,4 1,46 1,34 0,92 0,6866 
Chromosome 11 
AJAT03CT 5,3 0,64 0,57 0,6 1,0526 
AJAC01CA 9,6 1,26 0,89 1,16 1,3034 
AJTT03AT 9,7 0,7 0,6 0,9 1,5000 
AJTT03CA 9,7 14,2 0,74 1,58 2,1351 
AJTT02GA 9,7 0,26 0,11 0,05 0,4545 
AJTT03AA 13,6 0,99 1 1,05 1,0500 
AJAT03AA 17,6 1,67 1,58 1,41 0,8924 
AJAT01AA 21,6 0,71 0,87 0,95 1,0920 
AJGA02TT 31,2 0,53 0,22 0,24 1,0909 
AJTA01TT 39,3 0,74 0,62 0,75 1,2097 
AJTG05AT 39,3 0,5 0,52 0,44 0,8462 
AJAT06CT 44,6 3,08 2,13 1,49 0,6995 
AJAG01TA 48,7 0,5 0,5 0,5 1,0000 
AJAC01TA 53 1,71 1,21 0,78 0,6446 
Chromosome 12 
AJTT04AT 13,3 1,05 0,47 0,61 1,2979 
AJAC01GA 20,8 0,42 0,32 0,4 1,2500 
AJTT01CT 24,6 0,04 30,7 0,96 0,0313 
AJAA02TC 35,9 2 0,7 0,5 0,7143 
AJTC01CT 50,9 1,29 0,65 0,73 1,1231 
AJAT04CT 79,9 0,53 0,76 0,92 1,2105 
AJAG01TG 106,8 0,3 0,3 0,2 0,6667 
AJTC01TA 111,4 0,56 0,35 0,23 0,6571 
AJTT02AA 123,5 0,79 0,48 0,5 1,0417 
AJAA03TC 123,6 0,5 0,3 0,4 1,3333 
Chromosome 13 
AJTT01AG 15,2 1,02 0,89 1,21 1,3596 
AJAA03TG 28,5 1 1,3 1,4 1,0769 
AJAC04.0AT 28,5 0,51 0,68 0,87 1,2794 
AJTA01GA 28,5 1,51 1,97 2,19 1,1117 
AJTT04AA 32,4 0,31 0,32 0,49 1,5313 
AJTT02AC 36,7 0,71 1,35 1,29 0,9556 
AJAA01AT 44,5 0,8 0,7 0,6 0,8571 
AJAT02TG 64 1,01 0,68 0,67 0,9853 
AJTA01AG 72,9 15,39 13,84 5,67 0,4097 
AJGA02AA 76,9 1,02 0,95 0,94 0,9895 
AJAA03AC 136,1 0,7 0,8 0,5 0,6250 
AJAA01TG 151,2 0,3 0,2 0,2 1,0000 
AJAG04AG 177,9 0,9 0,4 0,3 0,7500 
AJTG02AG 183,4 0,57 0,77 0,76 0,9870 
AJTT02TG 183,4 1,4 1,51 1,29 0,8543 
AJTT02TT 183,4 0,95 0,04 0,04 1,0000 
AJTT02CA 183,4 1,28 0,7 0,5 0,7143 
AJGA02AG 183,5 1,88 2 1,38 0,6900 
AJGA02CT 183,5 0,3 0,26 0,34 1,3077 
AJTA01TC 187,9 0,3 0,32 0,35 1,0938 
AJAA03CA 200 1,09 1,29 0,78 0,6047 
AJAC03TT 200 5,47 3,89 3,18 0,8175 
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AJAT02AT 200 1,49 1,15 0,78 0,6783 
AJAA01AG 208,2 0,5 0,4 0,4 1,0000 
AJTG01TG 217,8 0,04 0,02 0,07 3,5000 
Group 31 
AJTT02CT 0 58,5 1,35 2,07 1,5333 
Group 12 
AJAG02AC 28,3 0,6 0,5 0,3 0,6000 
AJAG02TA 0 0,2 0,2 0,2 1,0000 
AJGA01AG 4 0,35 0,44 0,33 0,7500 
AJAC04TA 4 0,89 1,17 0,94 0,8034 
AJTG03AT 12,8 0,73 0,39 0,44 1,1282 
AJAC04AA 20,3 0,5 0,6 0,7 1,1667 
AJGA01AC 20,3 1,78 1,48 1,2 0,8108 
AJAT04AT 20,3 2,1 1,09 1,07 0,9817 
AJTT03CT 28,3 57,19 0,28 0,62 2,2143 
AJGA02AC 28,3 1,64 1,6 1,11 0,6938 
Group 14 
AJTG02CT 4 1,5 0,81 1 1,2346 
AJTT01TT 8,2 0,31 0,04 0,03 0,7500 
Group 16 
AJAT03AC 0 1,03 0,71 0,82 1,1549 
AJTC01GT 4,4 0,9 0,62 0,94 1,5161 
AJTG04AT 24,5 0,94 0,89 0,94 1,0562 
AJTT01AA 48,4 O,73 0,45 0,45 1,0000 
Group 2 
AJAA02TA 0 0,6 0,5 0,3 0,6000 
AJAG02TT 19,8 0,8 0,9 0,4 0,4444 
AJAC05AT 24,4 2,44 1,72 0,76 0,4419 
AJAA01TA 28,1 0,4 0,4 0,3 0,7500 
AJGA02TA 33,1 0,67 0,57 0,48 0,8421 
AJAG02AT 36,8 0,7 0,5 0,4 0,8000 
AJTT01TC 44,6 2,25 2 1,58 0,7900 
AJGA01GA 71,9 1,37 1,14 0,42 0,3684 
AJTT01GT 71,9 4,82 1,47 0,85 0,5782 
AJTA03AC 79,6 0,55 0,65 0,6 0,9231 
AJAC01TT 88,4 3,9 2,95 1,64 0,5559 
AJGA01AT 88,4 0,42 0,63 0,61 0,9683 
AJAT05AT 120,6 1,13 0,86 0,64 0,7442 
Group 20 
AJAT03TA 4,6 5,01 3,73 2,58 0,6917 
AJAA01GT 8,7 0,5 0,5 0,4 0,8000 
AJAT02AA 8,7 0,36 0,3 0,34 1,1333 
AJAT01AC 8,7 1,26 0,97 1,38 1,4227 
AJTC02TA 8,7 2,36 1,74 0,85 0,4885 
AJAA05AC 16,8 1,5 1 0,9 0,9000 
AJAT02GT 16,8 1,13 0,68 0,43 0,6324 
AJAT04TG 25,5 1 0,79 0,54 0,6835 
AJTT05AA 43,7 0,15 0,13 0,13 1,0000 
AJAT01TG 43,7 0,95 0,55 0,36 0,6545 
AJAT04AA 47,5 0,31 0,36 0,29 0,8056 
AJAT02CT 71,9 1,12 0,61 0,27 0,4426 
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AJAT01CT 84,2 1,98 0,96 0,84 0,8750 
AJTG01CT 84,2 0,98 1,09 0,87 0,7982 
AJTT06AA 84,2 0,16 0,16 0,1 0,6250 
AJAG03AT 92,7 1,5 0,7 0,7 1,0000 
AJGA02AT 92,7 0,85 0,64 0,58 0,9063 
Group 21 
AJAA01AC 0 1,2 1,6 0,8 0,5000 
Group 29 
AJAT01CA 0 0,33 0,35 0,23 0,6571 
Group 3 
AJTT07AA 40,7 1,63 0,88 0,71 0,8068 
AJAC01AG 44,2 1,44 1,6 1,1 0,6875 
AJTT01AC 49,5 0,49 0,36 0,4 1,1111 
AJTA02AT 51,4 0,29 0,34 0,29 0,8529 
AJAC01AT 63,8 0,88 0,84 0,79 0,9405 
AJAA02TT 75,5 1,9 0,9 0,6 0,6667 
AJTA01AT 86,4 0,58 0,36 0,45 1,2500 
Group 33 
AJTT01AT 8,1 0,52 1,65 1,21 0,7333 
AJGA01AA 22,5 1,28 0,86 0,62 0,7209 
Group 38 
AJTA02AG 7,5 1,24 0,65 0,54 0,8308 
AJAC01TG 11 0,65 0,75 0,66 0,8800 
AJGA01TA 15,8 0,64 0,63 0,64 1,0159 
Group 6 
AJGA01TG 0 1,03 0,71 0,57 0,8028 
AJGA01CT 0 0,64 0,33 0,35 1,0606 
AJTT01TG 0 2,08 2,48 0,46 0,1855 
AJAA02AT 8,5 1 0,9 0,9 1,0000 
AJAG01AT 19,4 0,4 0,5 0,8 1,6000 
No data 
AJAG02TG ........................... 0,7 0,6 0,4 0,6667 
AJAA01TC ............................ 1 0,9 1 1,1111 
AJAC04.5AT ............................ 0,45 0,27 0,21 0,7778 
AJGA04AT ............................ 0,56 0,76 0,5 0,6579 
AJGA05AT ............................ 0,37 0,35 0,32 0,9143 
AJAC02TA ............................ 0,92 0,67 0,83 1,2388 
AJGA03AA ............................ 0,86 0,7 0,61 0,8714 
AJTA01TG ............................ 3,91 2,62 2,38 0,9084 
AJTA03GA ............................ 0,72 1,69 1,18 0,6982 
AJTC02AG ............................ 0,43 0,33 0,44 1,3333 
AJTC02TG ............................ 0,12 0,51 0,43 0,8431 
AJTG04AG ............................ 0,88 0,77 0,76 0,9870 
AJTG05AG ............................ 1,16 2,48 0,49 0,1976 
AJTG02TG ............................ 0,04 0,15 0,1 0,6667 
AJTG03TG ............................ 2,41 1,11 0,83 0,7477 
AJAG03CA ............................ 0,3 0,3 0,3 1,0000 
AJAG05CT ........................... 0,6 0,3 0,4 1,3333 
AJAG01AC ............................ 0,09 0,16 0,11 0,6875 
AJAT01GA ............................ 1,69 1,22 1,04 0,8525 
Unlinked 
AJAG01AA ............................ 0,5 0,8 1 1,2500 
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AJAA02AC ............................ 1 1 0,6 0,6000 
AJAC03AG ............................ 3,74 2,89 2,71 0,9377 
AJAA01CA ............................ 1,39 0,89 1,01 1,1348 
AJAC02CT ............................ 3,33 2,04 2,29 1,1225 
AJGA03AT ............................ 1,41 1,11 0,54 0,4865 
AJAT06AT ............................ 0,66 0,47 0,51 1,0851 
AJAT02CA ............................ 0,8 0,62 0,34 0,5484 
AJTA01CT ............................ 0,73 0,69 0,77 1,1159 
AJTC01AT ............................ 0,86 0,8 0,38 0,4750 
AJTT03GA ............................ 10,92 2,82 1,23 0,4362 
 
D - AS-ATN x AJ – AS specific AFLP markers 
 
Marker Name 
CM distance along chromosome 
Relative Intensity 
Comparative Intensity ATN 
treated/Untreated AS Markers 
Non 
passaged Untreated  
ATN 
treated 
Chromosome 1 
ASAA01TC 16,2 0,6 0,2 0,3 2,1 
ASAA02CA 16,2 1,4 0,3 0,4 1,3 
ASTA01TT 16,2 1,1 0,3 0,6 2,3 
ASTA02AT 16,2 0,3 0,1 0,1 1,2 
ASTA02GT 16,2 1,5 0,9 0,7 0,8 
ASTG01AA 43,4 0,7 0,3 0,6 1,8 
Chromosome 5 
ASAA03TG 26,7 0,8 0,4 0,6 1,6 
ASAA02GA 54,4 0,9 0,2 0,4 1,8 
ASAC03AT 69,9 1,2 0,3 0,6 2,4 
ASAA04AC 69,9 0,3 0,1 0,2 2,3 
ASAC01AG 74,6 0,7 0,1 0,3 3,1 
ASTA01AC 74,6 1,3 0,4 0,2 0,5 
Chromosome 6 
ASAC02AT 11,3 0,8 0,2 0,4 1,5 
ASAT01AA 11,3 0,3 0,2 0,4 1,6 
ASTC01TC 11,3 0,2 0,2 0,2 1,1 
ASTG01AT 11,3 1,9 0,7 1,5 2,1 
ASTT01CA 44,2 0,0 3,5 1,5 0,4 
ASAG01TG 62,6 1,6 0,7 0,6 0,8 
Chromosome 7 
ASAA02GT 31,6 1,1 0,5 0,5 1,1 
ASAC01GT 31,6 0,7 0,4 0,8 1,9 
ASAA01CA 48,4 1,2 0,3 0,4 1,3 
ASAA05CA 62,2 1,0 0,4 0,7 1,7 
ASTT03CA 62,2 1,1 1,0 1,0 1,1 
ASAC05AA 69,7 0,9 0,5 0,6 1,2 
ASAT02AT 69,7 0,6 0,1 0,2 1,3 
ASTG01TC 77,5 0,2 0,3 0,3 1,2 
ASAG02CA 100,3 1,7 0,3 0,3 1,0 
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ASTT01AG 123,6 0,1 0,1 0,5 3,7 
ASAC01TA 127,6 1,2 0,4 0,3 0,8 
Chromosome 8 
ASAC01TG 30,8 1,2 0,3 0,9 3,3 
ASTA01AT 34,3 0,4 0,3 0,4 1,3 
ASAG01CA 38,2 1,4 0,1 0,5 6,6 
ASGA02AC 43,0 1,4 0,3 0,9 3,3 
ASTG02AA 50,8 0,1 0,6 0,7 1,1 
ASTC01CT 58,5 44,6 13,8 20,5 1,5 
ASAC01AT 73,2 0,4 0,1 0,3 5,4 
ASAT03AC 73,2 1,5 0,3 1,1 4,1 
Chromosome 9 
ASTA01GT 40,2 4,0 1,9 3,7 2,0 
ASAA04CA 40,2 1,0 0,5 0,8 1,7 
ASAC03CT 51,7 0,9 0,4 0,3 0,7 
ASTT05CA 51,7 0,9 0,7 1,6 2,3 
ASAT04AA 59,2 0,4 0,2 0,2 1,3 
ASTT02TT 71,1 388,8 0,1 0,5 8,8 
Chromosome 10 
ASGA01TC 7,2 0,5 0,1 0,3 3,1 
ASTG01CA 7,2 20,8 1,0 1,1 1,1 
ASTT01TT 10,9 0,0 3,1 0,5 0,2 
ASGA01CA 18,4 1,0 0,1 0,4 3,3 
ASAT05AA 18,4 0,3 0,2 0,2 1,5 
ASTA02AG 18,4 0,4 0,1 0,3 4,1 
Chromosome 11 
ASAG03CA 5,3 2,4 0,3 0,1 0,3 
ASAT03AA 5,3 1,0 0,5 0,4 0,8 
ASTC02AC 5,3 0,3 0,2 0,1 0,7 
ASTT02AA 5,3 0,1 0,1 0,1 1,4 
ASTA03GA 21,5 1,2 0,4 0,3 0,8 
ASTC01CA 21,5 1,2 0,6 0,5 0,9 
ASTA01TA 39,2 0,3 0,1 0,3 2,3 
ASTC01AC 39,2 0,1 0,0 0,1 3,5 
ASTG01TA 39,2 0,6 0,2 0,4 1,8 
ASAG01TA 48,7 0,6 0,3 0,4 1,3 
ASAA01TG 52,9 1,3 0,5 0,3 0,6 
ASAC02TA 52,9 1,7 0,1 0,6 4,6 
Chromosome 12 
ASAC02CT 20,8 0,8 0,2 0,3 1,6 
ASAA01AT 54,6 0,8 0,6 0,5 0,9 
ASAC03AA 54,6 1,0 0,4 0,6 1,8 
ASGA02AG 66,4 1,2 0,6 0,8 1,3 
ASTC01TA 111,4 0,6 0,1 0,4 2,6 
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Chromosome 13 
ASAA05AT 0,0 1,7 0,6 0,6 1,1 
ASTG02TT 3,9 0,8 0,1 0,1 1,4 
ASTA01AA 15,2 1,1 0,4 0,3 0,7 
ASTT02AG 15,2 0,1 1,6 1,5 0,9 
ASTT01GA 28,5 1,2 2,1 1,5 0,7 
ASAA01TA 36,1 1,6 0,1 0,3 2,9 
ASAA04TA 36,1 0,7 0,1 0,2 2,3 
ASTA02CA 36,1 0,4 0,2 0,4 1,7 
ASTA02CA 36,1 1,2 0,2 0,2 0,9 
ASAA03AT 44,6 0,3 0,2 0,2 1,3 
ASTA01AG 73,0 11,2 4,9 4,1 0,8 
ASTT02TC 132,5 0,0 0,0 0,0 2,0 
ASGA02TA 177,9 0,1 0,0 0,1 3,0 
ASAT01AC 177,9 0,9 0,3 0,4 1,5 
ASGA03CA 177,9 0,6 0,1 0,2 2,1 
ASTA03TA 183,5 1,7 0,4 1,0 2,7 
ASTG03AA 183,5 0,4 0,1 0,3 2,2 
ASTT02CA 183,5 0,0 0,9 0,9 1,0 
ASTA01CT 200,1 0,4 0,1 0,1 1,1 
ASTA01CT 200,1 0,8 0,3 0,5 1,9 
ASTT04AT 200,1 1,0 2,1 1,6 0,8 
ASAT01AT 209,2 1,3 0,3 0,6 1,9 
ASGA02AT 221,9 0,9 0,4 0,8 1,8 
Group 12 
ASAC01GA 4,0 1,2 0,4 0,5 1,1 
ASGA01AG 4,0 0,8 0,1 0,6 3,9 
ASAT09AA 4,0 0,4 1,0 0,3 0,2 
ASAT08AA 12,8 0,6 0,2 0,4 1,8 
ASAA01GT 20,3 0,7 0,3 0,4 1,5 
ASGA03AC 20,3 0,5 0,4 0,2 0,6 
ASGA01AC 24,4 1,4 0,4 0,7 1,8 
ASTA02TA 28,3 3,2 1,3 1,1 0,8 
Group 14 
ASTA03AA 0,0 2,7 0,3 0,9 2,8 
ASTA02AA 4,0 0,6 0,2 0,6 2,5 
Group 16 
ASAT04AC 0,0 1,0 0,5 0,4 0,8 
ASTG01TT 0,0 0,5 0,2 0,2 1,1 
ASTT01CT 4,4 0,0 0,9 0,7 0,8 
ASAG01CT 12,4 1,6 0,5 0,7 1,4 
ASAA03TA 32,2 0,6 0,2 0,3 1,2 
ASTT01AC 40,3 8,4 0,9 0,2 0,2 
ASTT03AA 59,2 0,1 0,1 0,1 1,6 
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ASTT01AA 74,5 0,2 2,3 1,6 0,7 
Group 2 
ASAA02AT 0,0 0,8 0,3 0,6 2,6 
ASAG01TT 7,8 1,5 0,4 1,0 2,5 
ASAC02AG 24,4 0,9 0,2 0,5 3,5 
ASTC01GA 24,4 3,6 1,3 2,8 2,2 
ASTT01AT 71,9 0,4 0,3 0,4 1,3 
ASTT04CA 71,9 46,8 2,0 1,9 1,0 
Group 20 
ASGA02CA 4,6 0,6 0,2 0,2 1,1 
ASAA04TC 8,7 0,8 0,2 0,4 1,8 
ASAA01GA 8,7 1,3 0,6 1,0 1,8 
ASTC02TC 8,7 0,0 0,0 0,0 1,5 
ASAA06AC 16,8 0,2 0,6 0,6 1,0 
ASAA03TC 43,7 1,1 0,3 0,5 1,7 
ASAA02TG 55,0 1,0 0,7 1,0 1,4 
ASAG01GA 64,2 2,3 1,0 1,8 1,9 
ASAC01CT 84,2 0,4 0,3 0,5 1,4 
ASTG02CT 84,2 1,1 1,2 0,9 0,8 
Group 21 
ASAA01AC 0,0 0,1 0,1 0,1 1,1 
Group 3 
ASGA01AT 40,0 0,8 0,1 0,3 2,1 
ASAA02TA 44,2 1,1 0,5 0,4 0,9 
ASAA03CT 44,2 2,6 0,6 1,4 2,3 
ASAT11AA 44,2 0,9 0,2 0,5 2,4 
ASAT02AA 63,8 0,2 0,1 0,2 3,0 
ASTA01CA 75,5 1,2 0,1 0,4 2,8 
ASTA01CA 75,5 0,8 0,3 0,4 1,4 
Group 30 
ASTT01TC 11,9 2,0 42,0 0,8 0,0 
Group 33 
ASTT02AT 0,0 0,1 0,0 0,0 0,5 
ASAT02AC 8,1 1,7 0,3 0,4 1,5 
Group 6 
ASGA01TA 0,0 1,9 0,6 1,2 2,0 
ASGA01GA 0,0 1,7 1,1 0,4 0,4 
ASTG01GA 0,0 0,1 2,5 1,1 0,4 
ASAT06AA 23,4 0,3 0,2 0,5 3,2 
No data 
ASTA04GA ............................................ 4,3 1,2 2,8 2,4 
ASTA04CA ............................................ 0,3 0,2 0,2 1,0 
ASTA02TG ............................................ 0,6 0,4 0,4 0,8 
ASTA02GA ............................................ 0,7 0,4 0,5 1,3 
 219
ASTA03TG ............................................ 0,7 0,3 0,5 1,9 
ASTA04TC ............................................ 2,7 3,2 3,0 0,9 
ASTA02TC ............................................ 1,0 0,3 0,3 1,3 
ASTA03TC ............................................ 1,8 0,4 0,5 1,4 
ASGA01AA ............................................ 1,3 0,3 0,5 2,1 
ASGA02AA ............................................ 1,3 0,4 0,8 2,0 
ASGA03AA ............................................ 0,0 0,0 0,1 4,0 
ASGA04AA ............................................ 1,6 0,7 1,0 1,4 
ASGA05AA ............................................ 2,7 0,5 0,8 1,5 
ASGA06AA ............................................ 1,4 0,5 0,7 1,6 
ASGA07AA ............................................ 1,8 0,3 0,8 2,9 
ASGA08AA ............................................ 0,8 0,4 0,6 1,4 
ASTA01GA ............................................ 1,4 0,3 0,3 0,9 
ASTA04TG ............................................ 1,7 0,2 0,2 1,2 
ASTA02TT ............................................ 0,8 0,5 0,4 0,7 
ASTA01TC ............................................ 1,8 1,0 1,2 1,2 
ASTC02GT ............................................ 1,4 1,9 2,0 1,0 
ASTA03CA ........................................... 0,4 0,1 0,1 1,4 
ASTA01TC ........................................... 1,3 0,3 0,5 1,6 
ASTC03AA ............................................ 0,5 0,3 0,2 0,7 
ASTC03TC ............................................ 1,4 0,7 1,3 1,9 
ASTG04AA ............................................ 0,4 0,2 0,2 1,0 
ASTG02TC ............................................ 0,6 0,1 0,2 1,2 
ASTG02GA ............................................ 0,1 1,3 0,7 0,6 
Unlinked 
ASAA04AT ............................................ 1,9 0,6 0,5 0,9 
ASAC06AA ............................................ 5,3 3,4 3,2 0,9 
ASAA01CT ............................................ 1,3 0,2 0,7 3,4 
ASAT07AA ............................................ 0,5 0,1 0,3 3,0 
ASTC01AA ............................................ 1,0 0,5 0,5 1,1 
ASTC02AA ........................................... 1,0 0,7 1,2 1,9 
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Artemisinin combination 
therapy (ACT) -  
As a response to increasing levels of resistance to antimalarial medicines, WHO 
recommends that all countries experiencing resistance to conventional 
monotherapies, such as chloroquine, amodiaquine or sulfadoxine–pyrimethamine, 
should use combination therapies, preferably those containing artemisinin 
derivatives (ACTs) for falciparum malaria. 
WHO currently recommends the following combination therapies (in alphabetical 
order): 
1. Artemether/lumefantrine  
2. Artesunate plus amodiaquine (In areas where the cure rate of amodiaquine 
monotherapy is greater than 80%) 
3. Artesunate plus mefloquine (Insufficient safety data to recommend its use 
in Africa)  
4. Artesunate plus sulfadoxine / pyrimethamine (In areas where the cure rate 
of sulfadoxine / pyrimethamine is greater than 80%) 
Note: Amodiaquine plus sulfadoxine / pyrimethamine may be considered as an 
interim option where ACTs cannot be made available, provided that efficacy of both 
is high. 
 
 
Clone -  A collection of parasites in which all individuals have been derived from a single 
cell by asexual reproduction.  
Therefore, a particular clone should represent a population of genetically identical 
parasites, assuming that no spontaneous mutations had taken place during parasite 
growth. 
 
 
Isolate -  A population of parasites that have been collected from mosquitoes, humans or 
rodents living in the wild on a single occasion and subsequently kept as deep-frozen 
material.  
An isolate does not necessarily represent a homogeneous parasite population and 
may contain more than one representative of the same species or different species. 
 
 
Line -  A population of parasites that have undergone one or more in vitro or in vivo 
laboratory passages.  
Usually, a line is produced when the parasites being passaged in the laboratory have 
been subjected to some kind of induced pressure, such as drug treatment. As for the 
isolate, parasites constituting a line may not be genetically identical.  
 
 
Linkage Group 
Selection (LGS) -  
Was devised for application to malaria parasites in order to locate genes that control 
selectable phenotypes such as drug sensitivity, growth rate and strain-specific 
immunity without the disadvantages of classical linkage analysis.  
LGS uses a genetic cross between two unrelated (genetically distinct) parasites of 
the same species, one of which is sensitive and the other resistant to the relevant 
selection pressure (such us drug treatment). Following cross-fertilisation between 
gametes of each parasite and zygote formation in the mosquito, there is 
recombination between the parental genomes during meiosis, producing haploid 
recombinant progeny.  
 
 
Minimum Curative 
Dose (MCD) -  
The MCD of each drug was first assessed in drug-selected parasites and untreated 
control lines. MCD was defined as the minimum dose of each drug that would 
prevent re-appearance of parasites in all five mice within each treated group at any 
time during the first 10 days of the follow-up period.  
 
 
N-fold resistance -  A resistance index was determined using the following equation: 
N-fold resistance = MCD drug selected parasites/ MCD drug unselected parasites 
 
 
Polymerase chain 
reaction (PCR) - 
Is a biochemistry and molecular biology technique for exponentially amplifying 
DNA, via enzymatic replication, without using a living organism (such as E. coli or 
yeast). As PCR is an in vitro technique, it can be performed without restrictions on 
the form of DNA, and it can be extensively modified to perform a wide array of 
genetic manipulations. 
PCR is commonly used in medical and biological research labs for a variety of 
tasks, such as the detection of hereditary diseases, the identification of genetic 
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fingerprints, and the diagnosis of infectious diseases, the cloning of genes, paternity 
testing, and DNA computing. 
 
 
Proportional 
Sequencing -  
Technique for analysing parasite mixtures. The method is rapid, and in principle can 
be applied to any single nucleotide polymorphism (SNP) at any locus, with only 
minimal requirements for optimisation and assay development. Proportional 
sequencing exploits the fact that during a PCR reaction, DNA is amplified in 
proportion to the initial template. 
 
 
Quantitative Polymerase 
Chain Reaction (RTQ-
PCR) -  
Is a modification of the polymerase chain reaction used to rapidly measure the 
quantity of DNA, complementary DNA or ribonucleic acid present in a sample. 
Like other forms of polymerase chain reaction, the process is used to amplify DNA 
samples, via the temperature-mediated enzyme DNA polymerase. 
PCR theoretically amplifies DNA exponentially, doubling the number of molecules 
present with each amplification cycle. The number of amplification cycles and the 
amount of PCR end-product should allow one to calculate the initial quantity of 
genetic material, but numerous factors complicate this calculation. The ethidium 
bromide staining typically used to assess a successful PCR prevents further 
amplification, and is only semi-quantitative. The polymerase chain reaction may not 
be exponential for the first several cycles, and furthermore, plateaus eventually, so 
care must be taken to measure the final amount of DNA while the reaction is still in 
the exponential growth phase. To overcome these difficulties, several different 
quantitative methods have been developed. 
The most sensitive quantification methods are done by the real-time polymerase 
chain reaction, where the amount of DNA is measured after each cycle of PCR by 
use of fluorescent markers. Other end-point methods measure DNA after PCR is 
completed. These methods depend on addition of a competitor RNA (for reverse-
transcriptase PCR) or DNA in serial dilutions or co-amplification of an internal 
control to ensure that the amplification is stopped while in the exponential growth 
phase. 
Although real-time quantitative polymerase chain reaction is often marketed as RT-
PCR, it should not to be confused with reverse transcription polymerase chain 
reaction, which is also referred to as RT-PCR, but is used to amplify RNA samples. 
The two methods may be used in concert to reverse transcribe RNA and then 
quantitate the resulting cDNA using real-time PCR (often referred to as real-time 
RT-PCR). 
 
 
RI - Delayed 
Recrudescence -  
The WHO 1973 definition of the level of parasite drug resistance remains in use.  
According to the WHO the asexual parasitaemia reduces to < 25% of pre-treatment 
level in 48 hours, but reappears between 2-4 weeks. 
 
 
RI - Early 
Recrudescence -  
The WHO 1973 definition of the level of parasite drug resistance remains in use. 
According to the WHO the asexual parasitaemia reduces to < 25% of pre-treatment 
level in 48 hours, but reappears within 2 weeks. 
 
 
RII – Resistance -  The WHO 1973 definition of the level of parasite drug resistance remains in use. 
According to the WHO there is a marked reduction in asexual parasitaemia 
(decrease >25% but <75%) in 48 hours, without complete clearance in 7 days. 
 
 
RIII – Resistance -  The WHO 1973 definition of the level of parasite drug resistance remains in use. 
According to the WHO there is a minimal reduction in asexual parasitaemia, 
(decrease <25%) or an increase in parasitaemia after 48 hours 
 
 
Sensitive Parasite (S) -  
 
The WHO 1973 definition of the level of parasite drug resistance remains in use. 
According to the WHO the asexual parasite count reduces to 25% of the pre-
treatment level in 48 hours after starting the treatment, and complete clearance after 
7 days, without subsequent recrudescence - Complete Recovery. 
 
 
Strain -  All parasites of a single subspecies present in a single isolate.  
For example, Plasmodium chabaudi chabaudi strain AS-sens is composed of all the 
parasites belonging to the P. c. chabaudi sub-species in blood isolated from the 
thicket rat Thamnomys rutilans. 
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